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Type 1 diabetes affects over one million Americans and an additional 40,000 new cases 
are diagnosed each year. The disease is characterized by the destruction of insulin-secreting beta 
cells in the pancreas by the immune system. Consequently, patients with type 1 diabetes rely on 
exogenous insulin for life. Due to the small volume of beta cells in healthy pancreas, it is 
extremely challenging to monitor disease progression (particularly at early stages when adequate 
control of blood sugar levels is still maintained) and assess treatment efficacy in patients with 
type 1 diabetes. Therefore, an accurate method to monitor and quantify the beta cell mass (BCM) 
through imaging has been an important goal of the diabetes community. 
This thesis describes the unique anatomy and physiology of the beta cells within the Islets 
of Langerhans and calculates the optimal physicochemical properties needed for a BCM 
molecular imaging probe. The molecular weight of exendin probes are near ideal for targeting 
the endocrine pancreas, and this molecule was analyzed in more detail. Receptor trafficking 
properties and plasma clearance play a major role in determining beta cell targeting versus 
background signal and were measured for a series of probes. Due to rapid downregulation of the 
receptor, slow plasma clearance does not allow for continual beta cell uptake and increases 
background, so more rapid clearance results in higher target to background signal . Additionally, 
the receptor expression of GLP1-R was measured for the first time and provided evidence for 
low exocrine expression of GLP1-R in addition to the high endocrine expression. Because this 
could explain poor clinical contrast of exendin probes, exocrine expression was investigated in 
	xv	
more detail. Using a transgenic mouse model, a very low expression of GLP1-R was confirmed 
on exocrine cells. Although absolute expression is very low (850 receptors per cell on exocrine 
cells versus 53,000 receptors per cell on beta cells), the much higher prevalence of exocrine cells 
(99%) relative to beta cells (1%) results in a significant total signal from the exocrine pancreas. 
Preliminary results show it is possible to preferentially block exocrine uptake to provide more 
specific beta cell signal. Multiple doses were administered to first saturate the exocrine with non-
detectable peptide followed by a imaging agent dose to label the beta cells. The dosing strategy 
completely blocked exocrine GLP-1R in healthy animal models. Because peptides often have 
poor stability and lower affinity due to the lack of secondary structure, exendin was used as a 
model system to study the impact of helix stabilization on improving peptide physicochemical 
properties. Using a unique cross-linker with exendin and GLP1 peptides, the helicity, protease 
stability, and affinity could be improved. The increase protease stability of the cross-linked 
peptides and use of exendin as a therapeutic led us to test the subcutaneous bioavailability. Near-
100% bioavailability was achieved through peptide stabilization, and the bioavailability of a 
slow-clearing version was also improved. The linker lipophilicity could be controlled to 
modulate the absorption and clearance rates of the fluorescent peptide. Overall, this thesis 
provides a theoretical analysis of imaging BCM, novel tools to manipulate peptide image probe 
properties, and experimental evidence of methods to improve the design of molecular imaging 
agents for beta cell mass.
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Chapter 1      
Introduction 
1.1 Publication Information 





Diabetes refers to a group of metabolic disorders where insulin insensitivity and/or a lack 
of insulin production results in elevated blood glucose levels. These broadly include type 1 
diabetes (previously known as “juvenile onset” diabetes, T1DM), type 2 diabetes (previously 
“adult onset”), and additional less prevalent variants (e.g. monogenic diabetes). Unregulated 
blood glucose levels have a negative impact on multiple organ systems and consequently pose a 
risk for stroke, heart disease, kidney failure, blindness, high blood pressure, and other chronic 
conditions that impair the quality of life. Currently, there are over 400 million cases of diabetes 
worldwide and the rate continues to rise1. Patients with diabetes must rely on medications and 
lifestyle changes to maintain glucose homeostasis. Aside from the morbidity, the financial 
burden of the disease constitutes approximately 10% of all health care costs in developed 
countries2. No cure currently exists and present strategies to prevent disease complications place 
a significant strain on healthcare systems. Therefore, it is important to understand the disease 
pathophysiology for the medical community and patients. The ability to image and follow 
disease progression would play a crucial role in understanding disease etiology and allow 
accurate monitoring during clinical trials for potential clinical translation of treatments. 
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Ultimately, improved treatments, transplants, and understanding of basic and clinical 
pathophysiology of the disease may lead to a permanent cure. 
 
Physiology of the pancreas/islets 
Despite the multi-organ involvement of the disease, the pancreas is a critical organ due to 
its central role in regulating blood sugar levels and metabolism. Located behind the stomach in 
humans, the pancreas is part of both the endocrine and digestive systems. Macroscopically, it 
consists of three regions – the head, body, and tail (Figure	 1.1A). Distinct tissues within the 
organ carry out the functions for each organ system. The exocrine pancreas primarily serves the 
digestive system and forms ~99% of the organ mass2. It is formed by acini, with each acinus 
consisting of secretory epithelial cells. The lumen at the center of each layer mediates the 
drainage of cellular secretions into a series of connected ducts. The ducts join to form the 
pancreatic duct, which empties into the duodenum. These secretions aid in digestion and include 
enzymes such as trypsin, chymotrypsin, elastase, ribonuclease, amylase, lipase, and others. The 
endocrine pancreas forms approximately 1% of the pancreas mass and carries out several 
functions through multiple distinct cell types. These functions include the secretion of insulin, 
glucagon, somatostatin, peptide YY, neuropeptide Y and pancreatic polypeptide (PP) directly 
into the blood for tight glucose regulation (endocrine function). Although the pancreas is mostly 
exocrine tissue by mass, the organ’s role in diabetes research is closely associated with the 
functionality of endocrine pancreas. 
	3	
	
Figure 1.1 Structure of the pancreas. 
A. Schematic of the pancreas with head, body, and tail portions labeled. The pancreatic duct runs 
along the organ and empties into the duodenum (not shown). B. Histology slide of a mouse islet 
with the blood vessels (CD31) stained in brown (hematoxylin counterstain). Adapted from 
Keliher et al., 2012. Notice the extensive vessels on the islet surface and within. A human (C), 
monkey (D), and mouse (E) islet of Langerhans stained for beta cells (insulin, red), alpha cells 
(glucagon, green), and delta cells (somatostatin, blue). The proportion of beta cells in humans is 




The endocrine pancreas is comprised of distinct microstructures known as islets of 
Langerhans. These individual clusters of cells range from 40-300 microns in diameter and 
account for 1-2% of pancreatic tissue (varying between species, Figure	 1.1B), although they 
receive 10-20% of arterial flow, a disproportionately higher amount compared to exocrine 
tissue4. They also have a higher density of vessels, with surface area measurements of 505 
cm2/cm3 for the islets versus 182 cm2/cm3 for the exocrine tissue5, 6. Cell types within each islet 
include alpha, beta, delta, and PP cells with differences in cytoarchitecture across species. These 
cells secrete glucagon (alpha cells), insulin (beta cells), somatostatin (delta cells), and pancreatic 
polypeptide (PP) with beta cells responsible for the central role of secreting insulin and lowering 
blood glucose. Although the ratios of different cell types vary between the head, body, and tail of 
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the pancreas, the beta cells are the most prevalent cells type (70-80% in mice) with the remaining 
fraction comprised of alpha cells, delta, and PP cells7. Incretins form another signaling axis in the 
regulation of metabolism. These peptides are secreted by the epithelial cells in the intestines and 
induce beta cell production of insulin. Two common incretin peptides include glucagon-like 
peptide-1 (GLP-1) and gastric inhibitory peptide (GIP). 
 
Disease background  
The most common types of diabetes are type 1 diabetes mellitus and type 2 diabetes 
mellitus. Type 1 diabetes is an autoimmune disorder characterized by T-cell destruction of the 
insulin-producing beta cells in the pancreas. The drastic reduction in beta cell functionality 
results in hyperglycemia and requires patients to depend on life-long insulin treatments to lower 
blood glucose levels for survival. Because the destruction occurs in adolescents and the early 
stages are largely asymptomatic, there is much to learn about disease progression. Though 
disease etiology is complex and the pathogenesis poorly understood, the examination of patient 
islet tissue from biopsies reveal the presence of insulitis in most patients (>50%). Much of this 
knowledge relies on histopathology from the 1960s and there is limited availability from pre-
diabetic patients due to the difficulty of obtaining samples from individuals at risk to develop the 
disease8. From these early studies and more recent data, disease progression is divided into two 
phases, the initial occult phase followed by overt diabetes. The occult phase, marked by insulitis, 
involves the aggressive infiltration of leukocytes. The transition to overt diabetes occurs once the 
majority of beta cells (60-80%) are destroyed and the remaining beta cell mass can no longer 
adequately control blood sugar levels. Healthy fasting blood glucose levels should be less than 
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100 mg/dL, and levels between 100 and 125 mg/dL are considered prediabetes, while levels over 
125 mg/dL indicate diabetes. 
 
The much more prevalent type 2 diabetes is reaching epidemic levels given the 
worldwide increase in obesity9. Accounting for 90-95% of all cases, type 2 diabetes is a complex 
heterogeneous metabolic disorder responsible for simultaneous dysfunctions in multiple organs. 
Disease etiology is complex with physical inactivity and genetic predisposition as the two critical 
causes for disease onset10. Onset of hyperglycemia is caused by multiple defects in glucose 
homeostasis including increased liver glucose production, decreased insulin secretion in islets, 
and insulin insensitivity. Although screening and diagnosis of the disease is readily available and 
established, no cure currently exists. The majority of cases can be prevented by lifestyle changes 
such as routine exercise and dietary modifications, but most patients will eventually require 
medication. Numerous effective and FDA-approved medications exist to alleviate symptoms, 
and research into new agents continues. Metformin is an oral pill often used as first-line therapy 
to lower hepatic glucose production. Sulfonylureas can be used to increase insulin secretion, and 
glitazones are insulin sensitizers. Glucagon-like peptide-1 (GLP-1) agonists (e.g. exenatide, 
liraglutide, dulaglutide) are incretin mimetics that can control blood sugar and promote weight 
loss. These agents must be injected, but research into slower clearing agents has reduced the 
frequency of dosing. Oral formulations of these peptides are actively being researched. Rather 
than supplying exogenous incretins, DPP-4 inhibitors, such as sitagliptin and saxagliptin, slow 
the degradation rate of GLP-1. They have the advantage of oral administration but do not 
promote weight loss. The newest class of diabetes drugs is sodium-glucose co-transporter 2 
(SGLT-2) inhibitors. Glucose is readily filtered from the blood by the kidneys, but these 
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transporters facilitate reabsorption to avoid loss of glucose in the urine. By inhibiting this 
transporter, blood glucose levels are reduced. These agents promote modest weight loss without 
a risk of low blood sugar, but the most common side effects include vaginal yeast and urinary 
tract infections. Finally, in some cases exogenous insulin is indicated11. 
 
Role of Imaging in Diabetes 
Attempts to cure diabetes have primarily focused on restoring or preserving beta cell 
function within the pancreas. This has proven challenging as no clinical procedure currently 
exists to quantify the beta cell mass (BCM) non-invasively in patients. Instead, biochemical tests 
using blood samples are used to estimate beta cell mass functionality, but these methods are 
insensitive to the early phase of the disease when the pancreas has excess capacity to control 
blood sugar levels12. An imaging technique with the resolution and sensitivity to quantify the 
BCM would greatly benefit the diabetes community but has so far remained out of reach. For 
type 2 diabetes, understanding the role that BCM plays in the disease could open up new avenues 
for treatment. Imaging could play an even more significant role in type 1 diabetes by increasing 
insight into the early stages of immune attack and monitoring immunomodulatory therapy, 
transplant, and other treatment strategies. Accurately quantifying the beta call mass during 
clinical trials would provide invaluable information on disease etiology and treatment efficacy, 
but the low fraction of beta cells in the pancreas is challenging to monitor.  
 
Particularly for type 1 diabetes, extensive research has been conducted on islet 
transplantation, since this treatment has the potential for curative results. One of the most 
successful and well-studied methods is the Edmonton Protocol where islets from multiple donors 
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are infused in the portal vein of the liver13. To date, long-term cures from transplantation are 
rare14 due to several causes. The transplanted islets are susceptible to the same type of immune 
rejection as any organ transplant (and patients must maintain life-long immunosuppressive 
therapy) and must also counter the autoimmune attack responsible for the initial loss of the islets. 
Additionally, the microvasculature must connect with the islets, since many are beyond the size 
where oxygen can efficiently diffuse from the surface to cells in the center15. Finally, the local 
microenvironment in the transplant site may impact long-term efficacy7. The ability to track 
transplanted islets would improve transplantation technique and post-surgical monitoring16.  
 
1.3 Imaging Modalities in Diabetes 
A significant effort has been placed on developing imaging agents for the pancreas due to 
its central role in diabetes. The focus of this chapter is primarily on methods to quantify the 
BCM given the importance in diagnosis and treatment monitoring of type 1 diabetes and 
potential implications in type 2 diabetes. However, several studies and reviews of molecular and 
metabolic imaging strategies for tissues outside of the pancreas are also presented to show the 
breadth of imaging applications in these diseases. 
 
Detecting changes in BCM and early stages of the immune attack in vivo hold high 
clinical relevance but no current combination of imaging agent and modality is ideal. At present, 
several imaging modalities are used in diabetes research each with their complementary strengths 
and weaknesses. These include magnetic resonance imaging (MRI), positron emission 
tomography (PET), single photon emission computed tomography (SPECT), fluorescence 
imaging, bioluminescence imaging, ultrasound (US), and x-ray computed tomography (CT). 
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With the exception of bioluminescence, the remaining modalities have seen or have potential for 
clinical translation (albeit limited for fluorescence). Tradeoffs such as spatial resolution, 
specificity, and the use or lack of non-ionizing radiation are considered in the following sections. 
Although it is a valuable research tool, bioluminescent techniques will not be discussed due to 
low imaging depth and difficulty of clinical translation. Each of the above imaging modalities 
will be described in turn, but first, some of the unique considerations when imaging the 
endocrine pancreas, particularly for molecular imaging of beta cells in type 1 diabetes, will be 
discussed to provide context for the reported studies. 
 
Imaging Limitations and Design Considerations for Pancreatic Imaging 
Quantitative analysis of molecular imaging of islets reveals several challenges to BCM 
quantification17. The two biggest obstacles are the small size of individual islets (40-300 µm) and 
the incredibly low volume fraction of islets in the pancreas. The small islet size relative to the 
resolution of current imaging modalities results in significant partial volume effects. Because an 
islet only occupies a fraction of a voxel in an image, any contrast, be it intrinsic or from 
exogenous imaging agents, is ‘diluted’ over the entire voxel volume. Voxel dimensions for PET 
and SPECT imaging are on the order of 1 cm3 under ideal imaging conditions, which can be 
difficult to replicate in a clinical setting. Recent literature indicate that quantification of 
radiotracers in structures lower than 3 cm in diameter will be subject to such partial volume 
effects and will require correction factors for accurate quantification18. Voxel sizes for US, CT, 
and MRI are smaller (~1 mm3), but these modalities suffer from a much lower sensitivity for 
exogenous contrast agents and are still well above the size of individual islets. Optical imaging 
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has both high resolution and adequate sensitivity, but the lower depth of imaging limits this to 
invasive procedures19. 
 
 The partial volume effects alone would not be a problem if the volume fraction were 
relatively large. For example, if islets occupied 50% of the tissue volume, this would only lower 
the measured contrast ~2-fold. Although islet volume fractions vary between species and disease 
states, and the low absolute value and distribution of islets in the pancreas can make it 
challenging to estimate20-22, most measurements indicate 1-2% of the total pancreas mass is 
occupied by islets. This results in a 50 to 100-fold reduction in islet contrast due to the partial 
volume effect, which places severe limitations on probe selection and design. 
 
 Given the small size and low volume fraction discussed above, the intrinsic contrast 
between islets and the surrounding exocrine pancreas is insufficient for beta cell mass 
measurements using US, MRI, or CT. Therefore, exogenous contrast agents have been used to 
monitor various aspects of diabetes, particularly type 1. These can be divided into targeted and 
non-targeted exogenous contrast agents. 
 
 The type of contrast agent is generally dictated by the sensitivity of the imaging modality. 
For molecular contrast, meaning a specific binding interaction between the contrast agent and a 
target, the sensitivity must be high. Some of the most highly expressed disease related targets, 
such as cell surface receptors over-expressed on cancer cells, have ~1 million receptors per 
cell23. Using a cell density of 5×108 cells/mL, if the targeting has no method for amplification 
(e.g. continuous internalization and recycling, a catalytic mechanism to trap probe, etc.), the 
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maximum concentration of target would be ~800 nM. Even if a highly expressed target were 
completely saturated, this is far from the millimolar concentrations needed for CT contrast agents 
and well below the micromolar concentrations typically needed for MRI contrast. This also does 
not account for partial volume effects. Microbubbles are available for US contrast but targeting 
is limited to blood vessels. This leaves PET, SPECT, (both with picomolar sensitivity) and 
fluorescence (nanomolar sensitivity) for targeted molecular imaging. Non-targeted exogenous 
contrast agents in MRI, US, and CT must rely on changes in local physiology such as blood flow 
(small molecule contrast agents) or blood volume/permeability (for macromolecular contrast 
agents)24. An important exception is iron oxide nanoparticles for MRI contrast. These 
nanoparticles can be detected at lower concentrations than the common chelated gadolinium 
MRI contrast agents. Nanoparticles extravasate in areas of increased vascular permeability and 
are taken up by local macrophages, particularly in inflammatory environments. Efforts to target 
nanoparticles to specific receptors, however, have generally not worked due to poor washout of 
the nanoparticles from tissue (resulting in the enhanced permeation and retention, EPR, effect)25. 
Therefore, they target specific cells but not through the typical molecular binding of most 
targeted contrast agents. 
 
 Focusing on molecular imaging agents, which can be designed to provide signal 
specifically from the islets, PET, SPECT, and fluorescence are three modalities that have the 
necessary sensitivity. Despite this sensitivity, the selectivity for islets is challenging given their 
small volume fraction. Sweet et al. analyzed the targeting requirements for such a probe with 
estimates on the required selectivity and affinity that highlight the formidable challenges in 
probe development. In addition to the low volume fraction and partial volume effects, they also 
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considered the challenge of measuring a loss in signal over time before the critical functional 
islet mass threshold is reached and a patient exhibits overt diabetes. For imaging probes that can 
reach intracellular targets, the probes must be 1000-fold more specific for beta cells than 
exocrine cells. Even cell surface targeting probes that completely lack binding to exocrine cells 
require extremely high affinity and rapid clearance to lower the signal from the extracellular 
space17. Despite these stringent requirements, there are probes that are close to meeting these 
criteria, although further work is required. For two of the probes, vesicular monoamine 
transporter 2 (VMAT2) and glucagon-like peptide-1 (GLP-1) receptor targeted agents, 
discussion on the presence of receptor expression in the exocrine pancreas is particularly salient 
in light of these strict requirements.  Overall, an effective clinical agent will require a 
combination of a high expressing target, a high-fidelity probe with strong binding affinity, little 
to no interactions/uptake in off-target exocrine tissue, and fast systemic clearance. In spite of the 




MRI offers relatively high spatial resolution in a non-invasive manner free from ionizing 
radiation. Many clinical instruments are capable of imaging with voxel dimensions of 1mm × 
1mm × 1mm, but sub-millimeter resolution is possible with higher field strengths19. High soft 
tissue contrast and potential for use with imaging probes make this a useful tool in diabetes 
imaging. The modality also allows for prolonged visualization of the region of interest compared 
to radionuclides. To date, MRI has been used to image transplanted islets as well as to study 
insulitis in animal models. The high resolution and lack of ionizing radiation makes MRI an 
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attractive option for diabetes imaging, particularly in pediatric populations, but the inability to 
distinguish between exocrine and endocrine pancreas without contrast agents limits the modality 
to particles reacted ex vivo such as islet transplantation, particles taken up in vivo for imaging 
insulitis (Figure	1.2), and gadolinium contrast agents to measure changes in tissue physiology in 
the clinic. 
 
There are multiple studies using MRI to study the efficacy of islet transplantation as a 
means of replacing the BCM for patients with type 1 diabetes. During islet transplantation 
surgery, significant cellular losses may occur due to multiple reasons including autoimmune 
rejection, mechanical stress on the cells, glucose toxicity, and damage incurred within the islets 
such as microvascular damage during the isolation process7. To study ways of minimizing islet 
failure during transplantation, cells are first labeled with a contrast agent prior to surgery. In 
mouse models, Turvey and colleagues were able to purify islets, load the cells with 
superparamagnetic iron oxide (SPIO) nanoparticles, and then visualize the particles in diabetic 
and healthy mice on T2-weighted MR images26. Distinguishing between functional and non-
functional islets proved challenging although further studies by Kriz et al. suggested it may be 
possible to detect decreases in islet mass27.  
 
Insulitis is marked by multiple microvascular changes including increases in vessel 
permeability to small molecules, volumetric flow rate of blood to endocrine tissue, and the islet 
vascular volume7. These changes can be readily investigated using MRI contrast agents. 
Medarova et al. were able to detect vascular changes using a streptozotocin induced mouse 
model of type 1 diabetes28. T1-weighted MR images revealed increased accumulation of the 
gadolinium-based contrast agent compared to healthy mice. Another example includes MR 
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imaging using CD8+ lymphocytes, where cells first internalize dextran-coated SPIO 
nanoparticles in vitro, resulting in intracellular accumulation. The re-administered cells were 
used to track the immune response in animal models of type 1 diabetes using NOD mice and 
detected decreases in the parenchymal pancreas in NOD mice when compared to control 
animals29, 30.  
 
Gaglia et al. were able to visualize islet inflammation caused by microvascular changes 
through MR imaging of dextran-coated magnetic nanoparticles (MNP) taken up by 
monocytes/macrophages in the clinic31, 32. An earlier study using ferumoxtran as a negative T2 
contrast agent was able to elucidate differences in delta T2 between patients with type 1 diabetes 
and healthy controls. The change in T2 signal is associated with macrophage uptake of the 
MNPs. Heterogeneity in MNP accumulation was also detected, and these heterogeneities are 
supported from past pancreatic histology from cadavers. A more extensive study using FDA-
approved ferumoxytol and imaging advances such as higher field strength, optimized pulse 
sequences, and improved visualization tools measured increased levels of pancreatic 




Figure 1.2 MR imaging of insulitis. 
The iron-replacement therapy agent ferumoxytol accumulates in macrophages. The increase in 
△R2* is higher in the pancreas of recent onset type-1 diabetic patients (left) than the controls 
(right), shown for a slice (top) or 3D reconstruction (bottom). The data indicate heterogeneous 




Significant progress has been made towards a non-invasive monitoring technique using 
targeted nuclear probes. PET and SPECT are modalities that offer some of the highest sensitivity 
(picomolar detection) with tradeoffs in resolution compared to CT and MRI. Recent efforts to 
pair PET and SPECT with CT or MRI have helped address this shortcoming by overlaying a 
high-resolution anatomical image with the molecular PET/SPECT data. PET has a higher 
sensitivity than SPECT due to the coincidence detection rather than using a less efficient 
collimator for image formation. However, PET isotopes can be challenging to synthesize and 
many have short decay half-lives. The high sensitivity of these nuclear imaging techniques 
allows for multiple approaches in diabetes research including the use of radiolabeled ligands to 




Targeted Molecular Imaging 
Targeting cell receptors provides a robust method for labeling abnormal cells as well as 
monitoring disease progression and evaluating therapeutic response. A detectable label, which is 
typically chemically conjugated to the targeting moiety, allows researchers to track the targeting 
ligand in the tissue of interest. Two of the most promising biomarkers for targeted molecular 
imaging include vesicular monoamine transporter 2 (VMAT2) and glucagon-like peptide-1 
receptor (GLP-1R)2. Neither ligand is perfect, and the search for alternative imaging probes 
continues33, 34. However, both of these targets and associated imaging agents 
dihydrotetrabenazine (DTBZ and exendin derivatives, respectively) have demonstrated potential 
in proof-of-principle studies in the clinic and will be discussed in more detail. Antibody-targeted 
imaging and metabolic tracers are also mentioned as alternatives. 
 
Vesicular monoamine transporters regulate the uptake of cytoplasmic monoamines to the 
secretory granules in neuroendocrine cells. Although VMAT2 was first used in the 1990s as a 
target for PET brain imaging in Parkinson’s disease, more recent immunohistochemical staining 
revealed VMAT2 expression in the islets of Langerhans, making it an attractive target for beta 
cell imaging as well. DTBZ is a strong binder for VMAT2, with subnanomolar Kd values and 
greater than 10,000-fold selectivity over VMAT1 (also expressed in the endocrine pancreas), and 
holds promise given that DTBZ is a clinically approved PET tracer. [11C]-DTBZ has been 
traditionally used for neural imaging of VMAT2 with high specificity, and Freeby et al. were 
able to estimate rat BCM in models of spontaneous type 1 diabetes using this probe35. The probe 
also detected decreases in BCM in STZ-induced diabetic rats, although accumulation was not 
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detectable in baboons. Variable expression across species makes interpretation challenging, and 
rodent studies may show the targeting of pancreatic nerve tissue rather than islets themselves36.  
 
Figure 1.3 VMAT2 targeted PET agents. 
Immunofluorescent staining of a healthy human islet; insulin (A), VMAT2 (B), and DAPI (blue, 
C). Merged image indicates most insulin expressing cells also express VMAT2 (C). Scale bars 
are 30 um37. 
 
The short half life of C-11 (20 min) can lead to some challenges, so researchers have 
created F-18 derivatives (110 min half life) with high affinity38. In vivo imaging of pancreatic 
BCM in type 1 diabetic patients compared to healthy controls with these agents has yielded 
promising results, but challenges remain. Using the VMAT2 radiotracer [18F]-fluoropropyl-
dihydrotetrabenazine (18F-FP-(+)-DTBZ), Normandin et al. and Freeby et al. have measured 
significant differences in pancreatic standardized uptake and binding potential in healthy 
volunteers and patients39, 40. Higher-than-expected uptake of the radiotracer was measured in the 
body and tail of patient pancreata despite the near complete loss of functionality. Non-specific 
uptake of the radiotracer and/or possible exocrine expression of VMAT2 are possible 
explanations for the higher signal, although estimates for exocrine expression by Freeby et al. 
suggest a low contribution to overall measurements (<10%). Non-specific contributions were 
estimated using the negative enantiomer and showed that uptake in pancreata accounted for at 
most 15% of the total signal2. The measured reduction in binding potential in patients compared 
to healthy controls (26% reduction) and the decreases in binding capacity (63% reduction) 
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suggest VMAT2-targted tracers hold clinical promise. However, since multiple groups have 
obtained findings that indicate patients with long-standing diabetes, where the BCM should be 
negligible, show pancreatic accumulation of labeled DTBZ (e.g. Goland et al.41), further 
investigation is required. Improvements in accuracy and decreases in off-target signal are needed 
for efficient clinical translation including accounting for VMAT2 expression in PP cells18. 
Expression differences in common lab species make this a challenging endeavor36. 
 
Glucagon-like peptide-1 receptor (GLP-1R) is a member of Family B1 of G protein-
coupled receptors. Activation of the receptor plays an important role in glucose homeostasis 
where the natural ligand GLP-1 helps stimulate insulin secretion in pancreatic beta cells42. 
Therefore, this receptor is a target of several clinically approved treatments for type 2 diabetes43. 
GLP-1R is highly expressed in islets, making GLP-1 and its analogues strong candidates for beta 
cell imaging. The high expression, along with high vascularization of tissue within the islets, has 
led to the development of multiple GLP-1 analogues for beta cell targeting. Native GLP-1 is 
rapidly degraded by dipeptidyl peptidase (DPP-IV) resulting in a < 2 min half-life in the blood44. 
To avoid high lysosomal breakdown of GLP-1, Gao et al. incorporated a lactam bridge along the 
peptide backbone, leading to higher binding affinity as well45. Perhaps even more promising is 
the exendin-4 peptide, originally isolated from Heloderma suspectum, more commonly known as 
the Gila monster. Multiple bioactive compounds were isolated from the venom of this foot-long 
lizard, one of only two poisonous lizards, including exendin-446. This peptide displays 
remarkable in vivo stability. Wild type exendin-4 shares 53% homology to GLP-1 and binds to 
GLP-1R with subnanomolar affinity47. The peptide is currently approved for treatment of type 2 
diabetes, and the interaction between the ligand and GLP-1R is well characterized. Gotthardt 
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visualized GLP-1R receptor positive tissues through SPECT imaging using [111In]-DTPA-Lys40-
Exendin-4 through in vivo imaging and biodistribution measurements in rats and mice48. Mukai 
demonstrated successful blocking of GLP-1R using pre-administration of excess non-radioactive 
exendin followed by subsequent delivery of truncated exendin in the form of [125I]-Bolton-
Hunter Exendin (9-39)49. The development of [18F]-Exendin (9-39) by Toyoda et al. showed 
promising uptake in the pancreas at 30 min with receptor specificity confirmed by similar 
blocking experiments50. However, intracellular trapping of the agonist form (wild-type exendin-
4) may improve retention compared to the non-internalized exendin (9-39) antagonist. More 
recently, Brom et al. demonstrated pronounced differences in pancreas uptake with 111In-labelled 
exendin in five patients with type 1 diabetes51. Quantitative PCR results from human tissue also 
suggested a favorable expression of GLP-1R in the islets compared to exocrine pancreas, 
indicating low off-target signal in patients. Similar to VMAT2 imaging, challenges remain. 
Karlsson and colleagues point out that the Brom et al. results may not account for the shrinking 
pancreas size, which may confound measurements in healthy versus diseased pancreata33.  
 
 Despite the promising clinical results, a significant obstacle facing GLP-1 imaging is low 
GLP-1 receptor expression in non-beta cells. Although a diffuse signal was reported for human 
exocrine pancreas slides labeled with radioactive GLP-152, recent studies have presented a 
clearer picture of the localization of this expression in humans and animal models53, 54. Zhang et 
al. used quantitative flow cytometry and biodistribution measurements to estimate the expression 
on beta cells and non-beta cells and found ~55,000 GLP-1 receptors per beta cell in a transgenic 
MIP-GFP mouse model55. Based on the specific uptake (%ID/g difference between blocked and 
unblocked mice) and a 1% beta cell fraction, the beta cell targeting only accounted for 50% of 
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the specific signal. The other half appeared to be diffusely spread throughout the mouse 
pancreas. A lower expression in the exocrine pancreas (~850 GLP-1 receptors per cell55) could 
explain this non-beta cell specific labeling and is consistent with other studies showing exocrine 
expression. 
 
The low beta cell fraction in the pancreas makes the specificity of the target crucial to the 
success of a probe, and GLP-1R faces similar challenges as VMAT2 in this regard. Willekens 
argue that the uptake of exendin in mouse models indicate binding to a receptor other than GLP-
1R56. This is based on their findings of 1) a similarly high transcription ratio between endocrine 
and exocrine tissue in mice and rats but 2) a much lower in vivo uptake between these two 
tissues. The comparable transcript levels indicate that expression may be similar in the exocrine 
pancreas between these species, but this is challenging to verify at the protein (translational) 
level due to the poor specificity of GLP-1R mouse antibodies57. Functional expression of GLP1-
R has been reported in mouse acinar cells58, and slightly higher translation in mouse exocrine 
pancreas (resulting in higher target expression) could be the culprit for the low (5:1) uptake 
between endocrine and exocrine pancreas in mice versus 50:1 for rats. The 20 pmol dose of 
radiolabelled exendin may saturate the exocrine pancreas while the endocrine pancreas is 
strongly labeled but well below saturation due to higher expression. Higher doses, such as 200 
pmol to 2 nmol used in fluorescence imaging, saturate both endocrine and exocrine tissue, 
resulting in higher endocrine to exocrine ratios. 
 
Understanding the differences between mouse and rat pancreas (and other species such as 
pig and non-human primate53, 59) is crucial for preclinical studies, but ultimately the human 
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pancreas is most important for clinical translation. Animal studies are critical for understanding 
the disease, but they can sometimes be misleading, such as variable density of beta cells in islets3 
and differences in prevalence as a result of gender differences and unpredictability of disease 
onset in non-obese diabetic (NOD) mice60-62. Other animal models such as BioBreeding (BB) 
rats are lymphopenic and display a near absence of CD4+ and CD8+ T cells, deviating from type 
1 diabetes in humans63. For targeted molecular imaging for diabetes research, differences 
between animals and humans can significantly impact results as well. Given the challenges in 
imaging beta cell mass, even small changes in receptor expression or beta cell number can 
influence imaging outcomes in preclinical models. Willekens et al. state that the rat pancreas is 
similar to humans given the low levels of In-111 exendin seen in some type 1 diabetic patients. 
Brom et al. show very low non-specific uptake in humans, which appears promising. 
Alternatively, the variability seen in pancreas uptake could be impacted not just by variability in 
patient BCM but also variable exocrine pancreas expression, pancreas size, and potentially non-
specific uptake due to inflammation51. There are several studies indicating GLP-1R expression in 
the human exocrine pancreas with radiolabelled GLP-152 and extensively validated antibodies53, 
54. Whether this off-target expression is sufficient to interfere with beta cell quantification is 
currently unclear.  
 
Although In-111 is not an ideal radioisotope for imaging (SPECT tracer versus PET, beta 
and Auger electron emissions, a longer half-life than needed), it is important to note that In-111 
exendin does have some of the best imaging agent targeting properties for a cell surface receptor. 
The low plasma protein interactions result in extremely low non-specific interactions as seen by 
the high blocking efficiency when delivered with high doses of cold exendin48, 51. Tc-99m and 
	21	
Ga-68 can suffer from non-specific interactions that decrease endocrine pancreas uptake and/or 
increase non-specific signal64. Cu-64 labeled peptides appear to have better pharmacokinetics 
than technetium and gadolinium65, but the islet uptake is slightly lower and the blocked pancreas 
(non-specific) uptake slightly higher than In-11166. Whether the higher sensitivity of PET 
outweighs these effects remains to be determined. In-111 is also a residualizing isotope, which is 
important for rapidly internalized agonists, such as exendin-4, that are trapped within the cell to 
avoid washout of probes that occurs even with seemingly high single-digit nanomolar affinity6, 
25. This is in contrast to isotopes such as iodine and F-18 that can wash out of the target cells 
upon internalization and degradation (depending on the linker and associated chemistry67).  
 
Antibodies specific to beta cell surface proteins that bind with high affinity have also 
been investigated as probes for BCM imaging and quantification. Several monoclonal antibodies 
(mAbs) have been reported that bind specifically to beta cells68, 69. These large (~150 kDa) 
proteins recognize specific epitopes through their variable regions, and their slow clearance 
results in efficient targeting. IC2, a rat IgM monoclonal antibody, is known to bind to sulfatide 
expressed on the beta cell surface in the insulin granula70. Results of the study using [111In]-
DTPA-IC2 were promising and demonstrated high uptake and specificity as well as high 
correlation between antibody accumulation in the pancreas and BCM between diabetic and 
healthy animals. However, several limitations exist for radiolabeled antibodies in the clinic, 
particularly the high background activity due to slow systemic clearance. Hampe and colleagues 
used fragments of K14D10 IgG to demonstrate that antibody fragments are able to clear systemic 
circulation quickly and bind to beta cells with high affinity71. However, analysis of the 
pharmacokinetics of protein imaging agents indicate the most efficient uptake occurs for either 
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very low molecular weight probes (< 3 kDa)6 or monoclonal antibodies25, with low molecular 
weight probes providing more efficient background clearance than the latter. 
 
 Serotonin synthesis is localized in islets and measurements of biosynthesis activity can be 
used to potentially quantify beta cells. One strategy uses a radiolabeled serotonin precursor 
hydroxy-tryptophan (HTP). Serotonin synthesis in healthy pancreata will result in the 
accumulation of radiolabeled precursor whereas pancreas from patients with type 1 diabetes will 
lack the molecular machinery required for synthesis72. Although both exocrine and endocrine 
cells take up HTP, the precursor molecule is quickly trafficked out of the cell unless it’s 
metabolized. Eriksson and colleagues demonstrated accumulation of [11C]5-HTP in the pancreas 
of healthy volunteers, noticeably in the tail and body regions where islets are more abundant. 
Compensating for loss of pancreas volume in patients, there was an observable decrease in tracer 
accumulation in diabetic pancreata (0.0028 %ID/g vs., 0.0046 %ID/g for patients and volunteers, 
respectively) between 40 and 60 minutes post-administration34. Because all neuroendocrine 
tissue undergoes serotonin biosynthesis, the tracer is not specific to beta cells, indicating that the 
near total beta cell loss found in patients with longstanding type 1 diabetes will result in only 
partial signal loss. Despite these challenges, [11C]5-HTP has potential for use in islet 
transplantation and regenerative therapies. 
 
Highly specific ligands to markers unique to beta cells are a challenge to develop. One of 
the reasons the debate over the significance of low-level expression in non-beta cell tissue for 
several imaging probes continues is due to the challenging circumstances from the small islet 
size and partial volume effects. For example, in cancer imaging, a few thousand EGFR receptors 
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per cell in healthy tissue would not be a major concern when imaging a tumor with a million 
EGFR receptors per cell. However, the 1% mass fraction of islets makes even low expression 
extremely pertinent. Also important is the non-specific uptake of probe in healthy tissue, 
particularly for residualizing radioisotopes that will be trapped in background tissue even once 
the plasma and interstitial probe has cleared. Even subtle changes to the molecule, such as the 
radiolabel, can impart large changes in protein interaction and non-specific uptake rates. These 
considerations, and differences between animal species used for preclinical testing and humans, 
remain an important consideration for all probes, including VMAT2 and GLP-1R. 
 
 
Nuclear Imaging of Insulitis 
To date, non-invasive PET methods for imaging insulitis include labeled lymphocytes 
and labeled peptide and protein ligands specifically targeting lymphocytes. The labeling of 
lymphocytes is performed ex vivo and cells are re-administered intravenously post-labeling. 
Ideally, the systemic circulating lymphocytes will migrate to the inflamed pancreatic tissue due 
to cytokine and chemokine signaling. Results from re-administered lymphocytes showed poor 
pancreas targeting in patients and animal work indicated uptake in the pancreas for both the 
control and test groups. As a result, the technique using labeled lymphocytes does not appear to 
be specific. A promising alternative for insulitis imaging involves radiolabeling interleukin-2 
(IL-2) with SPECT tracers. In short, uptake of [123I]-IL-2 resulting from lymphocyte invasion in 
the pancreas of non-obese diabetic (NOD) mice was quantifiable. Promising in vitro and in vivo 
results including high specificity and retention prompted administration of radiolabeled IL-2 in 
humans. Patients with a high risk of type 1 diabetes were also dosed and showed clear pancreatic 
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uptake as well73. Additional SPECT tracers have been used including Tc-99m with similar 
qualitative results. However, additional improvements are needed for accurate quantification. A 




Fluorescence imaging uses visible or near-infrared light to detect a dye with high spatial 
resolution (< 1 µm) and sensitivity (nM range). The excitation wavelength photon excites the 
dye, and a longer wavelength photon is emitted. Near-infrared fluorescent dyes are often used 
due to reduced background (autofluorescence) and higher tissue-penetrating properties of the 
light. Similar to radiolabeled ligands for PET/SPECT, a fluorophore is attached to a targeting 
ligand to generate the probe. Commonly, a commercially available dye is chemically conjugated 
to the targeting ligand using common chemistries (ester-amine reactions, maleimide-sulfhydryl 
linkages, azide-alkyne click chemistry or copper-free click reactions, etc.) to create the imaging 
probe, which is then administered to a patient or animal to label specific antigens. Although near 
infrared light can travel through several centimeters of tissue74, the tissue is highly scattering. 
Even a large difference in contrast between the target and background can be lost as the signal 
‘blurs’ under increasing tissue depth. Due to the scattering and absorption associated with 
fluorescence imaging, it is not possible to develop a fluorescent probe that will allow for non-
invasive real-time monitoring of BCM, where MRI or PET/SPECT may be more appropriate. 
However, the high resolution and ease of handling of fluorescent materials compared to 
radionuclides—including the ability to resolve subcellular structure and trafficking—make it an 
invaluable tool for research use in imaging agent design. Some pertinent parameters that can be 
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measured using fluorescent molecular imaging include receptor expression quantification, 
binding affinity, internalization rate measurements, plasma protein interactions, and imaging 
agent stability. 
 
With the availability of reactive fluorophores and fluorescent proteins, including near 
infrared (NIR) probes with higher penetration depths, there is increased use of fluorescent 
microscopy for determining localization of biomolecules under normal and diseased conditions. 
Hara et al. stably generated transgenic mice with the specific expression of green fluorescent 
protein (GFP) in the insulin-producing beta cells75. The tool has improved flow cytometry 
analysis and quantification of BCM ex vivo, although low imaging depth and poor optical 
properties of GFP preclude this method’s use for in vivo quantification. Given the low absorption 
of near infrared light by hemoglobin, NIR probes are quickly gaining popularity for labeling 
targeting ligands. For example, Reiner et al. chemically conjugated an NIR fluorophore via 
copper-catalyzed click chemistry to exendin-4 to generate a highly specific beta cell binder and 
demonstrate the loss in signal following streptozotocin treatment of mice76. 
 
Fluorescence Imaging for Molecular Probe Design 
The high resolution and real-time imaging of fluorescent probes make them excellent 
tools for insight into molecular probe design.  For example, the rapid internalization and 
intracellular trapping of exendin derivatives visualized through live cell imaging provides insight 
into the necessary affinity for these imaging agents. Distinct from the original analysis performed 
by Sweet et al.17, the fast internalization rate results in effectively irreversible binding, so the 
requirement for binding affinity for internalized and residualizing probes (those trapped within 
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cells following internalization) is not as strict as originally postulated. (In Sweet et al. it is 
assumed no internalization occurs and binding is at equilibrium.) Internalization and trapping 
using residualizing isotopes and/or linkers is an effective method to lower the required binding 
affinity and reduce washout of probe6. Notably, the slowly internalized exendin antagonist 
(exendin 9-39) is not an appropriate imaging agent, likely because it is not rapidly internalized 
and therefore it is subject to the strict affinity requirements for low molecular weight probes25.  
 
In addition to cellular trafficking, fluorescent derivatives can provide insight into absolute 
expression of imaging targets. Flow cytometry analysis of digested pancreas from mice that were 
administered fluorescent exendin-4 has provided absolute measurements of the accessible GLP-1 
receptor expression in vivo. Absolute expression levels can be difficult to measure, but they can 
assist researchers in determining the optimal dose, blocking doses, and required affinity. 
Fluorescent derivatives for VMAT2 targeting are more challenging to develop given its 
intracellular location. However, the recent report of a fluorescent derivative may aid in the 
understanding of VMAT2 targeting in the context of diabetes77. For these targets and others, a 
subsaturating dose is typically ideal to achieve maximum contrast between binding of probe in 
the target versus background tissues. This is balanced against a need for sufficient signal 
depending on the imaging modality. (For example, fluorescent doses are often higher than 
radiolabeled doses for animal imaging.) 
 
 Given the extremely small fraction of islets in pancreatic tissue, non-specific targeting 
and uptake, even in low quantities, can result in drastic overestimates for BCM. Fluorescently 
labeled ligands have been used to correlate non-specific in vivo uptake with plasma protein 
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binding and non-specific in vitro cellular uptake6. This may enable rapid in vitro screening for 
molecules with low non-specific uptake in vivo. Fluorescently labeled exendin-4 derivatives 
were used to show that probes with increased plasma protein binding also had higher non-
specific cellular uptake rates, which can contribute to background signal. Even if the bound 
exendin were internalized and trapped within beta cells, a long washout period before imaging 
would provide little benefit if the non-specific signal were also internalized. The longer washout 
would reduce extracellular probe that could intravasate into the blood and clear systemically, but 
the internalized probe would leak out of the beta cells and other cells at approximately the same 
rate. It is important to be cognizant of the impact of fluorophore conjugation on imaging agent 
properties similar to how chelators impact radiolabeled probes (along with the targeting ligand 
itself). The lipophilicity of a fluorophore can significantly impact clearance rates and the degree 
of off-target interactions. A parallel exists in radioimaging where additional chelator 
hydrophilicity may reduce sticking78, 79. This may be one reason why the In-111 labeled exendin 
was able to show large differences in the clinic51. Chelated In-111 is known to have very low 
interactions with plasma proteins, and In-111 has shown excellent specificity by having very low 
uptake in blocked controls in animal models80. 
 
Ultrasonography and Computed Tomography 
Abdominal ultrasonography (US) and computed tomography (CT) are common 
techniques used for traditional pancreatic imaging. Due its non-invasive nature, lack of ionizing 
radiation, and abundance in the clinic, US is one of the most frequent diagnostic tools. Although 
organ functionality and anatomical structures can be visualized, US is rarely used to detect the 
structural changes that occur during type 1 diabetes, and the modality faces numerous challenges 
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for quantifying and visualizing islets7. Computed tomography (CT) is an imaging technique used 
to visualize the anatomy of the pancreas due to differences in x-ray attenuation between tissues. 
Within the pancreas, however, both exocrine tissue and the islets share a similar density, making 
it difficult to differentiate between the two with available CT scanners. Though not suited for 
islet visualization, CT has been used to monitor tissue modifications during pancreas 
transplantation81. These methods have also been used to measure the size of the pancreas. The 
lower organ weight seen in some studies may complicate the interpretation of loss in beta cell 
mass, which could reflect a lower pancreas volume. Though not as common as type 1 and type 2 
diabetes, monogenic diabetes mellitus displays multiple characteristics that are detectable with 
traditional US and CT imaging including increased US reflectivity and reduced X-ray attenuation 
on CT82. Therefore, these modalities play an important secondary role in pancreas imaging. 
 
Multi-modal Imaging 
The tradeoffs of different imaging modalities for detecting and treatment of type 1 
diabetes including islet transplantation therapy and beta cell quantification suggest there may not 
be one ideal modality for this purpose, mirroring conclusions found in other diseases such as 
cancer.  Because of these non-overlapping weaknesses, multi-modal imaging, which combines 
methods such as PET/MRI, has gained use for clinical diagnostics. For example, PET images can 
provide functional information whereas MRI provides the complementary high-resolution 
anatomical images83. Medarova et al. have detailed a method of islet transplantation that allows 
for facile monitoring post-surgery using both MR imaging and optical imaging in mice84. The 
MN-NIRF (superparamagnetic iron oxide nanoparticles conjugated with a near-infrared probe) 
particles label islets with fluorescent imaging to corroborate MRI results. Combinations of 
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fluorescence and PET have been used to target N-glycoprotein with a monoclonal antibody 
specific for transmembrane protein 27 (TMEM27) and achieved measurable uptake in 
insulinoma xenografts in mouse models85. The expansion of multi-modal imaging will likely 
expand given the intrinsic drawbacks of each individual modality. 
 
1.4 Molecular Imaging Outside the Pancreas in Diabetes 
 Molecular and metabolic imaging outside of the pancreas is primarily focused on 
quantifying changes in metabolism and insulin resistance in organs such as the liver and skeletal 
muscle given the importance in type 2 diabetes. Additional studies have focused on pathological 
effects in organs such as the kidney and heart, which are common in the disease. Even with the 
important pathological role of insulin resistance, the failure of beta cells is considered the main 
culprit in the conversion to diabetes86. Although most diabetes research involves visualizing the 
pancreas, imaging other organs has increased our understanding of the pathogenesis of the 
disease, and examples of such studies are outlined below.  
 
 The most common techniques for examining metabolic changes associated with diabetes 
use radiolabeled metabolites for PET and SPECT imaging, magnetic resonance spectroscopy, 
and more recently, hyperpolarized MRI. Radiolabeled agents for metabolic studies include 18F-
fluorodeoxyglucose (FDG) for quantifying glucose metabolism, [11C]-palmitate and [123I]-
BMIPP (beta-methyl-p-iodophenyl-pentadecanoic acid) for measuring fatty acid utilization with 
PET and SPECT, respectively, and [11C]-glutamate and [11C]-methionine for amino acid 
metabolism87, 88. For example, impaired glucose transport and phosphorylation in response to 
insulin using PET has been demonstrated in skeletal muscle, the most important tissue for insulin 
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resistance, and results suggest there are deficiencies in glucose phosphorylation in the 
pathogenesis of type 2 diabetes89. This is consistent with magnetic resonance spectroscopy 
studies90, and similar results have been shown for the liver91.  [11C]-palmitate has shown the 
reduced conversion of fatty acids into triglycerides in muscle for obese patients, a major risk 
factor in type 2 diabetes. Brehm and colleagues measured reductions in insulin-stimulated ATP 
synthase flux due to increases in lipid availability for patients with insulin-sensitivity. These fatty 
acids are important regulators of glucose metabolism, further impacting insulin-mediated glucose 
utilization92. Other studies have focused on the pathological effects of diabetes in different organ 
systems. Recently, a hyperpolarized redox sensor, [13C]-dehydroascorbate (DHA) has been used 
to show reduced redox capacity prior to the onset of nephropathy in a diabetic mouse model93. 
Particular emphasis has been placed on imaging the heart due to the increased risk of 
cardiovascular disease in diabetic patients. Blood flow imaging (201Tl, 99mTc tetrofosmin, 99mTc-
sestamibi) and glucose metabolism (FDG) have been used to detect mismatch between perfusion 
and viable tissue after myocardial infarction87, which is more prevalent in diabetics. Specifically 
for diabetes, studies on metabolism include magnetic resonance spectroscopy, which has shown 
increased triglyceride content in the heart94. Molecular imaging will continue to develop in these 
areas to improve our understanding of the multi-organ pathological impact of the disease.  
1.5 Future Directions for Imaging Beta Cells 
Molecular imaging in diabetes has primarily focused on the endocrine pancreas given its 
central role in controlling glucose metabolism. The small size and low volume fraction of islets 
of Langerhans in the pancreas place considerable limitations for current imaging modalities. To 
date, a robust and widely adopted approach for quantifying beta cell mass remains elusive. This 
is a major limitation for researchers in the field when studying disease onset, progression, and 
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treatment options. The use of highly specific targeting ligands to bind defined biomarkers on 
beta cells in PET and SPECT imaging are making progress towards the goal of clinical 
quantification of beta cell mass. The high resolution and ease of use of fluorescence imaging 
make this an increasingly valuable tool for aiding in the design of improved imaging agents. In 
addition to quantifying beta cell mass through imaging, the early stages of type 1 diabetes 
characterized by insulitis and the multi-organ effects of metabolism in type 2 diabetes have also 
been investigated as well using multiple modalities including MRI, PET, SPECT, fluorescence 
imaging, and bioluminescence. Each modality has a unique set of strengths and drawbacks and 
each plays a crucial imaging role in studying the disease. The non-invasive nature of MRI and 
PET/SPECT and sensitivity to molecular markers (e.g. molecular resonance spectroscopy and 
hyperpolarized MRI contrast agents and radioactive PET and SPECT tracers) make these key 
modalities for clinical translation.  
 
 One of the biggest challenges for the future of this field remains the development of a 
robust imaging method for beta cell mass. What new approaches could help facilitate the 
development of such a probe (or adaptation of current probes to yield more reliable results)? 
Absolute quantification of target expression (across species and in humans), delivery rates (blood 
flow, vascular surface area, etc.) under various disease states, and probe properties (plasma 
clearance, cellular uptake and retention, binding affinity, etc.) can greatly facilitate the 
development of improved agents and interpretation of experimental results. For example, 
knowing the absolute number of GLP-1 receptors on endocrine versus exocrine cells rather than 
relative expression can facilitate strategies for improving specificity. Some of the basic 
principles of targeting specificity can be incorporated into screening methods34 provided the in 
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vitro expression profiles capture the in vivo situation.  At the same time, it is important to revisit 
the assumptions of earlier analyses, since new probes may act by different mechanisms. For 
example, GLP-1R agonists and tryptophan precursors act by cellular trafficking and 
residualization rather than a simple binding interaction, thereby side-stepping some of the 
affinity limitations outlined in earlier analyses. Fortunately, a plethora of models exist to 
describe the pharmacokinetics of these types of agents (including FDG) that can be used to scale 
the results to animal and possibly human studies24, 95. 
 
In silico simulations of molecular distribution continue to improve and may be adapted 
for pharmacokinetic simulations of imaging agents. For the purpose of the discussion here, 
simulations differ from models in that simulations require little to no experimental data to predict 
in vivo outcomes. In contrast, models often use extensive experimental data and are fit to the 
results. For intracellular targets, simulations of first-in-animal and first-in-man drug distribution 
could be adapted (with suitable adjustments for targeting in tissues) to describe specific and non-
specific distribution of small molecule probes96. Similarly, non-steady state simulations of probe 
distribution6, 97 can aid in the design of extracellular targeted agents. The use of in silico 
techniques can help guide experiments with current probes as well. As mentioned previously, 
recent evidence indicates that GLP-1R is expressed at very low levels in the exocrine pancreas in 
several species, including humans. Based on estimates of GLP-1R expression in mice and 
quantitative blocked and unblocked biodistribution, the expression is ~850 receptors per cell. 
However, this lower expression is significant versus endocrine uptake in the whole pancreas due 
to the low volume fraction of beta cells. If this low level expression in the exocrine pancreas 
could be blocked specifically without completely blocking the beta cell receptor expression, the 
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beta cell specificity of a subsequent radiolabeled agent would be greatly improved. The low 
molecular weight of exendin is close to optimal for an extracellular target in fenestrated tissue 
such as the pancreas, but it is still limited by permeability (the permeability surface area product, 
or PS/V) and not blood flow. Assuming the fenestrated permeability is similar between the 
endocrine and exocrine pancreas, the relative uptake is determined by the surface area. Estimates 
of S/V (cm2/cm3) for endocrine and exocrine pancreas are 505 and 182 respectively5, 98. 
Although delivery to the exocrine pancreas is expected to be about 3-fold lower, the amount of 
probe required to block these receptors is >10-fold lower than what would completely block islet 
uptake. Therefore it is theoretically possible to block this low exocrine signal without blocking 
the beta cell receptors using a low dose of unlabeled peptide, and in silico simulations can be 
used to identify the appropriate scheme. (In contrast, the close association between non-target 
cells expressing VMAT2 and reversible binding of DTBZ versus the ‘irreversible’ internalization 
of GLP-1R make blocking less feasible for VMAT2.) ‘Cold dosing’ using non-radioactive 
probes, has extensive precedent in the literature including the use with radiolabelled antibodies99, 
100 and in antibody drug conjugate delivery101. It is important to clarify here that ‘low dose’ 
refers to a dose that does not saturate the islets but does saturate the lower expression within 
exocrine tissue. Therefore, it may be much higher than the trace amounts of radioactive probe 
injected. A potential complication would be nausea and emesis seen with large doses of exendin, 
although these symptoms may be controlled for a single imaging session or an antagonist could 
be used. This may provide one avenue to improve specificity. 
 
 Another concern for agents delivered to sites of inflamed tissue includes accounting for 
changes in local transport properties due to the inflammation itself. For example, many probes 
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will have a higher effective permeability in the inflamed tissue during insulitis, potentially 
increasing local probe uptake. A structurally similar non-binding probe could be used to quantify 
the impact of inflammation on imaging agent concentration in the inflamed local environment. 
This could be critical if some of the significant inter-individual variability seen in clinical trials is 
due to differences in delivery and not just differences in beta cell mass102. SPECT offers the 
possibility of gating on two gamma ray energies, providing ‘two-color’ imaging, and adaptations 
for use with PET are being explored103. This could be employed for binding and non-binding 
controls95 to normalize results to differences in probe delivery from inflammation. Recently, 
Mathijs and colleagues used this dual isotope approach for delineating the pancreas relative to 
surrounding organs, such as the kidneys, in mouse imaging104. 
 
1.6 Design of Novel Exendin-based Probes 
Due to its optimal molecular weight and strong binding affinity for GLP-1R, the exendin 
model system is used to quantify the beta cell mass in vivo. Alanine scans of exendin-4 and data 
from Clardy et al. indicate multiple amino acid residues may be modified with little impact on 
binding affinity105, 106 for fluorophore conjugation. Seemingly safe residues include lysine at the 
12th position, methionine at the 14th position, and leucine at the 21st position. Given the presence 
of free amines in exendin-4, NHS ester and carbodiimide chemistries will not be used. Rather, 
click chemistry, with advantages such as bioorthogonality, stability, and low toxicity will be 
employed to conjugate various NIR dyes107. A recent solution for functionalizing proteins with 
bioorthgonal reactivity is to introduce L-azidohomoalanine into the peptide sequence during 
solid phase peptide synthesis or through methionine substitution in bacteria108-112. The free azide 
(N3) can be used to react to free alkynes on fluorophores or linkers. 
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Molecular weight is one probe parameter that can be easily adjusted using the azide 
moiety and is known to influence in vivo trafficking and transport properties such as vessel 
permeability, internalization, binding affinity, and biexponential decay parameters25, 113-115. For 
example, increasing molecular weight of a peptide may slow plasma clearance, but it may hinder 
cell surface binding. Kim et al 116, 117 successfully synthesized PEGylated dimeric exendin-4 
slower plasma clearance, and greater antihyperglycemic efficacy (exendin-4 is an FDA-approved 
drug for treating symptoms of Type 2 diabetes) but decreased binding affinity. For a therapeutic 
drug, the benefits of a higher molecular weight exendin are obvious. However, the molecular 
weight tradeoffs for exendin as an imaging agent are difficult to predict, hence the need for a 
mathematical model. For example, an extremely small imaging agent will leak out of plasma and 
quickly bind to GLP-1R; unbound probe will then quickly leak back to plasma. This in theory 
will give low background when imaging because probe residence time in the islets is relatively 
short; however, β-cells have little time to bind and internalize probe (internalized probe cannot 
leak out of cells back into plasma and is advantageous for imaging). On the other hand, a larger 
probe has a longer residence time in the islets, potentially causing a higher background signal 
when imaging. On the upside, β-cells will have more time to bind and internalize the probe, 
which improves imaging signal at longer times post injection. For the aforementioned reasons, 
both smaller and larger probes have the potential to be robust imaging agents, and modeling 
based on data collected from different molecular weight probes will help identify the optimal 
size. 
Ensuring low non-specific uptake of probe in tissue surrounding the pancreas will result 
in high signal to background ratio during imaging. Biodistribution studies indicate kidney uptake 
of exendin is 2-3 orders of magnitude higher on a per mass basis than other organs 76, 118-120. 
	36	
Because the kidneys are situated directly beneath the pancreas, reducing NIR-tagged exendin 
uptake in the kidney will help visualize the pancreas during imaging. Many peptides are 
degraded by proteases situated on the brush border of proximal tubule cells. Dipeptides are then 
endocytosed in the proximal tubule to recycle the amino acids, and associated tags are often 
trapped in these cells. Reducing proteolysis in the kidney may decrease renal uptake. However, 
Vegt et al showed cells expressing megalin in the kidney facilitated renal reabsorption of 
radiolabelled exendin118. Upon binding to megalin, exendin is endocytosed and degraded; the 
radiolabel may residualize depending on its chemical properties. Modifying exendin to resist 
proteolysis and megalin-mediated internalization and/or using a non-residualizing 
fluorophore/linker may help decrease kidney signal.  
	
	
1.7 Stabilized Peptides 
Peptides are in an ideal molecular weight range for efficient tissue targeting but suffer 
from protease instability. One strategy to improve protease stability, binding affinity, and helicity 
is through helix stabilization. Stabilizing, or conformationally restricting, the alpha helical 
secondary structure of peptides has been an exciting new technique for protein engineering121. 
The poor performances of many current peptide biologics are often a result of their poor stability.  
By engineering them to be more stable, proteins can function under a wide range of harsh 
conditions such as extremes in temperature and pH or protease digestion. Although the use of 
salt bridges, lactam bridges, and disulfides have been used previously as natural means of 
stabilizing alpha helices, recent breakthroughs, including novel side-chain cross-linking 
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chemistry and the expression of non-natural amino acids in bacteria, have renewed a growing 
interest in ‘stapled’ peptides121-125. 
Alpha helices are the most prevalent secondary protein structure. One turn of an alpha 
helix consists of 3.6 amino acid residues stabilized by intrachain hydrogen bond interactions 
between the i and i+4 residues. For this reason, previous work at stabilizing various peptides 
often crosslinked i, i+4 or i, i+7 residues126, 127. Despite progress being made at studying how to 
stabilize peptides, there has been slower progress on stabilization of peptides that bind to specific 
targets, such as exendin. 
Stabilizing exendin to resist proteolysis may allow it to clear from the kidneys without 
being reabsorbed, resulting in lower unwanted kidney signal during imaging. Bird et al 
demonstrated that by introducing multiple small staples across the backbone of the peptides 
including exendin, the resultant structures were more resistant to enzymatic digestion and had 
improved helicity124. Exendin, a peptide mostly helical by nature42, could benefit from additional 
helicity with higher affinity for cell surface receptors. 
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In conclusion, there are key challenges that must be overcome to develop an imaging 
agent for the clinic moving forward. One, there must be improvements in the specificity of PET 
and SPECT beta cell targeting probes as they represent the most advanced and well-
characterized approaches for BCM assessment in humans. The promising results in the clinic for 
both VMAT2 and GLP-1R targets still show overlap between healthy controls and type 1 
diabetics, which is short of the desired goal of quantifying a graded loss in beta cell mass. Two, 
the clinical application must be clearly defined for different imaging modalities. For example, 
given the radiation concern in pediatric populations, can a composite score of MRI measured 
inflammation, autoantibody titer, and other clinical data (e.g. functional tests) provide enough 
information for measuring patient response to treatment? Each of these methods has drawbacks 
individually, but progress in several areas may allow reasonable measurements of clinical 
response. One could envision PET/SPECT imaging playing a critical role in clinical trials for 
developing new treatments while MRI methods would be used for clinical practice to avoid the 
safety risk associated with ionizing radiation. Lastly, there is a need for more emphasis in 
imaging agent design. Due to the complexity of imaging beta cells, a clinically reliable probe 
needs to display ideal pharmacokinetic properties including high target uptake, low systemic 
concentrations during imaging, very low non-specific sticking to proteins, and next to zero off-
target uptake for maximum contrast. Given the expense of developing new probes and imaging 
techniques, particularly those requiring large animals, in vitro and in silico experiments can help 
guide the rational design of probes, efficiently set up animal experiments, and help interpret the 
results to maximize the information gained from animal imaging. These probes can facilitate our 
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understanding of diabetes, open up opportunities for new drug targets, and monitor progress in 
clinical trials to improve the outcome for this increasingly prevalent and costly disease. 
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Chapter 2 
Mechanistic And Quantitative Insight Into Cell Surface Targeted Molecular Imaging 
Agent Design 
2.1 Publication Information 
Zhang, L.*, S. Bhatnagar*, E. Deschenes, and G.M. Thurber. Mechanistic and quantitative 
insight into cell surface targeted molecular imaging agent design. Scientific Reports, 2016; 
25424 
	 	
Modifications	have	been	made	 to	 the	published	document	 to	 adapt	 the	 content	 to	
this	text.	The	goal	of	this	chapter	is	to	identify	key	properties	for	successful	peptide-based	
molecular	 targeted	 imaging	 agents.	 Identifying	 these	 properties	 will	 help	 aid	 in	 the	
development	of	a	successful	imaging	agent	for	targeting	beta	cells	for	type	1	diabetes.	
2.2 Abstract 
Molecular imaging agent design involves simultaneously optimizing multiple probe 
properties. While several desired characteristics are straightforward, including strong affinity and 
low non-specific background signal, in practice there are quantitative trade-offs between these 
properties. These include plasma clearance, where fast clearance lowers background signal but 
can reduce target uptake, and binding, where high affinity compounds sometimes suffer from 
lower stability or increased non-specific interactions. Further complicating probe development, 
many of the optimal parameters vary depending on both target tissue and imaging agent 
properties, making empirical approaches or past experience difficult to translate. Here, we focus 
on low molecular weight compounds targeting extracellular receptors, which have some of the 
highest contrast values for imaging agents. We use a mechanistic approach to provide a 
quantitative framework for weighing trade-offs between molecules. Our results show that 
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specific target uptake is well-described by quantitative simulations for a variety of targeting 
agents, whereas non-specific background signal is more difficult to predict. We compare two in 
vitro experimental methods for estimating background signal in vivo – non-specific cellular 
uptake and plasma protein binding. Together, these data provide a quantitative method to guide 
probe design and focus animal work for more cost-effective and time-efficient development of 
molecular imaging agents. 
 
2.3 Background 
Targeting cell surface receptors provides a robust method for identifying abnormal tissue, 
monitoring disease progression, and quantifying therapeutic response128. Typically, a detectable 
label (e.g. radioactive isotope, fluorescent dye, MRI, CT, or ultrasound contrast agent) is 
chemically conjugated to a targeting ligand to create the imaging agent. These agents are then 
administered to a patient or animal to target tissues that express antigens specific to the targeting 
ligand. Monitoring the targeting compound in vivo provides valuable insight into diverse 
biological processes such as cell signaling, tumor growth rates, and drug response depending on 
the system studied.  
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Scheme 2.1 Diagram of interplay between imaging probe properties and tissue properties 
	
	
 In vivo cell surface targeting is a complex interplay between tissue and imaging agent 
properties (Scheme	2.1). Investigators can manipulate the chemical or physical properties of the 
ligand by adding or removing functional groups to alter molecular weight, charge, affinity, and 
stability25, 129, 130. For example, molecular weight can be manipulated with recombinant 
proteins131, 132 or through PEGylation of small molecules to slow blood clearance129, 133. Plasma 
protein binding can also be manipulated through the net charge and charge distribution of small 
molecules134, 135. More recently, stabilization of peptide secondary structure has been used to 
increase cellular uptake and resistance to proteases, allowing for imaging at longer times124, 136, 
137. Equally important are the tissue properties and local physiology, which can vary widely 
between different tissues and in healthy versus diseased states138, 139. Depending on the target 
tissue, intrinsic transport parameters such as blood flow (Q) and blood vessel surface area to 
volume (S/V) vary. The diverse local physiology results in tissue-specific optimal imaging agent 















results. Likewise, computational approaches originally developed for therapeutics often require 
extensive experimental data or assume a pseudo-steady state drug concentration, which is not 
appropriate for imaging agent design. Many imaging agent models have been used to 
quantitatively analyze experimental data95, but these compartmental models were not designed to 
predict distribution based on probe properties. Therefore, most imaging agents are developed on 
a case-by-case basis with low throughput and cost intensive animal experiments. While a 
qualitative understanding of in vivo conditions offers insight on which parameters play a role in 
targeting, a quantitative model that is both mechanistic and predictive allows for much more 
efficient design of imaging probes.  
 To help guide the design of novel imaging agents against extracellular targets, we present 
a quantitative and mechanistic model for describing target tissue uptake and background signal. 
These simulations build on previously published models that incorporate the time-varying and 
spatially heterogeneous tissue concentrations present under non-equilibrium conditions following 
a bolus dose. The trade-offs in molecular properties can then be quantitatively compared for 
selection of the most promising agents to move forward with imaging probe development. 
 
2.4 Results 
A simplified system was used to identify the most important parameters for maximizing 
contrast under optimal conditions. Assuming a high affinity binder with no blood flow 
limitations, first-order uptake in background tissues, and probe degradation rates that are much 
slower than plasma clearance and internalization (SI), the maximum target to background ratio 
(TBR) can be expressed as 
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where P is the vascular permeability of the target tissue, S/V is the tissue vessel surface area to 
volume ratio, ε is the tissue interstitial void volume, and kint,ns is the non-specific internalization 
rate in background tissue. Based on these results, the salient design parameters for targeting 
contrast are molecular weight (impacting P), stability/residualization of the label, and non-
specific interactions. The optimal values of these parameters depend on the tissue blood flow, 
vessel-type, vessel surface area, target expression, and internalization rate. 
Table 2.1 Tissue physiology versus molecular weight 
Tissues Plasma flow 
(mL/min/g) 
Vasculature type S/V  
(cm-1) 
Imaging agent Mw 
(50% extraction, Da) 
Bone 0.29 Non-fenestrated, loose junctions 144 <570 
Heart 4.06 Non-fenestrated, loose junctions 211 <100 
Kidney 1.91 Fenestrated 350 <3600 
Liver 0.9 Sinusoidal, reticulo-endothelial 250 -- 
Lung 24 Non-fenestrated, loose junctions 250 <80 





Fenestrated 505 <3000 
Pancreas 
(exo) 
0.41 Fenestrated 182 <6900 
Spleen 0.57 Sinusoidal, non reticulo-endothelial 400 -- 























 Previous reports indicate that at molecular weights less than about 35 kDa, the efficiency 
of uptake in a tissue (% injected dose per gram) increases with reduced molecular weight due to 
increased permeability25. Eventually, the extraction fraction approaches 100% providing an 
upper limit on the benefit of small size. Molecular weight cutoffs were established for optimal 
extraction of the imaging agent from the circulation to the target tissue. The extraction fraction is 
a function of molecular weight, plasma flow rate, effective permeability, and S/V24. The 
correlation between effective permeability as a function of molecular size was fit for fenestrated, 
non-fenestrated, and tumor vessels. As previously reported by Schmidt et al., tumor data 
indicated 4.5 and 500 nm radius pores with fractional area to thickness ratios of 17.6 and 0.65 
cm-1 for small and large pores, respectively. Fenestrated vessels indicated 8 and 35 nm radius 
pores with fractional area to thickness ratios of 30 and 2 cm-1 for small and large pores, 
respectively. Non-fenestrated vessels suggested pore radii of 0.7 and 60 nm with fractional area 
to thickness ratios of 10 and 2 cm-1 for small and large pores, respectively. Using these 
permeability fits and a 50% extraction fraction cutoff, we predict that for targeting tumor, a 
molecule below 2200 Da will effectively extravasate out of the blood vessel into the target tissue 
(Figure	 2.1). Similar analyses are performed for organs and tissues with fenestrated or non-
fenestrated vasculature. For tissue with non-fenestrated vessels, such as bone, heart, liver, and 
muscle, the molecular weight cutoff for 50% extraction is low due to high blood flow rates and 
low permeability: bone (<570 Da), heart (<100 Da), lung (<80 Da), muscle (<600 Da). 
Fenestrated organs resulted in higher molecular weight cutoffs as seen by kidney (<3600 Da), 
endocrine pancreas (<3000 Da), and exocrine pancreas (<6900 Da).  
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Figure 2.1 Optimal molecular weight probes for different tissue types 
The values are based on 50% extraction fraction using the vessel type, blood flow, and vessel 
surface area. Tumors have elevated macromolecular permeability, but the elevated interstitial 
pressure may contribute to lower effective permeability than fenestrated tissue for low molecular 
weight compounds. The data and fit for tumor values are identical to ref.25 (left). The 50% 




 To examine the impact of affinity, we selected two series of compounds in this size range 
against a tumor antigen, HER2, and an endocrine pancreas target, GLP-1R, and compared 
experimentally measured versus predicted uptake. In the case of the high HER2 expressing 
tumor cell line (SKOV-3 > 106 receptors/cell), predicted uptake approaches the maximum value 
14-15 %ID/g at binding potential (BP = target concentration relative to dissociation constant, 
[T]/Kd) values of 50 or greater (Kd < 20 nM) for these slowly internalized affibodies. 
Experimental results indicate affibody molecules with measured Kd < 20 nM indeed achieve 14-
15 %ID/g experimentally (e.g. PEP07127 with a 3.8 nM Kd, Figure	2.2). For a tumor with ~30-
fold lower expression (LS174T tumors = 30,000 receptors/cell), the affinity must be 30-fold 
higher for the same BP. Therefore, the Kd must be < 0.7 nM for high uptake. In agreement with 
these results, PEP07127 has low uptake in LS174T xenografts, but ZHER2:342 (Kd = 0.022 nM) 
achieves high ~15%ID/g uptake. 
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The in silico predictions in most cases agreed with experimental results. These 
simulations assume complete residualization (all the internalized probe is trapped within the cell 
indefinitely). Metallic radionuclides such as technetium and indium are known to be 
residualizing labels140-144 over the time scale of the experiment, while halogen radionuclides such 
as iodine are non-residualizing145, 146. This could explain the lower iodinated compound 
experimental values in Figure	2.2. 
	
Figure 2.2 Computational model of tumor targeting with peptide agents versus 
experimental results 
Using the physiology of a tumor, the targeting efficiency (%ID/g) is graphed versus the 
internalization rate and binding potential (a function of target expression and affinity, left). These 
results are compared with a series of affibody molecules varying in affinity, radiolabel, and 
target expression (right). 
 
	
 The predicted uptake in the endocrine pancreas is very different from the tumor in both 
magnitude and shape. The higher blood flow and permeability results in much larger maximum 
uptake values but also more stringent binding affinity requirements (a general shift to the right of 
Figure	2.3). Because GLP-1R expression (54,000 receptors per cell) is closer to SKOV-3 levels, 
a high affinity requirement would be expected. However, the internalization rate of GLP-1R is 
much faster (2x10-3/s), trapping probe inside the cell before it can dissociate. Therefore, a Kd of 
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~10 nM is needed for efficient targeting. In agreement with these predictions, a decrease in 
affinity from 2.6 nM to 8.3 nM had a minimal impact on pancreatic uptake147. 
	
Figure 2.3 Computational model of endocrine pancreas targeting with peptide agents 
versus experimental results 
The physiology of pancreatic islets results in much higher potential targeting %ID/g due to 
higher blood flow and vascular density. The more efficient transport also shifts the contour lines 
to the right, requiring higher affinity due to faster washout (left). A comparison of predictions 
with published data on exendin based peptides of varying molecular weight and affinity 
highlights how the rapid internalization reduces the stringency in binding affinity despite the 
faster transport (right). 
 
	
Figure 2.4 Impact of vascular density on simulations 
Contour plots for tumor uptake of a small peptide to demonstrate the effect of blood vessel 
surface area to volume (S/V). Left plot uses an S/V value of 60 cm-1; Right plot uses an S/V 
value of 200 cm-1. Two noticeable differences between the plots include 1) a higher maximum 
tumor uptake with a greater S/V (top) and 2) near-maximum uptake occurs at a higher binding 
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To quantify the background signal, two additional probe data sets were examined – low 
molecular weight prostate specific membrane antigen (PSMA) ligands and integrin binding 
ligands. Plots of TBR versus blood clearance for both integrin and PSMA binders (Figure	2.5) 
show similar trends. In the case of PSMA binders, at 4 h post-injection, much higher TBRs 
(tumor to muscle ratio) can be achieved for compounds with low blood concentration (R2 = 0.69, 
MIP1095 omitted). MIP1072 and MIP1404, the compounds with the highest 4 h TBR at 171 and 
157, respectively, maintained relatively low blood uptake of 0.06 and 0.02 %ID/g, respectively. 
MIP1405, MIP1427, and MIP1428 achieved TBR values of 72, 31, and 42 respectively and 
displayed relatively slow blood clearance with 4 h blood uptake values of 0.26, 0.28, and 0.14 
%ID/g. Integrin binders show a similar relationship between TBR and blood uptake (R2 = 0.34, 
compound 17 omitted). These results indicate that in this size range (well below the renal 
filtration cut-off), more rapid plasma clearance benefits TBR by reducing the background. 
Although properties such as plasma protein binding may slow clearance and allow more time for 
target uptake, this effect is mitigated by the fact that plasma protein binding also reduces 
extravasation rates of the free probe.  
	
Figure 2.5 Impact of non-specific uptake in background tissue (i) 
For both low molecular weight PSMA binders (left) and integrin binders (right), the highest TBR 
values (arrows) occur for low blood signal. The lines indicate a general trend of lower TBR with 
higher blood signal. The circled data were excluded as described in the text. Although faster 
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clearance has the potential to lower target uptake and reduce TBR, these results indicate this is 
generally not the case in this size range. 
 
	
A correlation between charge and TBR was also investigated using uptake values from 
the PSMA and integrin targeting compounds. A plot of TBR versus the overall charge of all 
compounds at pH 7.4. The plot suggests no evident trend between charge and uptake (R2=0.05, 
R2=0.01 for PSMA and integrin binders, respectively) likely due to the importance of chelation 
chemistry in determining overall molecular charge and highlighting one challenge in prediction 
from pure structure. 
 A series of three affibodies was studied by Tolmachev et al. to examine the impact of 
affinity and physicochemical properties of small proteins on targeting148. Comparing peptides 
PEP05838 and PEP05541, the sequence was more hydrophobic149 for PEP05838, resulting in 
higher liver uptake (Figure	 2.6). The lowest uptake occurred for PEP07127, which notably 
differed by a hydrophilic residue in the middle of an otherwise hydrophobic patch on the surface. 
However, based on sequence alone, PEP07127 had an intermediate hydrophilicity, indicating 
secondary structure can play a driving role even for residue changes on a single alpha helix. 





Figure 2.6 Impact of non-specific uptake in background tissue (ii) 
For proteins/peptides, even a single alpha helix can result in secondary structure playing a 
significant role in determining non-specific uptake (C). The substitution of a single amino acid in 
the middle of a hydrophobic patch on PEP07127 reduced background tissue concentrations, 
resulting in the highest TBR and fastest blood clearance (D). 
 
	
 The data indicate that rapid plasma clearance is beneficial for molecular imaging agents 
in this size range, and we hypothesized that non-specific interactions could quantitatively explain 
the differences in clearance from the blood. However, there is no simple correlation between 
physicochemical properties of small molecules or sequence of peptides and efficient clearance 
due to the large number of non-specific low affinity (ionic, hydrophobic, colloidal) interactions 
that are difficult to predict from structure alone. To prospectively explore the impact of 
physicochemical properties on clearance, a series of fluorescent integrin binding peptidomimetic 
agents was synthesized using different fluorescent dyes to manipulate the physicochemical 
properties. Two different assays were used to measure non-specific interactions – a non-specific 
cellular uptake assay and an equilibrium plasma protein binding assay. The cell-based assay used 
excess non-fluorescent probe to block specific interactions and measured the increase in 
fluorescence signal over time, and the plasma protein binding assay was used as a surrogate for 
overall non-specific interactions. Plasma clearance of the probes was measured in C57BL/6 mice 
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over 24 h. The most hydrophobic agent had very rapid early phase decay but had higher signal at 
later times, while the more hydrophilic probes had increased clearance at 24 h. Rapid 
redistribution into tissues lowers the plasma concentration initially, but whole body clearance 
from tissues has a larger impact on TBR150.  Both the non-specific cellular uptake and plasma 
protein binding correlated with plasma clearance and can be run in a high-throughput manner 
(Figure	2.7). The methods each had different strengths. The plasma protein binding assay is cell-
free, resulting in less variability, and protein binding also affects uptake in the target tissue151, so 
it is useful for correlating with both uptake and background signal. However, for certain 
compounds it is difficult to achieve equilibrium using dialysis. In these cases, such as with larger 
peptides, proteins, and compounds that interact strongly with the dialysis membrane, the cellular 
uptake assay can be used.  
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Figure 2.7 High throughput methods for quantifying non-specific uptake 
Lower plasma protein binding and non-specific cell uptake generally correlate with faster plasma 
clearance for a series of integrin probes with the exception that very lipophilic compounds can 
redistribute rapidly in the tissue, causing high background but low plasma signal (A) particularly 
at early times (e.g. BODIPY 650 conjugate, B). Plasma protein binding, a common assay for 
small molecule drugs, correlates with non-specific cell uptake in vitro (C). For plasma protein 
binding, there are diminishing returns when lowering the fraction below ~60% bound (D). Based 
on the non-specific cell uptake assay, which is useful for agents that cannot undergo rapid 
equilibrium dialysis (e.g. due to molecular weight or membrane sticking), a non-specific in vitro 
cell uptake rate of less than ~10-5 s-1 also has diminishing returns (E) providing quantitative 
guidance on probe selection. Four exendin derivatives where plasma protein binding could not be 




 Given the increasing use of near-infrared fluorescence in preclinical studies and clinical 
applications (for intraoperative imaging), we measured the protein binding of a series of 
fluorescent dyes (Table	2.2, some dyes displayed higher variation than other compounds). While 
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the targeting ligand and linker also impact the overall plasma protein binding, the relative scale 
of these values can be useful in estimating overall probe PPB. 
Table 2.2 Plasma protein binding of near-infrared dyes and conjugates 
Compound Ex/Em (nm) % Plasma Protein Bound 
BODIPY 650 conjugate 646/660 99.6 ± 0.4 
Alexa Fluor 680 conjugate 684/707 78 ± 3 
IRDye 800CW conjugate 774/789 91 ± 2 
ZW800 conjugate 768/786 72 ± 7 
BODIPY 650 carboxylate 646/660 99.8 ± 0.3 
Alexa Fluor 680 carboxlyate 684/707 81 ± 6 
IRDye 800CW carboxylate 774/789 89 ± 3 
ZW800-1 carboxylate 768/786 81 ± 5* 
ICG-dye ~800/826 99.5 – 99.75* 
SIDAG dye 755/778 57* 
Alexa Fluor 647 carboxylate 651/672 76 ± 1 




 Molecular imaging agents can provide detailed insight into in vivo biological phenomena 
in a minimally invasive manner. However, the development of these agents is time consuming 
and costly. There are often tissue and target-dependent trade-offs between properties that 
maximize signal, foiling empirical approaches and extrapolation from published values. To 
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improve the design of imaging agents and help focus preclinical experiments on the most 
promising molecules, we analyzed and quantified the mechanistic trade-offs for probe 
development.  
 Parameters that determine target uptake for in vivo imaging can be categorized as either 
an imaging probe property or a tissue property (Scheme	2.1). Molecular weight and charge play 
a role in uptake and clearance, while affinity and label residualization impact target retention. 
These imaging agent values are all relative to the tissue properties, making generalizations 
difficult. For radionuclides, the choice of radioisotope and chelator are also critically important. 
Certain aspects such as ease of synthesis and stability of the complex in vivo are beyond the 
scope of this analysis. However, other properties, such as the radioisotope decay half-life (where 
isotopes with short half-lives are acceptable for rapidly cleared agents), residualization rate of the 
radioisotope, and chelation chemistry (which impacts plasma protein binding and non-specific 
interactions) all have an impact on the parameters discussed here. 
The molecular properties of the targeting probe are under the direct control of the 
researcher, and these must be optimized according to the target tissue type for maximum signal 
and contrast. Based on a previous analysis of targeting efficiency in tumors, two local maxima 
exist for target uptake – one at single kDa molecular weight ranges and one close to the size of 
antibodies25. For imaging agents, clearance is important for contrast, so lower molecular weight 
probes result in higher target to background ratios. Antibodies rarely have tumor to organ ratios 
above 100 and are typically 3-10152, 153. However, several low molecular weight probes cited in 
this work reach ratios above 100, and importantly, these high TBR values developed within 
several hours after injection versus days for antibodies. Therefore, we focused on the 
optimization of low molecular weight compounds in this analysis. 
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 Based on size versus permeability and clearance, a lower molecular weight is more 
efficient in target uptake. However, we sought to determine the optimal size of an agent, since 
eventually blood flow limitations negate any benefits from smaller size. Molecular weight 
cutoffs were established for various tissues using a 50% extraction fraction criterion (related to 
the vessel depletion number24).  Predictions indicate non-fenestrated organs with small pore sizes 
such as bone, heart, lung, and muscle have a significantly lower size cutoff compared to the 
fenestrated kidney and pancreas. The predictions also indicate that in organs with high plasma 
flow such as heart (4.06 mL/min/g) and lung (24 mL/min/g), the extraction fraction can be very 
low for many probes (albeit a low fraction of extremely high delivery).  
 The blood flow and extraction fraction determine the amount of probe reaching the tissue, 
but this does not account for binding and retention of the imaging agent at the target. While 
antibodies can readily be engineered for high affinity (~ 1 nM Kd), high affinity low molecular 
weight compounds can be more challenging to design154-157. Given this common trade-off 
between molecular weight and affinity (such as dimerization increasing apparent affinity but also 
molecular weight158), we next determined the required dissociation constant for efficient 
localization. 
 A predictive and mechanistic model was used for comparison with published values of 
tumor and endocrine pancreas uptake for two classes of targeting molecules (Figure	2.3,Figure	
2.4) – HER2 binding affibodies (MW ~ 6 kDa) and GLP-1R binding peptides (MW ~ 5 kDa for 
monomer). Tumor cell lines with high (SKOV-3) and low (LS174T) expression of HER2 were 
simulated for the HER2 agents. To account for varying expression levels, the binding potential 
was compared to the internalization rate. Varying either [T] or Kd to manipulate BP gave the 
same results. Predicted uptake values were calculated assuming tracer (subsaturating) doses. 
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However, tumor xenografts with low expression levels can readily be saturated, and several data 
points were excluded due to reported evidence of target saturation159. Because plasma protein 
interactions are not well-characterized for these molecules in the literature, a single value of 
plasma protein binding was assumed (42% bound); this is the experimentally estimated value for 
fluorescent exendin, a peptide with similar molecular weight and alpha helical secondary 
structure. However, the value could be higher due to possible interactions with other plasma 
proteins160.  
The simulation results agreed well with the literature reported values for HER2. With the 
very high expression levels in SKOV-3 cells, a 3.8 nM binder (PEP07127) is sufficient for high 
uptake, but a 50 nM Kd (ZHER2:4) lowers the signal. In contrast, the lower expression on 
LS174T xenografts results in lower uptake of the 3.8 nM binder and requires a 22 pM affinity 
(ZHER2:342) for high retention. (Note that the required affinity is also a function of the 
molecular weight, and for low affinity interactions, higher targeting efficiency can often be 
achieved by increasing the molecular weight above the optimal range discussed here25.) 
The model predictions are also in agreement with uptake of exendin monomers, dimers, 
and trimers in the endocrine pancreas despite very different tissue physiology. For the slowly 
internalized affibody-HER2 complex161, 162 (3.9x10-6 s-1), a very high affinity (< 1nM) was 
required for maximum uptake with moderate receptor expression (LS174T). In contrast, the 
much more rapidly internalized GLP-1 receptor (2x10-3 s-1) has a lower requirement (< 10 nM) 
for high uptake even with similar expression levels as LS174T (54,000 GLP-1 receptors versus 
30,000 HER2 receptors per cell) as seen with the 8.3 nM binder. Uptake is only noticeably 
reduced with a Kd of 20.9 nM. The model slightly over-predicts uptake, which could be a 
function of error in any of the model parameters that were not fit, such as plasma protein 
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binding, wt% of beta cells, permeability, etc. Importantly, these simulations highlight the 
differences in affinity requirements based on tissue properties and target internalization. Since 
these probes are given at tracer doses, internalization does not amplify the signal like it would for 
a saturating dose. However, it does reduce the required affinity since the probe is internalized 
and trapped prior to dissociation. These data demonstrate that the required affinity is a function 
of target expression, tissue physiology, and internalization rates. 
 Unlike target uptake rates that can be predicted with reasonable accuracy from sigmoidal 
binding curves and measured extravasation rates, the background signal is more challenging to 
predict. Low molecular weight agents are cleared more rapidly than higher molecular weight 
agents163, 164, but for small molecules well below the nominal renal molecular weight cut-off, 
non-specific interactions play a large role. For these agents, molecules that interact strongly with 
plasma proteins will have slower clearance times165, 166. While this may allow more time for 
uptake, this also reduces extravasation in the target tissue165, resulting in little to no net gain. In 
addition, non-specific interactions can increase background signal. 
Although there may be no net gain in target uptake relative to plasma protein binding, we 
hypothesized that molecules with weak plasma protein interactions and fast blood clearance 
times would have lower background uptake without a loss in target uptake, resulting in higher 
TBR when imaging. This is in contrast to known trends for larger proteins where lower 
molecular weight results in a higher TBR but at the expense of lower target uptake131. 
Importantly, plasma protein binding can be measured in a high-throughput manner in contrast to 
animal biodistribution experiments, thereby providing a screening tool. To demonstrate this 
trend, two published series of low molecular weight targeting ligands with varying affinity and 
clearance rates targeting either PSMA or integrin of the form αvβ3 were considered. At long 
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times post-injection, both sets of molecules showed that the highest TBR values were obtained 
with the lowest blood %ID/g. There was also a general correlation with higher TBR with lower 
blood signal, although two outliers existed in the data, and the data are scattered due to the many 
additional factors that impact TBR beyond background clearance (e.g. affinity). One exception in 
the PSMA set (Figure	2.5 dotted circle, left) is compound MIP1095, which exhibited both slow 
clearance and a high TBR. This molecule exhibited the strongest affinity for all PSMA binders 
tested (Kd = 240 pM), the highest tumor uptake (34.3 %ID/g), and the highest skeletal muscle 
uptake (0.26 %ID/g). This outlier demonstrates one of many quantitative trade-offs, where 
having a strong affinity at the cost of poor clearance can still result in a high TBR. All properties 
(not just plasma clearance) must be quantitatively considered together.  
The nine bivalent integrin-targeting agents designed with various spacer lengths also 
support the notion that molecules that have a low blood uptake at 24 h post-injection are able to 
achieve a higher TBR. Again, the highest TBR values corresponded to the lowest blood signal. 
One outlier is compound 17 (Figure	2.5 dotted circle, right), where both blood concentrations 
and TBR at 24 h were low at 0.031 %ID/g and 18, respectively. However, this results from 
unusually high muscle uptake of > 0.6 %ID/g, much higher than all the other compounds in the 
series and actually increasing from 4 to 24 h.  This suggests specific uptake of the probe in 
muscle or an experimental artifact.  
Weak and non-specific interactions between molecules are challenging to predict. These 
interactions are being investigated for large proteins such as antibodies, and comparisons with 
these findings provide some insight167, 168. Hydrophobic and charged patches on the surface of 
these proteins can increase colloidal interactions, changing the pharmacokinetic properties. 
Notably in the case of antibodies, non-specific tissue interactions increase clearance from the 
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normally long-circulating molecules169, while plasma protein interactions typically decrease the 
clearance of the normally rapidly-cleared small hydrophilic molecules discussed here. 
PSMA and integrin ligand results show there is no simple correlation between TBR and 
overall charge. Many of the charges come from the chelating agent, and chelator selection is a 
critical component of probe design170, 171. Some chelated metals have very low non-specific 
interactions like indium-DTPA while others have higher plasma protein binding and overall 
lipophilic properties like Tc-99m-DTPA150, 172. More hydrophilic chelators have been designed, 
but here again these do not completely correlate with physicochemical properties78, making 
predictions from structure alone challenging. 
Tolmachev and colleagues’ analysis of non-target uptake for affibodies as a function of 
hydrophobicity provides insight into peptide agent design compared to non-peptide small 
molecule ligands148. Compound PEP07127, due to an L18S amino acid substitution, disrupted a 
hydrophobic patch present in the original compound. Even for this small region on an alpha 
helix, the secondary structure played a role in non-specific interactions. As pointed out by these 
authors, the results are pertinent to the development of high affinity proteins and peptides, where 
many binding interfaces have hydrophobic regions driving high affinity148, highlighting a direct 
trade-off between affinity and background signal. Hackel et al. investigated the impact of surface 
charge and hydrophilicity modification on fibronectin compounds173. By manipulating the 
surface properties, they were able to control the distribution in the two major clearance organs, 
liver and kidney. Our current analysis does not focus on clearance organs, but for the integrin 
and PSMA binders, more efficient clearance from the blood generally correlated with lower 
signal in the liver and kidneys for these non-peptide agents.  
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The affibody results highlight the fact that predicting the impact of amino acid 
substitutions on the abundant in vivo low affinity interactions that depend on sequence and 
structure is extremely complex and challenging, particularly in the context of screening 
compounds where the structure may not be known. Rather, taking a lead from the protein 
engineering field167, 168, 174, experimental methods of measuring non-specific interactions in a 
high-throughput manner may be more fruitful. Hydrophobic and other non-specific interactions 
impact off-target uptake of these molecules and directly lower tumor to organ ratios. Conversely, 
the highest TBR value occurred for the compound with the lowest blood signal, consistent with 
the integrin and PSMA imaging agent series. The clearance is likely a direct result of increased 
plasma protein interactions, which is challenging to quantify for peptides. Accurate plasma 
protein quantification for lower molecular weight molecules is possible using several techniques, 
such as rapid equilibrium dialysis or ultrafiltration, and these were investigated next. 
To compare two methods of measuring non-specific interactions for correlating with 
plasma clearance, we generated a series of small molecule fluorescent peptidomimetics using 
different fluorescent dye structures to manipulate the physicochemical properties. Non-specific 
interactions due to lipophilicity have been characterized for many visible light fluorophores175, 176 
but less is known about these interactions for near infrared (NIR) fluorophores, which have in 
vivo advantages for imaging. In vivo clearance and non-specific uptake rates of peptidomimetics 
using NIR fluorophores such as AF680, 800CW, and ZW800 demonstrate the impact of non-
specific interactions on imaging agent design. The plasma clearance was measured over 24 h 
(Figure	2.7A) and compared to plasma protein binding measured by rapid equilibrium dialysis 
and non-specific uptake in cell culture. The cell uptake rates correlated with plasma protein 
binding, indicating these assays may be providing similar information on non-specific 
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interactions (Figure	 2.7C). The probes with lower plasma protein binding typically had more 
rapid alpha phase clearance and lower plasma signal at 24 h. Given the correlation with higher 
TBR in Figure	 2.5 and Figure	 2.6, this could be incorporated into high throughput screening 
methods for determining propensity to clear from tissue. Note that the most lipophilic agent 
(BODIPY 650 conjugate) had a fast early (alpha phase) clearance but higher signal at 24 h. It is 
important to distinguish rapid clearance from rapid redistribution of probe from plasma to tissue, 
since the former can lower background signal while the latter can significantly increase it (e.g. 
PEP05838, Figure	2.6148).  
The plasma protein binding assay has the advantage of a cell free system (reduced 
variability) and simultaneously provides data on target uptake (since it is generally unbound 
probe that enters tissue). However, commercially available assays typically only work for probes 
less than 1-2 kDa in size and can have problems with agents that have extensive interactions with 
the dialysis membrane, making the cell uptake assay a viable alternative. As an example, four 
exendin peptide conjugates were synthesized with varying hydrophobic properties. Although 
plasma protein could not be quantified due to their higher molecular weight, the non-specific cell 
uptake rate was significantly higher for the more lipophilic conjugates and correlated with the 3 
h plasma concentration in mice (Figure	2.7F). 
The relative values of plasma protein binding and non-specific cell uptake can be used to 
rank order compounds, but an absolute guideline is helpful in determining if further molecular 
engineering is warranted. Similar to reductions in molecular weight and increases in affinity, 
there are benefits of increasing hydrophilicity to reduce background (such as addition of PEG to 
integrin binders177), but eventually there are diminishing returns with further effort. Based on the 
data presented here and literature values (SI), a significant reduction in background is not 
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expected below 60-80% plasma protein binding or 10-5s-1 cellular uptake rate. (For comparison, 
pinocytosis rates178 have been estimated around 1.1x10-5s-1.) Further improvements beyond these 
levels may be obtained by reducing these parameters, but this is not without cost. Molecules in 
this size range that have no measurable plasma protein binding, inulin being a classic example, 
are very hydrophilic and flexible in direct contrast to most high affinity binding interfaces. 
Given the increasing use of near-infrared probes for preclinical studies and clinical 
intraoperative imaging, we quantified the plasma protein binding of several commercially 
available dyes to guide fluorescent probe development. While the conjugates of these dyes will 
have altered plasma protein binding (and lose the carboxylic acid once they are conjugated to an 
amine), the relative magnitude can be used to estimate overall properties. For dyes in the 680-
700 nm range, Alexa Fluor 680 had the lowest plasma protein binding of the dyes tested, while 
for the 750-800 nm range, ZW800-1 had the lowest plasma protein binding. These values, in 
addition to the dye residualization rates179, are helpful in rational design of NIR probes.  
 
2.6 Conclusion 
In conclusion, we have analyzed data from 28 low molecular weight probes to provide a 
quantitative and mechanistic framework for comparing cell surface imaging agents. The qualities 
of optimal imaging agents are well known, but in practice, there are many trade-offs. This 
analysis is designed to quantitatively determine the magnitude of these impacts to select the most 
promising agents for preclinical analysis. For example, data on blood flow and permeability 
could be used to identify an appropriate scaffold and/or library for screening based on the target 
tissue (Table	2.1). The internalization and expression level of the target can be used to define a 
target affinity or compare predicted retention of lead compounds (Figure	2.2). A high throughput 
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test of plasma protein binding and/or non-specific cellular uptake can be used to quantitatively 
compare the background signal (Figure	2.7). Alternatively, for a series of in vitro characterized 
compounds, these plots can be used to quantitatively compare the expected TBR based on 
molecular weight, affinity, and lipophilicity/non-specific interactions.  These data will help select 
the most promising candidates to move forward in a more quantitative and rational manner for 
molecular imaging agent design. 
 
2.7 Experimental Methods 
Computational Model Development 
 The original tissue simulation model was based on a non-linear partial differential 
equation model of tissue concentration with time-varying mixed boundary conditions and axial 
and radial gradients180. This model provides a self-consistent framework for simulating the 
distribution of agents from small molecule drugs to biologics and nanoparticles181. To limit the 
scope of the simulations, we used previous modeling results indicating that the highest target 
uptake occurs for very low molecular weight agents and those similar in size to antibodies25. In 
addition to high uptake, low molecular weight compounds benefit from rapid clearance and have 
demonstrated target to muscle ratios over 100182, 183. To focus on the design of imaging agents 
for extracellular targets, lipophilic compounds that can diffuse across plasma membranes with 
significant retained intracellular signal were excluded184. Finally, since imaging agents are 
ideally delivered at tracer doses, a subsaturating dose was assumed. Based on the four classes of 
pharmacokinetic behavior in tissue (blood flow-limited, permeability-limited, diffusion-limited, 
or binding/metabolism-limited agents)181, the lack of transcellular extravasation of highly 
lipophilic compounds and tracer dose eliminates the diffusion-limited and binding/metabolism-
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limited regimes, respectively, narrowing the analysis to blood-flow and permeability limited 
probes. Since peptide and protein-based agents form a large contingent of extracellular imaging 
agents, we focused on a permeability-limited model subject to blood-flow limitations. 
 A compartmental analysis assuming equilibrium binding was performed on plasma, 
tissue, and internal compartments (SI). Briefly, the imaging agent extravasates from the plasma 
compartment into the tissue compartment, where it is either receptor-bound or free. Bound 
imaging agent is then trafficked to the internal compartment. Binding equilibrium is assumed to 
be very fast relative to diffusion of the imaging agent out of the plasma. The model also assumes 
a sub-saturating tracer dose of imaging agent with the receptor in excess. It can be shown (SI) 
that the concentration of imaging agent in the extracellular tissue and internal compartments as a 
function of time can be represented by 
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The parameters are described in the supplementary file. This model was used in conjunction with 
experimental data and simplifying assumptions to quantify the impact of probe and tissue 
parameters on target to background signal. While high contrast is not always necessary for an 
imaging agent, in most cases (delineating diseased tissue, quantifying changes in receptor 
expression) high contrast is beneficial and reduces artifacts from surrounding tissue signal. 
 The strategy outlined in this approach aims to maximize TBR by internalizing the probe 
within the target cells and minimizing binding/sticking and internalization in non-target tissues. 
An alternative approach is to select targets that are slowly internalizing and design probes that 
rapidly leak out of cells once they are metabolized. This would lower the signal intensity in off-
target and clearance organs such as the liver and kidney. While this has been shown to improve 
target to background ratios for these organs185, there are several limitations to this approach. The 
internalization, metabolism, and clearance of the probe from non-target tissue has to occur much 
faster than in the target tissue. Since metabolism and clearance often takes several hours to a day 
or more, ideally the target would not be internalized significantly over this time frame. Because 
most cell surface proteins have a constitutive rate of several hours186, this greatly limits the 
number of applicable targets. As noted in Figure	2.3, this can increase the required affinity for 
high target uptake by 10 to 100-fold. Finally, the lipophilic chelate can increase plasma protein 
binding and liver uptake, lowering targeting efficiency. Although this approach can decrease the 
liver signal more than it decreases the target signal185, in contrast, the approach discussed in the 
current work decreases non-specific uptake while increasing target signal. This may explain why 
the reported TBR values for the current approach are much higher than those achieved by a non-
residualizing agent185.  
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Permeability versus Molecular Weight 
 The relationship between molecular radius and permeability was modeled using a two-
pore representation as described by Schmidt et al25. Previously reported measurements for 
permeability (P) for small molecules, peptides, proteins, polymers, and liposomes were compiled 
from literature (SI) and fit to determine the radii and fractional area of small and large pores. To 
quantify the extraction ratio of various molecular weight molecules, the permeability was first 
calculated using the two-pore prediction with the appropriate tissue vasculature. Then, using 
experimentally measured values for plasma flow rate and S/V (SI), a mixed flow and 
permeability-limited model was adopted from Tofts et al. to predict the fraction of imaging agent 
extracted from blood to tissue24. Organ systems were categorized as either fenestrated (kidney, 
pancreas), non-fenestrated (bone, heart, lung, muscle), or tumor for analysis (SI). A two-pore 
model was used to generate optimized fits for each of the three categories based on vasculature 
type. 
 
Affinity versus Expression and Internalization 
 To predict uptake in various tissue types, a previously published model was used180.  In 
short, the non-linear partial differential equation (PDE) model utilizes a Krogh cylinder 
geometry of tissue vessels with both axial and radial gradients for the imaging agent. Plasma 
concentration is modeled with biexponential decay with local concentrations determined by 
blood velocity and vessel permeability. A list of parameters used for tumor and endocrine 
pancreas uptake predictions are found in the supplementary data (SI). Experimentally measured 
affinity values were adjusted for temperature assuming constant free energy of binding. 
MATLAB was used to solve the system of nonlinear PDEs using finite differences to quantify 
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tissue uptake. To generate a full %ID/g contour, internalization rates were varied between 10-6 s-1 
to 10-2 s-1. Fixing antigen concentration and varying affinity generated a range of binding 
potential from 10-1 to 1000. Identical results were obtained when varying the binding potential 
by fixing affinity and varying the antigen concentration. Predicted uptake values were compared 
with experimentally determined values reported in the literature. For endocrine pancreas 
simulations, whole organ %ID/g was converted to islet %ID/g assuming islets are 1 wt% of the 
pancreas. Uptake values with 10% increases and decreases in internalization rate, affinity, and 
antigen expression were used as simulation error. 
 
Plasma Clearance versus Contrast 
  The impact of plasma clearance on TBR was investigated using previously published 
data from mammary and prostate tumor models (SI). In short, small molecule inhibitors targeting 
prostate-specific membrane antigen (PSMA) with various dissociation constants and blood 
clearance rates were used to target LNCaP or PC3 xenografts in mouse models. Measured values 
for tumor and skeletal muscle uptake were used to calculate the TBR, which was then plotted 
against the blood concentration. A similar analysis was performed for various integrin binders 
targeting mammary adenocarcinomas in a mouse model and HER2-binding affibodies. TBR for 
both sets of compounds were also plotted against the total compound charge at physiological pH 
to demonstrate a lack of trend between uptake and molecular charge (SI). An analysis of non-
target uptake was performed as well for molecules of varying hydrophobicity using previously 
published data of anti-HER2 affibodies (SI). Additionally, a correlation between plasma 
clearance and non-specific interactions was explored for exendin, a 4 kDa therapeutic peptide 
used to treat type 2 diabetes. The hydrophilic dye Alexa Fluor 680 or a lipophilic non-sulfonated 
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Cy7 dye were conjugated to exendin147 using either directly to the 14th position or using a helix-
stabilizing linker187 to generate four variants. The peptides were administered intravenously in 
C57BL/6 mice and the plasma concentration monitored over time. Non-specific cellular uptake 
for peptide conjugates in HT1080 cells was quantified as well using in vitro assays (SI).  
 
Plasma Clearance versus Non-specific Interactions 
The targeting ligand was synthesized by ChemPartner (Waltham, MA) as an ester.  The 
ester was hydrolyzed with 150 µL of ethanol and 7 µL of 1M NaOH per mg of drug overnight, 
neutralized with 1M HCl, and dried under vacuum.  IRDye 800CW NHS ester was obtained 
from LI-COR (Lincoln, NE), ZW800-1 NHS ester was obtained from Curadel ResVet Imaging 
(Worcester, MA), and Alexa Fluor 680 NHS ester and BODIPY 650/665-X NHS ester were 
obtained from Life Technologies (Carlsbad, CA). The hydrolyzed integrin binder was reacted 
with the fluorescent dyes in a 1:1.5 molar ratio in the presence of 2 µL of triethylamine per mg of 
drug overnight and purified using a preparative scale Luna C18(2) column (Phenomenex; 
Torrance, CA) on a Shimadzu reverse phase HPLC unit. Successful conjugation was confirmed 
by ESI-MS and MALDI-TOF (SI). 
All animal experiments were approved by the University of Michigan Institutional Animal Care 
and Use Committee (IACUC) and carried out in accordance with their guidelines. To quantify 
the blood clearance, the fluorescent compounds (15 nmol) were injected via the tail vein in 
C57BL/6 mice. Blood samples were collected at predetermined time points and the plasma 
concentration of the compounds was quantified using an Odyssey CLx. To quantify non-specific 
uptake rates, MDA-MB-231 cells were plated in 96 well plates and allowed to attach overnight. 
The cells were incubated with 200 nM of non-fluorescent ligand for 15 minutes followed by a 
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co-incubation with 10 nM or 20 nM of fluorescent ligand and 100 nM of non-fluorescent probe. 
At 15, 30, 45, and 60 min, the cellular uptake was quantified using an Attune Acoustic Focusing 
Cytometer (Applied Biosystems) with fluorescent beads (Bangs Laboratories, Inc.) to quantify 
the non-specific uptake rate. Plasma protein interactions were quantified for commonly used, 
commercially available far-red and near-infrared fluorescent dyes. For IRDye 800CW, ZW800, 
BODIPY 650, Alexa Fluor 680, and integrin conjugates, a Rapid Equilibrium Dialysis (RED) 
plate was used following the manufacturer’s protocol. 
Rapid Equilibrium Dialysis (RED) was used to quantify plasma protein binding for 
various fluorescent dyes (carboxylate form) and fluorescent conjugates. RED plates are available 
with membrane molecular weight cutoffs of either 8 kDa or 12 kDa. Given that many of the 
fluorescent conjugates are >1 kDa, the 12 kDa plate were used to reduce the equilibration time 
between chambers. The 12 kDa RED plate gave consistent results with small variation for all 
compounds tested except for ZW800 carboxylate, as seen in the higher standard deviations 
reported. It is possible the overall net positive charge on the molecule is responsible for 
interactions with the dialysis membrane. The 8 kDa RED plate resulted in lower plasma protein 
binding, which would be unexpected based simply on equilibration time. An ultrafiltration 
method (Centrifree Ultrafiltration Device, Millipore) resulted in lower but variable values of 41 
+/- 9% bound for ZW800 carboxylate. 
With the exception of ICG and SIDAG, which do not have functional handles for 
conjugation, the other dyes contain a carboxylate group that will not be present once the dye is 
conjugated to the targeting ligand. The optical properties of ICG are highly dependent on the 
microenvironment of the dye, which is impacted by plasma protein binding and partitioning188, 
189. Additionally, ICG is often delivered at very high doses, which can potentially saturate some 
	71	
binding sites in plasma and increase the free fraction. The estimates here are based on a 
subsaturating concentration of ICG190. 
 For cellular uptake experiments, HEK-293 cells were used initially. However, the high 
blocking dose of integrin binder caused dissociation of these cells, so the cancer line MDA-MB-
231 was used instead. Pinocytosis rates for macrophages and some tumor cell lines can approach 
1.1x10-5/s from fluid phase uptake178. Therefore, the measured uptake rates are postulated to be 
higher due to non-specific association with the cell surface and internalization. 
 
Exendin non-specific uptake 
 
	
Figure 2.8 non-specific uptake assay of exendin in HT-1080 cells 
 
HT1080 cells were grown in 24-well tissue culture plates. After adhering overnight, cells 
were incubated with 100 nM of different fluorescent exendin conjugates at 37°C. Fluorescent 
exendin conjugates are conjugated with either lipophilic or hydrophilic fluorophores to increase 
or decrease non-specific plasma protein and membrane interactions. After the each time point, 
cells were harvested and analyzed on an Attune Focusing cytometer to quantify the intracellular 
signal as a function of time. A blocking control was performed with excess non-fluorescent 








































Modeling Simplifications and Analysis 
 
	
Figure 2.9 Simplified compartmental model for imaging agent concentration 
	
It is assumed the compartments are well-mixed, at equilibrium, and “tissue” compartment 
consists of bound and free imaging agent. In actuality, imaging agent leaves plasma and into the 
target tissue; once in the tissue, the free imaging agent binds to target receptors. We assume 
binding equilibrium is very fast compared to diffusion of the imaging agent out of the plasma. 
The model assumes the receptor in excess. For these two reasons: 1) fast equilibrium and 2) 
receptor in excess, target tissue and receptor-expressing cells are combined into one 
compartment. 
 
Assuming biexponential decay in plasma, the governing equations are shown below: 
Pplasma
Pplasma,0
= Ae−kα t + Be−kβt   













Assuming Ptissue is the total imaging agent concentration in the islet is the sum of Pfree and Pbound. 

























The overall balance on extracellular islet concentration Pislet can be written 
  
The initial condition is P(t=0)tissue=0. Substitute Pplasma(t), and the equation can be written in the 
form 
  
Multiplying both sides by the integrating factor  and reverse product rule the RHS to give 
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This will model the extracellular concentration of probe in the tissue. 
To find the intracellular concentration, we use the governing equation for the intracellular 
compartment 
  
Boundary condition is at t=0, Pint=0. With appropriate substitutions, the resulting ODE can be 
written in the form 
  
Multiplying both sides by the integrating factor  and reverse product rule the RHS to give 
  
integration and application of the boundary condition gives (with appropriate coefficients) 
 
with   
 
and 
   
 
 
Table 2.3 Assumptions for model validation 
Model assumptions 




= kintPbound − kdegPint
dPint
dt
+ kdegPint = be
































































2. No blood flow limitations Important for tumors, which have slower 
blood flow rates. An extremely rapid 
clearance may not allow the tumor vessels 
to fill with probe. 
3. Non-specific uptake is linear with 
concentration 
There could be non-linear background 
uptake (e.g. target specific), but 
pinocytosis, non-specific binding, etc. are 
often linear. 
Simplifying assumptions 
4. High affinity Assumes all probe that enters tissue binds 
and does not dissociate, so optimal 
assumption. Internalization may help put a 
limit on the affinity, since once ke >> koff, 
all of the bound probe internalizes. 
5. kdeg << kα 
         and 
    kdeg << kint 
This is an optimal estimate to maximize the 
signal. 
6. The imaging time is greater than kα so 
the majority of probe is cleared from the 
blood 
This is a optimal estimate. The signal in 
blood (both target and non-target) will 
lower the specific TBR since it is non-
specific signal.  
The combination of assumptions 4 and 5 above allows us to assume kdeg ~ 0 so  




For the target tissue, starting with the model solution above: 
At long times, all the blood and surface signal is gone, so only Pint determines the signal. 
 






















































For non-target tissue, assuming first order internalization of probe non-specifically in the 
tissue. This in place of the high affinity assumption, but all other assumptions apply. 




(kint − kα )

















































































































































































































If the uptake is non-specific and linear with concentration, this is the same as a very low affinity 
antibody where the bound portion is linear with concentration (Kd à large): 
 
The first term incorporates washout from the tissue for the unbound probe, and the 
second term is linear in concentration. The form is first order, but the mechanism is completely 
different, so we will substitute a new constant, kint,ns, which stands for k internalization, non-
specific (ns): 
 
We will also assume that the imaging time as after plasma clearance but before significant 





































































































































































































































































































The initial plasma concentration (dose) and plasma clearance cancel from the analysis. 
The PS/V terms do not cancel, since these are the permeability surface area products for the 
target and non-target tissues, which can be different. 
 
The permeability surface area product on the right is for the non-target tissue: 
 
 
































































































































































































Since the physiology of the target tissue is difficult to manipulate, the probe should be designed 
to have minimal non-specific uptake. 
 
Additional points of distinction: 
a. If there is no non-specific uptake in the background tissue, then the background always 
goes to zero at long times. This assumption is likely not true and ignores the background from 
autofluorescence or instrument noise (for radioactivity).  
b. Faster clearance helps to keep assumption 5 and 6 true (imaging after everything cleared 
from the blood but little degradation), which is not the case for antibodies, for example. 
c. The internalization rate, kint, can help if there is low expression of target in the tissue. The 
internalization and recycle will prevent the dose from reaching saturation (since super-saturating 
doses lower the TBR). In other words, it helps maintain assumption 1.  
d. Lower affinity would increase washout from the target tissue, lowering the TBR. 
e. The MW of the probe affects clearance, but this appears to cancel out for TBR. However, 
the permeability of the target and non-target organs are a function of MW. For certain tissues 
(such as tumors), maximizing the ratio of permeabilities between target and non-target tissue 
would maximize the TBR. 





Scheme 2.2 Reaction for generating fluorescent αvβ3 targeting ligands 
Hydrolysis (top) yields a carboxylic acid. Primary amine (bottom) reacts with NHS ester on 




Table 2.4 Purification and characterization of fluorescent conjugates 














A: 0.1 % TFA in H2O 





A: 0.1 % TFA in H2O 





A: 0.1 % TFA in H2O 
B: 0.1 % TFA in MeCN 






































Table 2.5 Capillary permeability data 




































































































Na 23 0.1 Kidney 7600 Fenestrated 197 
Na 23 0.1 Pancreas 3600 Fenestrated 98 
Urea 60 0.18 Kidney 36000 Fenestrated 197 
Cr-EDTA 357 0.22 Pancreas 2200 Fenestrated 98 
B12 1353 0.85 Pancreas 1100 Fenestrated 98 
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Inulin 5000 1.52 Kidney 1440 Fenestrated 198 
Insulin 6000 1.66 Pancreas 348 Fenestrated 98 
Albumin 66000 3.55 Kidney 71 Fenestrated 199 
Albumin 66000 3.55 Pancreas 26 Fenestrated 98 
Hydrophilic 
solute 

























- 3.6 Muscle 0.47 Non-
fenestrated 
200 





Hexose 180 0.42 Dog heart 93 Non-
fenestrated 
201 
































Inulin 5300 1.52 Dog heart 24 Non-
fenestrated 
201 










α-Globulin 45000 3.55 Dog heart 0.606 Non-
fenestrated 
201 
Albumin 66000 3.55 Dog paw 0.519 Non-
fenestrated 
201 
Albumin 66000 3.55 Dog heart 0.313 Non-
fenestrated 
201 







Capillary permeability data for various compounds in different types of tissue. All 
permeability (P) values are experimentally determined and reported in literature as effective 
permeability, which account for convective and diffusive contributions. Molecular radii of 
compounds for kidney and pancreas permeability were compiled from literature204, 205. For tumor 
permeability, molecular radii of compounds were calculated based on previously reported 
methods for globular proteins and PEG chains when not stated in the reference25. Vasculature 
type, whether fenestrated or non-fenestrated, followed criteria listed by Sarin et al206. 
 
Table 2.6 Organ flow rate data 








Bone 0.17 1.5 10.73 207, 208 
Heart 0.28 0.28 0.5 208, 209 
Kidney 0.8 0.298 1.67 207, 208 
Liver 1.1 0.951 5.49 208, 209 
Lung 4.38 0.191 0.73 207, 208 
Muscle 0.8 7.9 38.4 208, 209 
Spleen 0.05 0.1 0.50 207 
 
Plasma flow rate, organ volume, and organ mass % were compiled from the literature. To 
convert plasma flow rates to mL/min/g, organ masses were used. Organ masses were either 
reported or calculated using organ mass % and total animal mass of 25 g for mouse data208. For 
tumor, a literature reported value of 0.1 mL/min/g was used as the blood flow rate and converted 
to plasma flow rate assuming a hematocrit of 0.45210. Endocrine and exocrine pancreas plasma 
flow rates were reported in literature4.  
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Table 2.7 Islet simulation parameters for Krogh cylinder predictions 
Symbol Parameter Value Notes Reference 
C0 Initial Plasma 
Conc 
1 fM Dose dependent  
Q Blood flow 0.029mL/s/g Not rate limiting 98, 211 
v Vessel velocity 0.6 mm/s  212 
[T] GLP-1 Receptor 
Conc 
Varied   
P Permeability 2.1x10-5 
cm/s 
10-fold higher than non-
fenestrated normal tissue 
98, 213 




100 um2/s Not rate-limiting 25 
S/V Capillary 
surface area to 
tissue volume 
505 cm2/cm3 Extremely high in islets 5 
ε Void fraction 0.1 Interstitial space in 
pancreas (adapted from 
insulin) 
98 




0.012 /hr Fluorescent dye specific 179 
A Fraction fast 0.91  147 
kfast Alpha clearance 0.174 min-1  
147 
kslow Beta clearance 0.0169 min-1  
147 




Varied   
ke Receptor 
internalization 
Varied   
ρ Tissue density 1000 g/L   
PlasmaBound Fraction Plasma 
protein bound 
0.43 Measured  
Simulation 
time 
 3 h   
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Table 2.8 Tumor simulation parameters for Krogh cylinder predictions 
Symbol Parameter Value Notes References 
C0 Initial Plasma 
Conc 
1 fM Dose dependent  
Q Blood flow 0.0016 
mL/s/g 
Not rate limiting 217 
[T] Receptor Conc Varied   
P Permeability 8x10-6 cm/s Figure 2.1 Figure 2.1 




100 um2/s Not rate-limiting 25 
Rkrogh Krogh cylinder 
radius 
60 um  219 
ε Void fraction 0.2  220 




4x10-6 s-1 In111 half life of 48h 222 
A Fraction fast 0.9972  
218, 223 
kfast Alpha clearance 2.83 h-1  
218, 223 
kslow Beta clearance 0.03 h-1  
218, 223 




Varied   
ke Internalization Varied   
ρ Tissue density 1000 g/L   





 4 h   




Table 2.9 HER2 and GLP-1R ligand properties for Krogh cylinder predictions 







3.9*10-6 1*10-6 15 99mTc N 23, 161, 224 
ZHER2:4 5.0*10-8 3.9*10-6 1*10-6 2.4 125I N 23, 161, 223 
ZHER2:342 2.2*10-
11 















3.9*10-6 1*10-6 15 111In N 23, 161, 225 
PEP05541 1.2*10-
10 
3.9*10-6 1*10-6 12.9 111In N 23, 148, 161 
PEP05838 1.6*10-
10 
3.9*10-6 1*10-6 15.5 111In N 23, 148, 161 
PEP07127 3.8*10-9 3.9*10-6 1*10-6 14.3 111In N 23, 148, 161 
ZHER2:2395 2.7*10-
11 
3.9*10-6 2.5*10-8 6.9 99mTc Y 161, 224, 226 
ZHER2:342 2.7*10-
11 
3.9*10-6 2.5*10-8 19 111In N 159, 161, 226 
PEP05541 1.2*10-
10 
3.9*10-6 2.5*10-8 7.4 111In N 148, 161, 226 
PEP05838 1.6*10-
10 
3.9*10-6 2.5*10-8 10.8 111In N 148, 161, 226 
PEP07127 3.8*10-9 3.9*10-6 2.5*10-8 1.71 111In N 148, 161, 226 
800CW 
monomer 
2.6*10-9 0.002 6.3*10-8 50 - N 147 
800CW 
dimer 
8.3*10-9 0.002 6.3*10-8 45.7 - N 147 
800CW 
trimer 
2.1*10-8 0.002 6.3*10-8 24 - N 147 
 
Previously published data on tumor and endocrine pancreas uptake. For tumor, several 
affibody probes were considered in addition to various radiolabels. For islet targeting, three 
exendin-based compounds were considered. For predicted uptake values, dissociation constants 
were recalculated assuming constant activation energy to account for temperature differences 
between affinity measurements and the in vivo experiments. 
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Chapter 3      
Quantitative Impact Of Plasma Clearance And Down-Regulation On GLP-1 Receptor 
Molecular Imaging 
3.1 Publication Information 
Zhang, L. and G.M. Thurber. Quantitative Impact of Plasma Clearance and Down-regulation 








Quantitative molecular imaging of beta cell mass (BCM) would enable early detection 
and treatment monitoring of type-1 diabetes. The glucagon like peptide-1 (GLP-1) receptor is an 
attractive target due to its beta cell specificity and cell surface location. We quantitatively 
investigated the impact of plasma clearance and receptor internalization on targeting efficiency 
in healthy B6 mice. Four exenatide-based probes were synthesized that varied in molecular 
weight, binding affinity, and plasma clearance. The GLP-1 receptor internalization rate and in 
vivo receptor expression were quantified. Receptor internalization (54,000 receptors/cell in vivo) 
decreased significantly within minutes, reducing the benefit of a slower clearing agent. The 
multimers and albumin binding probes had higher kidney and liver uptake, respectively. Slow 
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plasma clearance is beneficial for GLP-1 receptor peptide therapeutics. However, for peptide-
based imaging agents, exendin-based probes are used to demonstrate downregulation of GLP-1 
receptor and non-specific background uptake in the exocrine pancreas results in a higher TBR for 
fast-clearing agents.  
 
3.3 Background 
Type-1 diabetes mellitus (T1DM) is the result of an autoimmune destruction of beta cells, 
leading to loss of endogenous insulin production and unregulated blood glucose levels. Although 
the pathophysiology of T1DM is under investigation, the ability to monitor and measure the 
pancreatic beta cell mass (BCM) is important for assessing the magnitude of autoimmune 
destruction12, 227-232. Most patients display symptoms after losing the majority of their beta cell 
mass, complicating efforts to prevent further destruction using immunomodulatory therapy233, 234. 
The ability to accurately measure beta cell mass would also be informative during clinical trials 
to test the efficacy of treatment 235. Although the regional distribution of beta cells within islets 
of Langerhans differs across species, the BCM makes up fewer than 2% of the pancreatic mass 
in humans102, 236. Due to this low fraction of beta cells in the pancreas, a robust, non-invasive 
technique for monitoring and measuring BCM to predict disease onset has proven elusive84, 235. 
Currently, stimulated insulin secretion to indirectly measure the BCM showed success with 
healthy animal models but failed to predict the development of diabetes because of its limited 
ability to monitor BCM functionality12, 237, 238. Other studies were able to correlate 
hyperglycemia only with large reductions in BCM239, 240. Imaging agents developed for targeting 
beta cells such as antibodies, sulfonylureas, and vesicular monoamine transporter (VMAT) 
receptor agonists have been used in the past but face problems due to low target-to-background 
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ratios (TBR) during imaging, often from low target expression or poor specificity70, 241-244. There 
is a strong demand in the diabetes community to establish an imaging technique to quantify and 
monitor the beta cell mass as the destruction of these cells is responsible for the onset of type-1 
diabetes76. However, quantitative imaging is challenging because islets are 100-300 microns in 
diameter, much smaller than the resolution of PET and SPECT. Consequently, quantification of 
probe concentration will be diluted significantly by partial volume effects245-250. Additionally, the 
loss of beta cell mass requires measurement of a reduction in signal in the context of increased 
non-specific uptake due to inflammatory conditions during insulitis17  
Exendin-4, a 39-amino acid peptide originally isolated from Heloderma suspectum, is  
used for the treatment of type 2 diabetes, and the ligand-receptor interaction between exendin 
and glucagon-like peptide-1 receptor (GLP-1R) has been characterized for imaging beta cells in 
T1DM5, 47, 76, 251. Expression of GLP-1R in beta cells, high vascularization of tissue within the 
islets of Langerhans, rapid binding kinetics, and in vivo target specificity have led to the 
development of multiple radiolabeled exendin molecules to track the beta cell mass as well as 
detection of insulinomas5, 76, 251-257. Owing to its fast binding kinetics, rapid uptake in target 
tissue, and ability to be stabilized to resist protease degradation, exendin and related peptides 
have been investigated as molecular imaging agents for measuring beta cell mass in vivo45, 76, 187. 
However, current approaches lack the sensitivity required for clinical application252, so more 
development is needed. Modifications such as PEGylation have shown prolonged therapeutic 
effects258, 259, which may benefit a slower-clearing imaging agent if rapid distribution and blood 
clearance result in low targeting. An imaging agent that clears from the blood slowly has more 
time to accumulate in the target tissue, and in the well-vascularized islets, endocytosis of GLP-
1R agonists occurs rapidly214, suggesting a slower clearing agent may theoretically result in a 
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higher TBR in the pancreas. However, potential downregulation of GLP-1R expression may 
reduce beta cell internalization rates to values lower than non-target uptake at longer times, and 
TBR will be reduced due to high background signal from lack of clearance. The multiple 
competing factors require quantitative analysis of molecular probe properties to design efficient 
imaging agents. The paucity of data on several parameters, including the number of GLP-1 
receptors per cell and transient changes in internalization rate and down-regulation prevented 
accurate simulations of optimal probe properties. To quantify the internalization rate of GLP-1R 
and determine the role of receptor recycling, downregulation, and plasma clearance on imaging 
contrast, we synthesized a series of molecular imaging probes based on the exendin-4 peptide 
that vary in molecular weight and plasma clearance to determine the impact on TBR (Scheme	
3.1). We also measured the time-dependent internalization rate using a quenchable probe and 
quantified the in vivo receptor expression. The data will help the design of improved imaging 





Scheme 3.1 Design and synthesis of various near-infrared exendin-based imaging agents 
Design and synthesis of fast clearing IRDye 800CW conjugates and a slow clearing Cy7 
monomer. Di-alkyne and tri-alkyne linkers were used to simultaneously generate exendin 
multimers and conjugate IRDye 800CW. Exendin crystal structures (PDB 3C59) are shown with 
the modified residues highlighted in red.	
	
3.4 Results 
To test the effect of plasma clearance on beta cell TBR, both fast and slow clearing 
exendin conjugates were synthesized. Based on its position pointing away from the binding 
pocket of GLP-1R, the methionine at the 14th position (M-14) was substituted with 
azidohomoalanine (AHA) during solid phase peptide synthesis. Novel heterobifunctional linkers 
were synthesized to simultaneously link multiple exendin molecules and enable fluorophore 
conjugation using copper catalyzed click chemistry. Three conjugates of varying molecular 
weight— IRDye 800CW (800CW) monomer, 800CW dimer, and 800CW trimer— that rapidly 
clear from blood were synthesized. Careful consideration was taken when choosing dyes, since 
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they can strongly influence the rate of extravasation and renal filtration due to interactions with 
albumin165. A highly charged and hydrophilic IRDye 800CW fluorophore was used to generate 
fast clearing multimers of exendin and a hydrophobic Cy7 fluorophore was selected to 
synthesize a slow clearing exendin monomer. Additionally, AF488 and AF647 conjugates were 
synthesized for internalization rate measurements and receptor expression quantification, 
respectively. 
After synthesizing 1 and 2, the linkers were conjugated with the fluorophores and 
peptides. All fluorescent exendin probes were purified using HPLC and characterized by 
MALDI-TOF (Figure	 3.1). MALDI spectra for monomers were collected using reflectron 
positive mode; spectra for 800CW dimer and 800CW trimer were collected using linear positive 
mode. 
 
Figure 3.1 MALDI traces of purified imaging agents demonstrating successful synthesis 
Lower molecular weight conjugates ionized using reflectron-positive mode whereas larger 
molecular multimers were ionized using linear-positive mode. CHCA matrix used for all 
samples. 
 














Although crystallography for the receptor-ligand interaction for exendin indicate the M14 
residue points away from the binding pocket42, the affinity was measured to test the impact of 
fluorophore conjugation to the 14th position as well as confirm avidity effects of the 800CW 
dimer and trimer. Eleven or twelve-point affinity curves were generated in triplicate from 
binding assays using NIT-1 cells (Figure	3.2).  
 
Figure 3.2 In vitro receptor binding assay to quantify binding affinity 
Affinity curves indicate a strong affinity of all conjugates to GLP-1R with fitted Kd values. Data 
collected using flow cytometry and GLP-1R expressing NIT-1 cell line.	
	
Fluorophore conjugation had minimal impact on the affinity, and all fluorescent 
conjugates of exendin maintained high affinity for GLP-1R (Table	3.1). For 800CW dimer and 
800CW trimer, despite multivalency, the affinity decreased to values of Kd  = 8.3 ± 1.2 nM and 
Kd  = 20.9 ± 2.5 nM, respectively. It is likely that the steric hindrance resulting from adjacent 
exendin helices for the dimer and trimer overshadowed gains from avidity. 
	  



















Table 3.1 Summary of binding affinity and molecular weight information for conjugates 
Compound Fluorophore Expected MW Binding affinity 
(nM) 
AF488 monomer Alexa Fluor 488 4750 3.0 ± 0.2 
AF647 monomer Alexa Fluor 647 -- 4.6 ± 0.4 
800CW monomer IRDye 800CW 5219 2.6 ± 0.5 
800CW dimer IRDye 800CW 9523 8.3 ± 1.2 
800CW trimer IRDye 800CW 13745 20.9 ± 2.5 
Cy7 monomer Cy7 4768 12.4 ± 1.4 
 
 
Glucagon-like peptide-1 receptor, a member of the seven-transmembrane family of 
GPCRs, has been shown to internalize GLP-1 peptide with a rapid half-life of 2-3 min and a 
recycle half-life of 15 min 214. To verify that M14 exendin has no impact on receptor activation 
and subsequent endocytosis, internalization rates were measured on NIT-1 cells using a modified 
protocol from Schmidt et al186. After cells were allowed to internalize continuously for 
predetermined amounts of time, the total intensity per cell was compared to the surface quenched 
intensity per cell. The intensities plotted against time (Figure	 3.3a) were then fitted to a 
compartmental binding and internalization model to yield a rapid, early internalization half-life 
of 5.7 ± 0.9 min and a slower, long-term internalization half-life of 220 ± 10 min (Figure	3.3c). 
The biexponential fit indicates that the early, rapid binding and internalization phase accounts for 
68% of fluorescent intensity in the first 3 h of GLP-1R internalization. Additionally, by 
comparing the quenching of surface receptors incubated on ice (no internalization) with those 
after extended internalization, we estimate that the surface expression of GLP-1 receptor is 
downregulated between 55-60%. The slower internalization that is apparent at longer times (>30 
min) is likely a result of GLP-1R downregulation and slower receptor dynamics. Qualitatively, 
live cell time lapse imaging of NIT-1 (Figure	3.3b) and HEK-293 cells transfected with GFP-
GLP-1R agree with the results of the internalization assay. Surface binding and internalization 
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occur rapidly at early times, while images at longer times (60 and 180 min images) show small 
increases in fluorescence intensity. 
 
Figure 3.3 In vitro internalization assay results to quantify GLP-1R internalization rate 
In vitro internalization assay indicates rapid surface binding and internalization followed by 
slower internalization and GLP-1R downregulation (a). Live cell imaging of NIT-1 cells labeled 
with AF488 monomer (green intensity, b). Cells nuclei stained with Hoechst 33342 (blue). Fitted 
values for internalization and receptor expression (c). 
 
	
To measure in vivo clearance and biodistribution of the 800CW monomer, dimer, trimer, 
and Cy7 monomer, 0.5 nmol of fluorescent probe was injected via tail vein in C57BL/6 mice and 
allowed to circulate. Blood samples were taken at multiple time points, and the half-lives of 
exendin conjugates in plasma were calculated by fitting the data to a biexponential decay (Figure	
3.4a). As anticipated, the 800CW conjugates cleared rapidly. We observed a fast decay of the 
majority of probe within a few minutes followed by a slower (~30 min) clearance phase for each 
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(Table	3.2). The clearance half-lives for all molecular weight variants were rapid and there was 
no significant difference among the different constructs (fast clearance p = 0.68; slow clearance 
p = 0.69). Cy7 monomer had much slower (> 7-fold) plasma clearance due to the hydrophobic 
nature of the fluorophore and plasma protein binding165. After the last blood sample was taken, 
the animal was sacrificed and the organs were weighed, homogenized, serial-diluted, and imaged 
to quantify normalized uptake (Figure	3.4b).   
 
Figure 3.4 Plasma clearance of IRDye 800CW and Cy7 conjugates 
Plasma clearance is rapid for all the hydrophilic IRDye 800CW conjugates, while the lipophilic 
agent clears slowly (a). Biodistribution shows higher non-specific uptake of multimers in the 
kidney and Cy7 uptake in the liver (b). Clearance rates were not significantly different between 
the monomer, dimer, and trimer. 
 
Uptake was higher in the kidney for the dimer and trimer compared to the 800CW and 
Cy7 monomers, and the Cy7 monomer was higher in the liver than the 800CW probes (p = 0.03). 
No significant differences were detected in the total pancreatic uptake between all constructs. 
With a blocking injection, non-specific/exocrine pancreatic uptake for the slower-clearing Cy7 
monomer measured 0.55	 ±	 0.04	 %ID/g whereas 800CW monomer was 0.3	 ±	 0.1	 %ID/g.	
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Subtracting %ID/g of blocked pancreata from experiments without blocking, the specific uptake 
in the islets was quantified to be 0.5 ± 0.1 %ID/g and 0.5 ± 0.4 %ID/g for the 800CW monomer 
at 3 h and Cy7 monomer at 5 h, respectively. 
 
Table 3.2 Plasma biexponential decay data of various exendin conjugates in mice 










3.9 ± 0.6 41 ± 3 0.91 ± 0.02 2180 
800CW 
dimer 
4.0 ± 2.0 25 ± 3 0.86 ± 0.06 2780 
800CW 
trimer 
3.0 ± 0.5 30 ± 3 0.96 ± 0.01 2140 
Cy7 
monomer 
17.0 ± 7.0 160 ± 30 0.67 ± 0.08 20180 
 
An AlexaFluor-647 monomer was injected intravenously in MIP-GFP mice to quantify 
receptor expression. Ex vivo labeling of isolated beta cells resulted in inconsistent signal 
intensity, so in vivo saturation was used to quantify expression levels. Macroscopic pancreas 
scans (Figure	3.6a) show AF647 signal in punctate spots several hundred microns in diameter, 
and confocal imaging of the pancreas from MIP-GFP mice indicate colocalization between the 
exendin-647 monomer and GFP expression (Figure	3.6b). Macroscopic images of the pancreas 
from mice injected with 800CW monomer, 800CW dimer, 800CW trimer, and Cy7 monomer 
(Figure	3.6c) indicate similar islet specific targeting across all constructs tested. Digestion of the 
pancreas into a single-cell suspension followed by fluorescence intensity measurements by flow 
cytometry indicated GLP-1R expression levels at 54,000 ± 3000 receptors/cell in vivo. A GLP-
1R expression measurement with NIT-1 cells indicated 17,000 ± 4000 receptors/cell. Cells 
incubated with collagenase for 15 min had < 5% change in cell surface labeling.	
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 To quantitatively analyze the impact of plasma clearance, molecular weight, binding 
affinity, and receptor internalization and down-regulation on targeting, we used a previously 
validated tissue transport simulation5, 76, 180, 181 incorporating the parameter values measured in 
this work (SI). The results showed this partial differential equation simulation can be simplified 
to an ordinary differential equation (compartmental) model without loss in accuracy (Figure	
3.5). In short, the imaging agent extravasates out of the pancreatic vasculature and is either 
specifically internalized after binding to GLP-1R, nonspecifically internalized by the exocrine 
pancreas, or washes out of the tissue. Both specific uptake in the islets and the non-specific 
internalization in the exocrine pancreas and nearby non-target organs such as liver and kidney 
are important for determining the target to background ratio in the pancreas.  
	
Figure 3.5 Compartmental analysis of transient probe concentrations 
Analysis of transient probe concentrations using receptor expression, binding rates, 
internalization kinetics, and biodistribution parameters. At later times, the majority of the probe 
is predicted to be in the internalized compartments for both target and non-target tissue, 
highlighting the importance of minimizing non-specific internalization. 
 
	
Additionally, kidneys express GLP-1R260, 261 but signal is dominated by non-specific 
uptake due to scavenger receptors and transporters in the proximal tubule. In the pancreas, GLP-
1R is weakly expressed in acinar cells of the exocrine pancreas whereas endocrine expression 
dominates53, 54. With the experimentally determined time-dependent internalization rates as 
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inputs for the compartmental model, we demonstrate TBR is maximized with rapidly cleared 
agents and decreases as uptake in non-target tissue increases. This is primarily due to the down-
regulation in receptor internalization at longer times and increased non-target tissue uptake for 
slow clearing agents.   
	
Figure 3.6 Macroscopic pancreas scans and confocal microscopy images using a transgenic 
mouse model 
Macroscopic pancreas scans indicate punctate spot formation for all exendin conjugates (a, c). 
Confocal microscopy demonstrates islet specificity using a transgenic MIP-GFP mouse through 
colocalization of GFP and probe (b). 
	
	
Additionally, dose of Cy7 monomer was optimized. Although the dose was subsaturating 
for the faster clearing agents, the slower clearance of the Cy7 monomer could potentially super-
saturate the pancreas and lower the %ID/g. To verify 0.5 nmol of Cy7 monomer does not 
saturate the pancreas, the dose was reduced (Figure	 3.7) and %ID/g measurements were 
	101	
repeated. %ID/g values were not statistically significantly different between the higher and lower 
dose of Cy7 monomer, indicating the original dose of 0.5 nmol was sub-saturating.  
	





Figure 3.8 Normalized uptake comparison between dosages to demonstrate subsaturating 
kinetics 
 
To compare the predictive model and experimental results, the concentration in the islet 
must be converted into the organ level percent injected dose per gram of pancreas tissue 


























































Cy7 monomer (reduced dose)
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(%ID/g). To make this conversion, the fraction of beta cells within the pancreas must be known. 
Using the data from Figure	3.4b, the simulations (details below) indicate that both 800CW and 
Cy7 monomer probes yield approximately 60-80 nM concentration within the islets. If we 
assume the islet fraction is 2% in the tissue, and use an algebraic equation to convert the signal 
into specific uptake in the pancreas262, then the predictive model is in agreement with our 
experimental results.  
 
% 𝐼𝐷 𝑔 =




% 𝐼𝐷 𝑔 =
70 𝑛𝑀 0.02 100%
211 𝑛𝑀 1.4 𝑚𝐿 1 𝑔/𝑚𝐿 = 0.47 %𝐼𝐷/𝑔 
 
However, this result requires further discussion. We and others have measured the beta 
cell fraction to be lower than 2% in rodents, closer to 0.7%76, 263. This would mean a higher 
concentration in the islets is required to agree with the experimentally measured %ID/g. The 
current concentration is close to a saturating dose, so it is unlikely that higher uptake in the islets 
(assuming receptor concentration and internalization estimates are correct) could come from the 
islets themselves. Low-level expression on exocrine cells may explain this specific uptake 52, 264. 
Using the same formula above, assuming the islet fraction is 0.7%, and assuming the remaining 
specific uptake is from GLP1-R expressed on exocrine cells, we estimate ~850 receptors per 
exocrine cell. If this is indeed the case, a low ‘cold’ dose that saturates the exocrine pancreas but 
not the islets may help in specificity. (The ratio of delivery to receptors is much higher in the 
exocrine pancreas than the islets, making it feasible to preferentially saturate these cells.) A 
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similar approach is used in the clinic for radioimmunotherapy (RIT) by blocking normal tissue 
receptors prior to delivering the radioactive dose to tumor tissue 265. 
 Another aspect of the model that we could not directly measure was the plasma protein 
binding of the fluorescent peptides. In the absence of more specific data, we assumed the bound 
fraction of the dye-peptide conjugates was the same as literature reports of IRDye 800CW and 
cypate after conjugation to a small tumor-targeting peptide165: 31% and 97.5% for IRDye 
800CW and Cy7, respectively165. Plasma protein binding has a major impact on the transient 
distribution of imaging agents. If no plasma protein binding were present, the predicted uptake in 
the islets would be far above saturation, which does not agree with our experimental results. This 
is in part due to the very high vessel surface area, blood flow, and permeability of the fenestrated 
capillaries. In addition, plasma protein binding is the mechanism for slower plasma clearance of 
Cy7, so it must be incorporated into the model. For a rapidly cleared monomer, reducing this 
plasma protein binding may be another way to improve the efficiency in islet uptake, achieving 
the same amount of specific targeting with a lower dose. A radiolabeled exendin with a 
residualizing, low plasma protein bound 111In tag has been used to demonstrate higher pancreas 
uptake in mice48. 
 
 To determine the impact of affinity, the wash out rate is compared with the 
internalization rate. Assuming binding reaches equilibrium in the tissue (which would occur 
within seconds given the effective antigen concentration and on rate), the rate of wash out 
depends on the PS/V and unbound probe. It is also assumed the on-rate is not significantly 
impacted by the trimer, which could be violated given the lower affinity. However, if the trimer 
has the same off-rate, then the on-rate would only change by 10-fold given the 10-fold higher Kd.  
	104	
Additional results include simulated islet and exocrine pancreas concentrations for the fast 
clearing IRDYE 800CW monomer and slow clearing Cy7 monomer. 
	




Figure 3.10 Simulation concentrations for islet and exocrine pancreas for Cy7 
	
	
Figure 3.11 HEK-293 binding assay 
Blocking both transfected and untransfected HEK-293 cells with non-fluorescent exendin prior 
to labeling with fluorescent exendin suggests non-specific binding to non-GLP-1R sites are low 
compared to receptor specific binding. 
 

































































Despite growing interest in developing GLP-1R imaging agents, the impact of plasma 
clearance and receptor kinetics on targeting efficiency have not been fully elucidated. The 
plasma clearance of exenatide has been manipulated through peptide/protein fusions266-268 and 
PEGylation258, 259 for drug treatment. However, ideal pharmacokinetics for imaging agents are 
typically very different than effective therapeutics. For example, rapid internalization of the 
GLP-1 receptor has been demonstrated upon peptide binding76, 214. While this can be problematic 
for therapeutics as endocytic pH changes and protease activity may rapidly degrade the 
molecule115, internalization is often beneficial for imaging agents by trapping a pH-tolerant 
residualizing label within the cell269. To quantify the impact of plasma clearance and 
internalization on the molecular imaging of GLP-1 receptors, we generated a series of exenatide-
based probes, measured GLP-1 receptor expression and internalization rates, and tested probe 
pharmacokinetics and imaging properties in vivo. 
 To investigate the effects of molecular weight on uptake in target and non-target tissue, a 
bifunctional linker was created to simultaneously crosslink multiple exendin peptides and 
conjugate a highly charged and fast clearing 800CW dye (Scheme	3.1). Additionally, a slower 
clearing exendin conjugate was synthesized using a more hydrophobic Cy7 dye that binds to 
plasma proteins165. All conjugates were synthesized with moderate yield (32-70%) with expected 
molecular weights as shown by MALDI-TOF and maintained strong binding affinity for GLP-
1R. Exendin-4 is reported to bind to GLP-1R with single-digit nanomolar affinity, and all 
fluorescent monomers maintain high affinity after conjugation due to the M14 position oriented 
away from the receptor binding interface42. Unexpectedly, the 800CW dimer and 800CW trimer 
molecules resulted in weakened affinity upon crosslinking. This is likely due to steric effects that 
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outweigh any benefit from avidity. A longer linker between the peptides may reduce this effect, 
but the cellular kinetics mitigate any benefit. The rapid internalization of GLP-1 receptor results 
in most of the probe being internalized before it can dissociate, similar to many antibodies270.  
 Literature reports on the internalization of GLP-1 receptor ligands vary in both rate and 
time-dependence, with some showing linear uptake over time271 and others indicating rapid 
internalization followed by down-regulation214, 272. To determine the potential amplification of 
cell labeling by internalization and recycling, NIT-1 cells were incubated with excess probe at 
37°C to allow for continuous uptake. The surface signal was quenched at each time point to 
decouple surface-bound and internalized probe. Fast surface labeling and internalization 
indicated by punctate vesicles in the cytosol occurred within minutes, consistent with previous 
observations. A time-lapse video (SI) along with live cell images at short times (<5 min) indicate 
the presence of numerous punctate, intracellular spots indicative of receptor trafficking upon 
internalization. This initial phase of uptake was followed by a much slower rate of continual 
internalization (half-life 220 min versus 5.7 min). This 38-fold reduction is predicted to lower the 
impact of sustained targeting on islet signal. 
Additionally, we sought to measure the endogenous expression level of GLP-1 receptor 
in mice. Reports of absolute receptor expression levels are rare and often variable in the 
literature. Levels on RIN-m5f cells have been reported as 1,107 receptors/cell273. However, our 
results in vivo indicate a higher expression based on signal intensity76. The reduced expression 
on the insulinoma cell line may be a result of adaptation to cell culture. Because labeling islet 
cells ex vivo resulted in variable signal, we injected a saturating dose (1.2 nmol) of AF647 
monomer into MIP-GFP mice and harvested the pancreas after only 30 min to minimize 
continuous uptake. After obtaining a single cell suspension, the cells were run on flow cytometry 
	107	
and compared to quantitative beads. The results indicate 54,000 receptors per cell in B6 mice and 
17,000 receptors per cell for NIT-1 cells. 
 To test whether slow clearance can be used to increase islet labeling, the different 
constructs were injected into B6 mice, and the plasma clearance was measured. At 3 h (for the 
rapidly cleared probes) or 5 h (for the slowly cleared monomer), the animals were sacrificed and 
biodistribution was quantified274. For plasma clearance, no statistically significant difference 
occurred for the monomer (5.3 kDa), dimer (9.5 kDa), and trimer (13.7 kDa) labeled with 
800CW. This is consistent with molecules that are well below the ~60 kDa cut-off for renal 
filtration275. However, the monomer with a lipophilic Cy7 dye showed over a 7-fold increase in 
AUC due to plasma protein binding and reduced renal clearance165.  
 The targeting of islets for each probe was confirmed by imaging the pancreas of each 
mouse, with islets readily apparent as bright, punctate foci ~100-300 microns in diameter. Using 
a MIP-GFP mouse, which expresses GFP exclusively in the beta cells, colocalization confirmed 
islet specificity. All 4 constructs showed excellent islet specificity, but no statistically significant 
differences occurred in the pancreas %ID/g.  The lack of higher uptake from the more slowly 
cleared agent is likely due to the down-regulation and slower net internalization of GLP-1 
receptors upon sustained exposure to exendin peptide. Since the initial rapid internalization is 
responsible for the majority of specific beta cell signal, a slow clearing imaging agent with 
detectable concentrations in the blood at longer times is not advantageous when the goal is to 
maximize the TBR. 
 Off-target uptake is equally important in designing effective imaging agents as 
demonstrated by the biodistribution. Despite similar plasma clearance rates, the renal uptake of 
the dimer and trimer are 3-fold higher than the monomer. After filtration by the glomerulus, 
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degradation and scavenger receptors in the renal proximal tubule recycle amino acids and 
peptides, preventing excretion in the urine118. Uptake of the dimer and trimer in the proximal 
tubule by scavenging receptors appears to be more efficient than the monomer and highlights a 
drawback of multimerization. Our results here are consistent with other reports276, 277 showing 
higher renal uptake for multimers, motivating the development of high affinity monovalent 
constructs132, 275, 278 rather than using avidity to compensate for low affinity. Although not 
statistically significant in all cases, the dimer and trimer generally have higher signal in other 
tissues as well. Non-specific internalization in off-target tissues is a major determinant of probe 
TBR, particularly for rapidly cleared low molecular weight agents. The rapid plasma clearance 
allows imaging after the majority of probe is removed from the blood (< 0.5% in the case of the 
monomer, dimer, and trimer). However, due to the residualizing IRDye 800CW label179, both 
specifically and non-specifically internalized IRDye 800CW label wash out of tissue extremely 
slowly, negating any benefit of later imaging times. 
 The lipophilic Cy7-conjugate had ~10-fold slower clearance than the IRDye 800CW 
monomer, but tissue differences were more modest when the majority of probe had cleared from 
the plasma. One significant difference was the higher liver uptake of the Cy7 monomer. An 
alternative approach to slow clearance is to add an albumin binding peptide sequence through 
solid-phase synthesis 267, but increased liver uptake	 due	 to	 longer	 plasma	 exposure	 and/or	
scavenger	uptake279, 280 and down-regulation of GLP-1R may not provide any targeting benefit 
over the more rapidly cleared monomer. In the pancreas, total uptake of 800CW and Cy7 
monomers was not statistically different (p = 0.26). To measure the specific uptake in the 
pancreas (versus total uptake), mice were given a large dose of wild-type exendin-4 45 minutes 
prior to injection of either 800CW monomer or Cy7 monomer. The higher non-specific uptake in 
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the pancreas (p = 0.024), despite having 5 h to clear (versus 3 h for 800CW), is consistent with 
the internalization conclusions: the majority of specific uptake in the target tissue occurs on the 
time scale of minutes given the rapid internalization rate of GLP-1R. Slower clearance does not 
increase specific uptake as demonstrated by similar specific %ID/g between the Cy7 monomer 
and 800CW monomer. Considering the fact that islets only make up 1-2% of the pancreas mass, 
specific uptake of 0.5% ID/g on a whole pancreas basis means the efficiency of uptake within the 
islets must be 25-50% ID/g. Although the high blood flow, fenestrated capillaries, and large 
capillary surface area provide excellent delivery to the islet, this analysis suggests equal 
consideration should be paid to reducing non-specific uptake in the tissue due to charge and 
hydrophobic interactions148, 167, 168. Additionally, ratio imaging may help normalize the non-
specific uptake to better quantify specific targeting281. Being able to quantify plasma protein 
binding, blood clearance rate, and non-specific uptake rate in the exocrine pancreas as well as 
nearby organs such as kidney and liver will aid in imaging agent design when scaling to the 
clinic. Given the penetration depth limitations of whole-body optical and fluorescence imaging, a 
radiolabeled agent will ultimately quantify BCM in patients. However, fluorescence imaging 
with animal models will precede radiolabeling because optimal physicochemical probe 
properties are measured more readily using fluorescence.  
 To determine the impact of down-regulation and plasma clearance on imaging, a 
mechanistic, quantitative, and predictive model was used to examine the interdependent 
parameters. No experimental data were fit to the kinetic model, allowing for an independent 
comparison of islet targeting. A full distributed-parameter simulation180, 181 was first conducted 
to show that the rapid diffusion and highly vascularized islet results in relatively homogeneous 
islet distribution, enabling the use of a compartmental analysis. The kinetic analysis using the 
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receptor expression, internalization kinetics/downregulation, and biodistribution parameters from 
this work indicate a rapidly cleared agent provides higher TBR than a slowly cleared agent (SI). 
The predicted uptake values were within experimental error of the measured uptake values. 
However, some small discrepancies suggest the possibility of low-level exocrine pancreas 
binding, and plasma protein binding of the fluorescent-exendin derivatives was an important 
parameter in the simulations (SI). The model also predicts that after the imaging agent is 
eliminated from blood and the interstitium at longer times, TBR remains relatively constant due 
to similar clearance (kdeg) of specifically and nonspecifically internalized probe.  This TBR is 
higher for the fast clearing monomer due to lower exocrine uptake.  
Sweet et al. estimated that the signal from islets would need to be 10-fold higher than 
non-specific exocrine signal for accurate BCM quantification17  Since beta cells form ~1% of the 
pancreas, the beta cell signal needs to be 1,000-fold higher than exocrine cells. Our results 
indicate that the overall islet specific signal is 1.7 to 2-fold higher than exocrine signal, within 
reach of the 10-fold specificity required for accurate BCM imaging. A quantitative and 
mechanistic understanding of other targeting molecules71, 282 rather than exclusively 
biodistribution data will help make rational comparisons between agents. These quantitative 
simulations can also focus design efforts for improvements in the development of new agents to 
achieve the necessary specificity. 
 
3.6 Conclusion 
 We investigated the impact of plasma clearance and receptor down-regulation using four 
different GLP-1 receptor imaging agents varying in molecule weight and plasma clearance. The 
high affinity of the monomeric probe was sufficient for specific targeting, whereas higher non-
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target tissue uptake, particularly in the kidney, highlights the drawbacks of imaging with 
multimeric peptides. Targeting of a plasma protein binding probe was mitigated by the rapid 
down-regulation of the receptor. Our results indicate the ideal BCM imaging agent clears quickly 
from blood to benefit from early rapid internalization while avoiding non-target uptake at later 
times. High levels of receptor expression (> 50,000 receptors per cell), rapid internalization, and 
an easily accessible cell surface location make GLP-1 receptor an attractive target for BCM 
quantitation, and simulations help identify the most important areas for improvement. Lowering 
non-specific interactions through peptide stabilization187, 283 and/or accounting for this signal 
through ratio imaging281 will help increase the precision and sensitivity of beta cell mass 
measurements for the early detection of type 1 diabetes. 
 
3.7 Experimental Methods 
All chemicals, unless specified, were purchased from Sigma-Aldrich (Milwaukee, WI) 
and were used as received. Fluorochromes AF647 alkyne and AF488 alkyne were purchased 
from Life Technologies (Carlsbad, CA); Cy7 was purchased from Lumiprobe (Hallandale Beach, 
FL); IRDye 800CW was purchased from Licor (Lincoln, NE). Mutant exendin-4 
(HGEGTFTSDLSKQXEEEAVRLFIEWLKNGGPSSGAPPPS), where X is the non-natural 
amino acid azidohomoalanine, was purchased from Innopep (San Diego, CA). Reversed phase 
high performance liquid chromatography (RP-HPLC) and size-exclusion chromatography were 
performed on a Shimadzu LC unit using Luna C18(2) and Yarra SEC-2000 columns, 
respectively (Torrance, CA). ESI-MS data were obtained using an Agilent Q-TOF 1200 series. 
MALDI-MS spectra were collected using a Bruker Autoflex mass spectrometer. NMR spectra 
were collected using a Varian MR400 spectrometer. All MALDI-TOF and ESI-Mass 
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Spectrometry data were collected at the University of Michigan Department of Chemistry’s Core 
Facility. Fluorescence microscopy was performed using an Olympus FV 1200 microscope and 
an Olympus-IX81 spinning disk confocal microscope. 
 
Preparation of N,N’-di(prop-2-yn-1-yl)pentane-1,5-diamine (1) and 5-amino-N,N,N-tri(prop-2-
yn-1-yl)pentan-1-aminium (2) 
N-Boc-cadaverine (800 µmol) was added to potassium carbonate (2.4 mmol) in 2 mL 
acetonitrile (MeCN). Propargyl bromide in toluene was added dropwise (2.0 mmol) and the 
reaction mixture was stirred overnight at room temperature before being concentrated under 
reduced pressure. The reaction mixture was filtered and deprotected using 50% trifluoroacetic 
acid in dichloromethane, and purified using preparative RP-HPLC using a constant gradient of 
5:95 of MeCN:H2O to yield 1 and 2 (212 µmol, 27%;127 µmol, 16%). 1: 1H NMR (400 MHz, 
CD3OD): d: 4.22 [d, J = 2.4, 4 H], 3.37 [t, J = 2.8, 2 H], 3.32 [t, J = 7.6, 2 H], 2.94 [t, J = 7.6, 2 
H], 1.82 - 1.68 [m, 4 H], 1.47 [quint, J = 7.6, 2 H]. HRMS: m/z calculated for C11H18N2: 
178.1470, found: 179.1543 [MH+]. 2: 1H NMR (400 MHz, CD3OD): d: 4.50 [d, J = 2.4, 6 H], 
3.64 - 3.59 [m, 5 H], 2.95 [t, J = 7.6, 2 H], 1.89 - 1.85 [m, 2 H], 1.75 [quint, J = 7.6, 2 H], 1.48 
[quint, J = 7.6, 2 H]. HRMS: m/z calculated for C14H21N2: 217.1705, found: 217.1699. 
 
IRDye 800CW conjugation to (1) and (2) 
IRDye 800CW NHS ester (1 µmol in DMSO) was added to an aqueous solution 
containing either 1 or 2 (10 µmol) buffered with 7.5% sodium bicarbonate. The reaction was 
stirred at room temperature for 30 min followed by purification on preparative RP-HPLC (12 
mL/min; A: 0.1% trifluoroacetic acid in water, B: 0.1% trifluoroacetic acid in acetonitrile; 20-
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60% B 0.1-10 min) to give fluorescent di-alkyne and tri-alkyne 3 and 4, respectively; 3: tR = 8.4 
min; 4: tR = 7.3 min MALDI-TOF: 3: m/z calculated: 1160.42, found: 1163.49; 4: m/z calculated: 
1198.47, found: 1201.49; 
 
Preparation of Cy7 alkyne 
Propargylamine (5 µmol) was added to 200 µL of 1:1 water:acetonitrile buffered with 
7.5% sodium bicarbonate. Cy7 NHS ester (0.5 µmol in DMSO) was added and the reaction was 
stirred at room temperature for 30 min followed by purification on preparative RP-HPLC (Cy7 
alkyne: 65% B 0.1-20 min: tR = 16.4 min). HRMS: m/z calculated for C14H21N2: 586.3797, 
found: 586.3795.  
 
Preparation of fluorescent exendin monomers 
AF488 alkyne (0.2 µmol), AF647 alkyne (0.2 µmol), IRDye 800CW alkyne (0.2 µmol), 
or Cy7 alkyne (0.2 µmol) was added to 200 µL of water followed by CuSO4-TBTA (20 nmol) 
and sodium ascorbate (1 µmol). Lastly, mutant exendin (0.2 µmol) was added and the reaction 
mixture was stirred at room temperature for 12 h followed by purification using preparative RP-
HPLC (AF488 monomer: 20-55% B 0.1-17 min: tR = 15.3 min; AF647 monomer: 20-30% B 0.1-
4 min, 30% B 4-7 min, 30-55% B 7-17 min: tR = 15.3 min; IRDye 800CW monomer: 20-70% B 
0.1-15 min: tR = 9.7 min; Cy7 monomer: 30-90% B 0.1-22 min: tR = 11.1 min). MALDI-TOF: 
AF488 monomer: m/z calculated: 4750, found: 4754; AF647 monomer: m/z calculated: MW of 
dye unpublished, found: 4859; IRDye 800CW monomer: m/z calculated: 5219, found: 5220; Cy7 
monomer: m/z calculated: 4768, found: 4764. 
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Preparation of IRDye 800CW dimer and IRDye 800CW trimer 
3 or 4 (0.2 µmol) was added to 200 µL of water followed by CuSO4-TBTA (20 nmol) and 
sodium ascorbate (1 µmol). Lastly, mutant exendin (0.6 µmol for IRDye 800CW dimer, 0.8 µmol 
for IRDye 800CW trimer) was added and the reaction mixture was stirred at room temperature 
for 12 h followed by purification using SEC-HPLC at a flow rate of 1 mL/min phosphate 
buffered saline (PBS), pH 7.4. MALDI-TOF: 800CW dimer: m/z calculated: 9523, found: 9536; 
IRDye 800CW trimer: m/z calculated: 13745, found: 13758. 
 
Cell culture and stable transfection cell line generation 
NIT-1 cells were generously provided by Dr. Ralph Weissleder’s Laboratory and used for 
in vitro receptor binding assays due to NIT-1 expression of GLP-1R. Cells were grown in F12K 
containing 10% (v/v) FBS, 50U/mL penicillin, 50 µg/mL streptomycin, and 1.5 g/L sodium 
bicarbonate. The passage number for NIT-1 cells was between 4-8 for affinity measurements of 
all fluorescent exendin conjugates as well as internalization rate determination. For transfected 
cells, human embryonic kidney cells (HEK293) were grown in DMEM containing 10% (v/v) 
FBS, 50U/mL penicillin, and 50 µg/mL streptomycin. To generate a stable cell line, HEK293 
cells were first cultured in 6-well plates and transfected using Lipofectamine 2000 following the 
manufacturer’s instructions to express GLP-1R (GFP-tagged, Origene) and then selected with 1 
mg/mL G-418. 
 
In vitro receptor binding assay 
NIT-1 cells were plated, grown for 48 hours, harvested with 0.05% trypsin-EDTA, 
washed, and resuspended in PBS with 0.1% bovine serum albumin (BSA). The cells were then 
	115	
aliquoted and suspended in binding buffer containing fluorescent exendin conjugates ranging in 
concentration on ice (0.025-250 nM). The cells were then washed two times with 0.1% BSA in 
PBS and then immediately analyzed using an Attune Acoustic Focusing Cytometer (Applied 
Biosystems) or a LICOR Odyssey CLx scanner (Lincoln, NE). Affinity curves and statistical 
analyses were carried out using Prism 6.0 software. 
 
Internalization assay 
The internalization protocol was adapted from a previously published method for 
antibodies and antibody fragments186. Briefly, NIT-1 cells were subcultured into 24-well tissue 
culture plates, allowed to adhere, and grown for 48 h. After washing once with media, cells were 
incubated in binding buffer containing 40 nM AF488 monomer in media and allowed to 
internalize continuously at 37°C for 3 h, while controls were kept at 4°C. At 15, 30, 60, 120, and 
180 min, cells were washed once with chilled 0.1% FBS in PBS and placed on ice. Cells were 
then incubated with 100 µL cell dissociation buffer (Gibco) for 5 min, lifted, and pelleted in 
microcentrifuge tubes. Lastly, cells were then resuspended in PBS or a dilution of 0.4% trypan 
blue in PBS (dilution factor 4) and analyzed using an Attune Acoustic Focusing Cytometer to 
differentiate between surface and internal fluorescence at various time points. Live cell time 
lapse images were collected at 37°C on an Olympus-IX81 spinning disk confocal microscope 
using a 488 nm laser line to corroborate the cytometry results. The cytometry results were fit to a 
multi-compartmental model with linear kinetics on MATLAB to calculate the internalization 




All animal experiments were conducted in compliance with the University of Michigan 
University Committee on Use and Care of Animals (IACUC). For determining plasma clearance 
half-life, IRDye 800CW monomer, IRDye 800CW dimer, IRDye 800CW trimer, or Cy7 
monomer (0.5 nmol) was injected in the tail vein of C57BL/6 mice. Blood samples were 
collected at 1, 3, 5, 15, 30, 60, and 180 min; in the case of the Cy7 monomer, blood was also 
collected at 300 min. 10 µL of whole blood was mixed with 20 µL of 10 mM EDTA in PBS, and 
spun down to isolate the plasma. Plasma samples were quantified with controls using a LICOR 
Odyssey CLx scanner to determine absolute concentration in the blood. After the last time point, 
the mice were sacrificed and the organs resected and visualized macroscopically on the Odyssey 
CLx. To confirm in vivo specificity of the fluorescent exendin conjugates, a 15 nmol dose of 
non-fluorescent, wild-type exendin-4 was administered via the tail vein 45 min prior to injecting 
the fluorescent conjugate. All in vivo receptor expression and biodistribution experiments 
(blocked, unblocked for each probe) were done in triplicate. 
 
In vivo GLP-1R quantification 
To measure the expression level of GLP-1R in vivo, a saturating dose of 1.2 nmol of 
AF647 monomer was injected in the tail vein of transgenic mice containing GFP under the 
control of the mouse insulin promoter (MIP-GFP mice, Jackson Laboratory Strain B6.Cg-
Tg(Ins1-EGFP)1Hara/J). At 30 min post-injection, the mice were sacrificed and the pancreas 
resected. Successful islet targeting was confirmed using an Odyssey CLx scanner and by 
verifying colocalization of GFP and AF647 signal using fluorescence microscopy. After 
confirming specific islet targeting, the pancreas was incubated at 37°C for 15 min in 1 mg/mL 
collagenase type XI in PBS with continuous mixing to obtain a single cell suspension. The cells 
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were analyzed with an Attune Acoustic Focusing Cytometer to determine the fluorescence 
intensity of AF647 on the GFP-positive β-cells. After accounting for quenching effects of 
conjugating AF647 to exendin, a calibration curve generated with Quantum Alexa Fluor 647 
MESF beads (Bangs Laboratories, Inc.) was used to determine the GLP-1R expression level in 
vivo. 
 
Ex vivo biodistribution 
The following protocol was modified from a previously published protocol for measuring 
uptake of fluorescent antibodies ex vivo274. Briefly, after animals were sacrificed, organs were 
resected, weighed, and incubated at 37°C in a mixture of RIPA buffer in PBS supplemented with 
6 mg/mL collagenase type IV for 30 min. Next, 0.05% trypsin/EDTA was added and the digest 
solution was incubated for another 30 min at 37°C before being homogenized using an FB-120 
Sonic Dismembrator. Each homogenized organ was then serial diluted in a 96-well plate and the 
fluorescence was quantified using an Odyssey CLx scanner. A calibration curve was generated 
using known amounts of fluorescent exendin in the digest solution and the %ID/g was calculated 





Rslow: Free receptor/antigen undergoing slow internalization 
Rfast: Free receptor/antigen undergoing fast internalization 
Pfree: Free peptide in the interstitium 
Pbound,slow: Surface bound peptide on a slow internalizing receptor 
Pbound,fast : Surface bound peptide on a fast internalizing receptor 
Pexocrine: Free peptide in exocrine pancreas 
Pint: Internalized peptide 
Pint,nonspec: Internalized peptide in the exocrine pancreas (assumed to be non-specifically 
internalized) 
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Pplasma: Concentration of peptide in plasma 
kon: On rate for binding 
koff: Off rate for binding 
kint,slow: Slow internalization rate 
kint,fast: Fast internalization rate 
kint,nonspec: Non-specific uptake rate in exocrine and non-target tissues 
kdeg: Degradation rate – includes protease digestion and loss of probe (residualization rate179) 
A: Fraction fast for plasma clearance or fraction fast internalization 
S/Vtarget: capillary surface area to tissue volume ratio for target tissue 
S/Vexocrine: capillary surface area to tissue volume ratio for exocrine/background 
P: Vascular permeability 
Xplasma,bound: Fraction of probe in plasma bound to plasma proteins 
 
	
Figure 3.12 Compartmental analysis for in vivo studies 
Plasma clearance is modeled as a biexponential decay function: 
  
 
Target tissue pathway: 
Free peptide compartment: 
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This concentration is calculated using 54,000 receptors/cell and 7e8 cells/mL. 
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Figure 3.13 Compartmental model for fitting fast and slow internalization rate constants 
Fast pathway: 
Free receptor compartment: 
 





Free receptor compartment: 
 





= kint,slowA*Psurface,initial − konPfree *Rfast + koff Pbound , fast − kint,slowRfast
dPbound , fast
dt
= konPfree *Rfast − koff Pbound , fast − kint, fastPbound , fast
dPint, fast
dt
= kint, fastPbound , fast − kdegPint, fast
dRslow
dt
= kint,slow (1− A)*Psurface,initial − konPfree *Rslow + koff Pbound ,slow − kint,slowRslow
dPbound ,slow
dt
= konPfree *Rslow − koff Pbound ,slow − kint,slowPbound ,slow
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Table 3.3 Measured and literature parameters used in mechanistic and predictive model 
Symbol Parameter Value Notes References 
C0 Initial Plasma 
Conc 
211 nM Dose dependent Measured 
Tcell Receptors/cell 54,000 C57BL/6 Mouse Measured 
Q Blood flow 173 
mL/min/100g 
Not rate limiting 98, 211 
[Cell] Beta cell density 7x108 cells/mL  21 
[T] GLP-1 Receptor 
Conc 
63 nM Based on 7x108 cells/mL Calculated 
P Permeability 2.1x10-5 cm/s 10-fold higher than non-
fenestrated normal tissue 
98, 213 
kon Binding rate 1.4x106 /M/s  
214 
Kd Binding Affinity 2.6/12.4 nM  Measured 
D Diffusion 
Coefficient 
100 um2/s Not rate-limiting 25 
S/V Capillary surface 
area to tissue 
volume 
505 cm2/cm3 Extremely high in islets 5 
ε Void fraction 0.1 Interstitial space in 




= kint,slowPbound ,slow − kdegPint,slow
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insulin) 








0.012 /hr Fluorescent dye specific 179 
A Fraction alpha 
See Chapter Measured kfast Alpha clearance 
kslow Beta clearance 
Vplasma Plasma volume 1.4 mL  
285, 286 
 
 The uptake in islets was simulated using an adaptation of a previously published and 
validated tissue transport model 97, 287. Literature values for the parameters are listed in Table	3.3 
along with experimentally measured parameters. For the islet uptake, no parameters were fit to 
the experimentally measured %ID/g values. 
To model the exocrine/background concentration, the non-target uptake rate in the 
exocrine pancreas was experimentally determined for both the 800CW and Cy7 monomers. By 
first blocking GLP-1R in vivo with non-fluorescent exendin, the non-target uptake in the 
exocrine pancreas was approximated using the %ID/g of fluorescent exendin post-blocking. 
Subtracting %ID/g of blocked pancreata from experiments without blocking, the specific uptake 
in the islets was quantified to be 0.5 ± 0.1 %ID/g and 0.5 ± 0.4 %ID/g for the 800CW monomer 
at 3 h and Cy7 monomer at 5 h, respectively. Assuming plasma protein binding fractions of the 
free IRDye 800CW and Cy7 for the monomers (31% and 97.5%, respectively), non-target uptake 
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rates were fit for the exocrine pancreas using a compartmental model and found to have an 
uptake half-life of 61 ± 18 min and 9.2 ± 0.7 min for 800CW monomer and Cy7 monomer, 
respectively. Using this non-target uptake rate, an exocrine concentration was modeled. The 
target tissue (islet) concentration was simulated by combining surface bound and internalized 
probe. The exocrine concentrations match experimentally determined pancreatic concentrations 
from blocked experiments. However, the predicted islet concentrations were lower than 
experimental values (if there is a < 2% beta cell fraction in the pancreas). This could be due to 
error in the total receptor concentration (receptors/cell and islet cell density) or exocrine cell 
receptor expression (discussed above). However, islet expression is still high enough to quantify 





Chapter 4      
Blocking Exocrine Glucagon-Like Peptide-1 Receptor In The Mouse Pancreas For 
Accurate Beta Cell Mass Quantification In Diabetic Models 
4.1 Abstract 
The ability to measure beta cell mass early in the development of type-1 diabetes (T1DM), 
before insulin insufficiency and elevated glucose levels, would be transformative for the diabetes 
community. Exendin imaging agents have shown promising results in preclinical animal models 
of disease. However, results in the clinic have so far failed to accurately quantify beta cell mass. 
One of the surprising outcomes was higher than expected signal in long-term T1DM patients, 
which should have no beta cells. Recent evidence by our lab and others indicates that a very low 
level of expression on exocrine cells could be contributing to this falsely high signal due to their 
much higher abundance. The goal of this work is to develop a successful imaging strategy in 
animal models of T1DM by blocking non-specific/exocrine probe uptake to increase beta cell 
specificity. Using a multi-dose strategy with a lipophilic blocking agent, it was possible to block 
near-100% of exocrine signal while sparing a sufficient amount (15-20%) of the endocrine 
receptor for imaging. This provides a feasible method to block exocrine receptors and 





Unregulated blood glucose levels resulting from diabetes negatively impact over 400 
million patients worldwide. In addition to the financial burden, which constitutes approximately 
10% of all healthcare costs in developed countries, patients are at risk of kidney disease, 
peripheral artery disease, and stroke and must rely on medications for life as no cure currently 
exists. Understanding disease pathophysiology has long been an interest for both the medical 
community and patients. However, diabetes remains challenging to study due to the inability to 
directly monitor the human pancreas, the central organ in the disease. Insulin-secreting beta cells 
play a pivotal role in disease progression but they cannot be directly observed. Functional 
studies, such as measuring insulin secretion or glucose monitoring, are not sensitive to early 
stages of the disease due to excess insulin secretion capacity of the beta cells. A non-invasive 
molecular imaging method for quantifying the beta cell mass (BCM) will prove invaluable for 
monitoring disease progression and assessing treatment efficacy. 
There is currently no method for measuring the insulin-secreting BCM during the 
progression and treatment of diabetes. Molecular imaging approaches are promising, but the 
small size of islets of Langerhans where beta cells reside and low fraction of beta cells in the 
pancreas (~1% in healthy patients) have prevented the development of a translatable method. 
The inability to measure beta cell mass (BCM) in the clinic is a major roadblock to 
understanding the basic etiology of the disease, monitoring islet transplants, and measuring the 
efficacy of immunomodulatory therapies. Extensive research has been conducted to develop an 
imaging approach, but the small size and low fraction of islets in the pancreas have so far 
prevented a translatable method. One of the most advanced imaging targets has recently shown 
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higher than expected signal in patients that completely lack beta cells. Recently, others and we 
have demonstrated that off-target binding of glucagon-like peptide 1 (GLP- 1) receptor imaging 
agents has confounded the development of a probe for measuring beta cell mass in diabetes. New 
evidence indicates that low-level expression of glucagon-like peptide 1 receptor (GLP-1R) on 
non-target (exocrine) cells in the pancreas is responsible for the lack of specificity of these 
agents. Low levels of GLP-1R expression on exocrine cells are reported in mice, monkeys, and 
humans and can be blocked with unlabeled peptide without saturating beta cells, thereby 
allowing a follow-up imaging dose to specifically quantify BCM in animals and humans. This 
problem presents an opportunity to develop a translatable approach for beta cell imaging. By 
blocking non-specific/exocrine probe uptake, beta cell specificity can be improved for clinical 
translation. 
To preferentially block the exocrine GLP-1R while maintaining free beta cell receptor for 
imaging agent labeling, a multiple dose strategy will be demonstrated using mouse models. 
Multiple doses are required to completely block the exocrine cells due to trafficking of the 
receptor. An exocrine saturating dose of lipophilic fluorescent exendin is first administered to 
block surface receptors and intracellular receptor that is recycled to the surface (due to the slow 
plasma clearance of the lipophilic peptide). The lipophilic molecule may also have slower 
diffusion into the Islets of Langerhans, sparing some of the desired target (endocrine receptor). 
An imaging dose is then administered to rapidly target the endocrine beta cells.  
	
4.3 Results 
Exendin is Taken Up Specifically by Low GLP-1 Receptor Expression in the Exocrine Pancreas 
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To independently verify exocrine GLP-1R expression, either blocking or imaging agent 
doses were administered intravenously to GLP-1R knockout mice. Comparing the fluorescence 
intensities quantified by flow cytometry, the exocrine signal from a wild type mouse receiving a 
high blocking dose of non-fluorescent exendin was lower than an unblocked mouse but the same 
as GLP-1R knockout mice (blocked or labeled). This indicates exendin binds specifically to 
GLP-1R (but not to any other receptors) and confirms a low level of exocrine GLP-1R 
expression. 
 






Figure 4.2 Demonstration of GP-1R expression in exocrine cells.  
Three wild-type and 3 GLP-1R KO mice were injected with saturating doses of AF647 exendin. 
Three mice each were also injected with 15-fold excess of unlabeled peptide followed by AF647 
exendin. The single cell suspension was run on flow cytometry. Exocrine cells showed a low but 
robust signal that could be blocked. Endocrine cells showed a much higher specific signal that 
could be blocked, as expected. 
 
 
 Exocrine Pancreas GLP-1R Can be Selectively Blocked 
 Three sets of healthy B6 mice were injected with either labeling, blocking, or low 
“exocrine-blocking” doses of exendin. For the labeled mice, 1 nmol of AF647 probe was injected 
via the tail vein, and the mouse was sacrificed 15 min after the probe injection. For complete 
blocking of GLP-1R, 15 nmol of exendin are injected followed 10 min later by 1 nmol of 
AF647-exendin, and sacrificed 15 min after the imaging probe injection. For the low “exocrine-
blocking” dose, 170 pmol of Cy7-exendin is injected i.v. followed 10 min later by 1 nmol of 
AF647-exendin. 5 min after the imaging dose, a 15 nmol “post-block” dose of exendin is 
injected i.v. to “quench” any remaining receptor that traffics to the surface of exocrine cells. 10 
min later (15 min after imaging probe injection), the mouse is sacrificed. The pancreas were 
removed and digested into a single cell suspension followed by cytometric analysis. The results 
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indicated near 100% of exocrine pancreas blocked in all sets of mice. A significant fraction of 
the endocrine beta cell receptors were blocked as well (80-86%).  
Preliminary results showed that a hydrophilic probe could not selectively saturate the exocrine 
pancreas relative to islets. The working hypothesis is that the probe could rapidly diffuse into the 
islets such that blocking was limited by the thermodynamics of binding rather than the kinetics 
of delivery. Multiple doses of the Cy7 probe were required to completely block the exocrine cells 
due to trafficking of the receptor. To prevent trafficking in the exocrine while waiting for the 
imaging dose to clear from the blood, a high non-fluorescent post-block dose was injected 5 
minutes after the imaging agent dose.  
Table 4.1 Endocrine and exocrine blocked values for exocrine blocking dosing strategy 
 Endocrine (beta cells), % 
blocked 
Exocrine, % blocked 
Set 1 86 100 
Set 2 80 100 
Set 3 85 98 
 
 Preliminary results with streptozotocin (STZ)-induced diabetic mice indicated a lack of 
islets both macroscopically (whole organ image) and at a cellular level (flow cytometry). 
Endocrine fluorescence intensity for STZ-treated mice, whether receiving a high-blocking dose 
or only an imaging dose, indicated a complete lack of beta cells in the pancreas. The exocrine 
intensity, however, was significantly higher for mice that received only the imaging agent dose. 
The results suggest GLP-1R expression in the exocrine tissue for mice treated with STZ.  
 Blood sugar levels were recorded for all animals before injection to ensure all healthy 
animals had significantly lower blood glucose levels than diseased animals. Healthy animals had 
levels ranging from 140-250 mg/dL of glucose, whereas STZ-treated animals had levels ranging 
from 400-600 mg/dL. 
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4.4 Discussion 
Exendin remains a promising targeting ligand for measuring BCM, but clinical 
translation has not been as successful as anticipated. Recently, multiple labs have demonstrated 
imaging agent signal from non-beta cell have confounded the development of a probe for 
quantifying the beta cell mass for type 1 diabetes. This inability to monitor the functioning BCM 
in real time is a hindrance to understanding disease progression, monitoring islet transplants, and 
assessing treatment efficacy of immunomodulatory therapies.  
The two most promising targeted molecular ligands for beta cells, namely agents for 
VMAT2 and GPL-1R, have shown higher than expected pancreas signal in long-term diabetics 
where there should be no beta cells remaining. Recent evidence by our lab and the literature has 
demonstrated low-level expression of GLP-1R in the exocrine tissue. This low level expression 
on non-target tissue, which remained elusive and controversial for many years due to the lack of 
specific antibodies against the receptor, is responsible for the lack of specificity of radiolabeled 
exendin-based imaging agents in the clinic. For this reason, there is a need to overcome the low 
expression in the exocrine pancreas tissue in order to develop a robust strategy for quantifying 
the beta cell mass in the clinic. The goal of this work is to develop a delivery strategy to 
specifically target beta cells to improve specificity. The strategy includes blocking the low level 
of GLP-1R expression in the exocrine tissue due to the large differences in receptor density 
(~850 receptors/cell versus 53,000 receptors per cell in exocrine and endocrine, respectively).  A 
subsequent imaging dose can then specifically quantify BCM in animals and humans. Endocrine 
and exocrine receptor expression level was previously quantified and appropriate blocking doses 
were formulated to simultaneously saturate exocrine tissue while subsaturating the beta cells. 
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To generate the blocking peptide, a lipophilic Cy7 fluorophore was covalently conjugated 
to exendin peptide via copper-catalyzed click chemistry. The molecular weight was verified via 
ESI-MS and targeting specificity was verified using an in vitro binding assay. The imaging dose 
was similarly synthesized by conjugating a hydrophilic Alexa Fluor 647 fluorophore to exendin. 
The more lipophilic Cy7 exendin conjugate has a lower diffusion coefficient in tissue, which 
prevents unwanted diffusion of the blocking dose to the endocrine beta cells. As a result, the 
blocking dose is delivered ‘locally’ (i.e. it doesn’t diffuse significantly between the endocrine 
and exocrine tissue) at a rate proportional to the permeability surface area product (PS/V). This is 
consistent with previous work (data not shown) using a hydrophilic exendin as the blocking dose 
where high amounts of endocrine GLP-1R were blocked, presumably from diffusion into the 
islets from the exocrine tissue. Additionally, a lipophilic Cy7 exendin will clearly slowly from 
the blood allowing for the blocking dose to block recycled intracellular receptor. Previous data 
indicate islets of Langerhans reach maximum imaging agent signal 3-5 minutes post intravenous 
injection in mice. For this reason, a hydrophilic imaging agent dose was chosen to quickly 
saturate the endocrine beta cells. 
Given the similar GLP-1R mRNA profiles between mice and rats but large difference in 
exocrine uptake of exendin imaging probes, other groups have speculated that the probes may be 
binding a different receptor in mice. To confirm that these probes are only binding to GLP-1R in 
both the islets and exocrine pancreas, a GLP-1R knockout mouse model (courtesy of Dr. Dan 
Drucker) was imaged with our fluorescent probes. Fluorescence provides the single-cell 
resolution needed to quantify endocrine versus exocrine signal compared to radiolabels. It was 
demonstrated fluorescent exendin probes bind exclusively to GLP-1R in the pancreas (both beta 
cells and exocrine cells). To obtain this result, both wild type and knockout (GLP-1R-/-) mice 
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were injected with 1 nmol of exendin-AF647 intravenously, and the pancreas was harvested 20 
min later, digested, and analyzed by flow cytometry. A second set of mice received a large (15 
nmol) blocking dose of exendin 10 min prior to the 1 nmol fluorescent dose. The wild type 
controls show very high signal in the beta cells as expected. Importantly, unblocked GLP- 1R 
knockout mice showed the same exocrine signal as blocked mice, indicating that only GLP-1R is 
contributing to the exocrine uptake. The signal intensity ratio between beta cells and exocrine 
cells is ~40 which is consistent with our published estimate from biodistribution data. These 
fluorescent probes and flow cytometry data provide the extreme sensitivity necessary for 
measuring the very low but specific exocrine cell uptake. Despite these challenges and the 
controversy surrounding expression in different cell types, these data support a low-level 
expression of GLP-1 receptor in exocrine cells, which is consistent with other animal studies, 
physiological function of the receptor in exocrine cells, multiple reports showing ex vivo 
expression in humans, and the high signal intensity in some patients in clinical trials but not 
others (due to patient-to-patient variability in exocrine expression).  
After verifying exocrine GLP-1R, a blocking dose was implemented to preferentially 
block exocrine GLP-1R. This presents several challenges: the target and non-target cells are in 
the same tissue, and the blocking dose is more efficiently delivered to the undesired target tissue 
due to increased S/V (505 cm2/cm3 versus 180 cm2/cm3). As previously described, the first 
challenge was overcome using a lipophilic blocking dose with slow tissue diffusion. The binding 
and rapid internalization of the blocking dose allows for the selective blocking of exocrine cells 
through rapid binding. The challenge of more efficient delivery to the beta cells can be overcome 
by comparing the absolute GLP-1R expression on exocrine and endocrine cells. Despite a 3-fold 
higher surface area to volume in the endocrine tissue, there is a 50-fold greater receptor 
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expression. This indicates a 17-fold lower dose is required to saturate the exocrine compared to 
the islets of Langerhans. Although these predictions suggest a 17-fold difference, experiments 
indicated a 6-fold difference using a lipophilic Cy7-exendin blocking dose. The data indicate it is 
possible to block all exocrine receptors in the mouse pancreas while retaining approximately 15-
20% of the receptors on beta cells for probe binding. The remaining receptors are dramatically 
higher than required for PET or SPECT imaging given the high sensitivity of the modalities. 
Therefore, the ability to completely block the exocrine signal was the highest priority.  
 
4.5 Conclusions 
A successful imaging agent capable of quantifying changes in BCM during the 
progression of type-1 diabetes mellitus (T1DM), type-2 diabetes, and during therapeutic 
intervention would be invaluable to the diabetes community. Based on our data and literature 
reports, the pancreatic uptake of exendin probes in humans and animal models is sufficient for 
detection, but the major problem is the high signal in T1DM patients where there should be no 
signal. The goal of this work is to develop a successful imaging strategy in T1DM by blocking 
non- specific/exocrine probe uptake to increase beta cell specificity. Our central hypothesis was 
that the low level of GLP-1R expression on exocrine cells in mice could be blocked with 
unlabeled peptide without saturating beta cells, thereby allowing a follow-up imaging dose to 
specifically quantify BCM. Using a multi-dose strategy by pre-blocking exocrine cells with a 
lipophilic exendin followed by an imaging dose and a large post-imaging dose block (to prevent 
uptake during plasma clearance of the imaging probe), near-100% exocrine blocking could be 
achieved while sparing a sufficient amount (15-20%) of the endocrine receptors. This strategy 





4.6 Experimental Methods 
Preparation of fluorescent exendin monomers 
AF488 alkyne (0.2 µmol) was added to 200 µL of water followed by CuSO4-TBTA (20 
nmol) and sodium ascorbate (1 µmol). Lastly, mutant exendin (0.2 µmol) was added and the 
reaction mixture was stirred at room temperature for 12 h followed by purification using 
preparative RP-HPLC (AF647 monomer: 20-30% B 0.1-4 min, 30% B 4-7 min, 30-55% B 7-17 




All animal experiments were conducted in compliance with the University of Michigan 
University Committee on Use and Care of Animals (IACUC).  To block exocrine GLP-1R, 170 
pmol of Cy7 exendin was injected intravenously. After 10 min, 1 nmol of AF647 exendin was 
administered. After 5 min 15 nmol of non-fluorescent exendin was administered to block 
recycling exocrine receptors while the imaging agent cleared from the circulation. 10 min later, 
the animal was euthanized and the pancreas removed for macroscopic imaging to confirm 
targeting specificity. ‘Labeled’ and ‘blocked’ mice were used to determine the range of exocrine 
values. For ‘labeled’ conditions, the animal received 1 nmol of AF647 exendin and was 
euthanized 15 minutes after injection. For ‘blocked’ conditions, the animal received 15 nmol of 
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non-fluorescent exendin; 15 min later, the animal received 1 nmol of AF647 exendin and was 
euthanized 15 min later. 
The Jackson Laboratory treated mice with streptozotocin (STZ). Animals were given 
daily IP (interperitoneal) injections of STZ once per day for 5 consecutive days. At the same 
time, control mice will be injected with saline solution following the same protocol. On the 16th 
day after the initial injection, blood glucose levels were measured. 
 
Pancreas Digest 
 Pancreas were digested in 1000U/ml collagenase IV at 37°C for 15 min with intermittent 
shaking. The digest solution was filtered, washed 2 x with media (F12K w/ 10% FBS), and 
washed 2 x with PBS before quantified using flow cytometry (Attune). The remaining cells were 
fixed using 4% paraformaldehyde. 
 
Insulin Stain 
The fixed cells were incubated overnight at 4 oC with a rabbit anti-insulin primary 
antibody (dilution 1:150 in PBS with 0.1% BSA supplemented with 1% goat plasma), followed 
by a 30 min room temperature incubation with goat anti-rabbit IgG FITC secondary antibody 
(dilution 1:50 in PBS with 0.1% BSA). Insulin positive cells were shown to be labeled with 
AF647 exendin using flow cytometry. 
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Chapter 5      
A Dual-Purpose Linker For Alpha Helix Stabilization And Imaging Agent Conjugation To 
Glucagon-Like Peptide-1 Receptor Ligands 
5.1 Publication Information 
Zhang, L., T. Navaratna, J. Liao, and G.M. Thurber. A dual-purpose linker for alpha helix 
stabilization and imaging agent conjugation to glucagon-like Peptide-1 receptor ligands. 







 Peptides display many characteristics of efficient imaging agents such as rapid targeting, 
fast background clearance, and low non-specific cellular uptake. However, poor stability, low 
affinity, and loss of binding after labeling often preclude their use in vivo. Using the glucagon-
like peptide-1 receptor (GLP-1R) ligands exendin and GLP-1 as a model system, we designed a 
novel alpha helix stabilizing linker to simultaneously address these limitations. The stabilized 
and labeled peptides showed an increase in helicity, improved protease resistance, negligible loss 
or an improvement in binding affinity, and excellent in vivo targeting. The ease of incorporating 
azidohomoalanine in peptides and efficient reaction with the dialkyne linker enables this 
technique to potentially be used as a general method for labeling alpha helices. This strategy 
should be useful for imaging beta cells in diabetes research and in developing and testing other 
peptide targeting agents. 
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5.3 Background 
The ability to image and observe cellular phenomena both in vivo and in vitro plays a 
crucial role in understanding disease progression and treatment response 288, 289. Molecular 
imaging agents enable investigators to probe the dynamics of specific biologic interactions in 
normal and pathological conditions. In principle, peptides are ideal imaging agents due to their 
low molecular weight275, rapid clearance from background tissues, and ability to mimic protein-
protein interactions for high binding specificity290. However, these agents suffer from several 
problems including poor stability due to proteases, low affinity from lack of a stable 
conformation, and difficulty in labeling with fluorescent and/or radioactive probes without 
disrupting binding291. Due to recent advances in synthesis techniques, there is renewed interest in 
using stabilized alpha helices with improved protease resistance and binding affinity for targeting 
both intracellular292, 293 and extracellular294 proteins. Side chain cross-linking reactions to 
promote an alpha helix conformation include olefin metathesis295, copper catalyzed azide-alkyne 
reactions296, 297, lactam ring formation298, and disulfide bonds299, 300 among others294. 
In many cases, stabilizing the alpha helix increases helicity, improves binding affinity, 
and/or increases protease resistance301. However, this is not universally true since the 
introduction of the side chain cross linker necessarily introduces two mutations into the sequence 
and the linker addition itself, which can each change intra- and inter- molecular interactions302-
304. The sequence mutations and cross linker can impart both positive and negative contributions 
to the free energy of helix formation and free energy of binding, making the net impact 
challenging to predict a priori from structural considerations alone.  
In the context of imaging agent development, while these stabilizing structures have the 
potential to improve protease stability and binding affinity by locking molecules in a helical 
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conformation, this exacerbates the problem of labeling the peptide since multiple modifications 
must now be done without disrupting the binding interface. To address this issue, we synthesized 
probes using a novel linker to simultaneously label and stabilize an alpha helix to improve 
protease stability while maintaining in vitro and in vivo binding affinity. This was compared with 
two non-fluorescent stabilizing linkers (Scheme	5.1) to separate the impact of the fluorophore 
from helix stabilization.  
	
Scheme 5.1 Linker design and synthesis 
A Boc-protected hydrophilic spacer was alkylated with propargyl bromide and deprotected to 
provide a free amine for fluorophore conjugation (A). Propargyl ether (top) and 1,3-
diethynylbenzene (bottom) were used to test steric effects of the dye and rigidity of the linker 
(B). The crystal structure of exendin (left, PDB 3C59) and GLP-1 (right, PDB 3IOL) are shown 
with the modified residues highlighted in red (C) and the double mutant sequences (D). The 




One promising application of targeting peptides is to utilize modified glucagon-like 
peptide 1 receptor (GLP-1R) binding peptides for imaging beta cells in diabetes305, 306. Beta cells 
express moderate to high levels of GLP-1 receptor resulting in excellent target specificity versus 
exocrine cells within the pancreas. These properties have led several investigators to explore the 
use of radiolabeled exendin molecules for tracking beta cell mass in diabetes45, 65, 253, 254, 287, 305, 
306. However, the molecular properties of the radiolabeled peptide require further optimization 
before obtaining clinical utility65, 254. Using a novel dialkyne linker with a functional handle for 
attaching an imaging agent, we synthesized a dual-purpose linker to simultaneously stabilize and 
label alpha helices. Here we demonstrate the improved protease resistance and in vivo targeting 
of these stabilized glucagon-like peptide-1 receptor (GLP-1R) ligands for visualizing the beta 
cell mass in the pancreas.  
The ligands GLP-1 and exendin share significant homology and bind the same pocket on 
GLP-1R, but they exhibit distinct differences. Exendin binds in a straight alpha helix while GLP-
1 has a small kink around glycine-22307. Exendin also has significant helical structure in solution 
while GLP-1 is almost completely disordered308. This allowed us to investigate several aspects of 
the linker including the impact on helicity, flexibility, affinity, and stability. 
 One turn of an alpha helix constitutes approximately 3.6 amino acid residues. As a result, 
i, i+4 and i, i+7 are frequent candidates for crosslinking residues between either one or two 
adjacent loops298. To generate a staple across two loops, we postulated that non-natural azide-
containing amino acids could be introduced and crosslinked at i, i+7 residues in exendin-4 and 
GLP-1 through incorporation of azidohomoalanine (AHA) during solid phase peptide synthesis 
(SPPS). A novel dialkyne linker is used to bridge the two AHA side chains and stabilize the helix 
while introducing a functional handle for labeling. The chemistry utilizes the well-studied copper 
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catalyzed azide alkyne cycloaddition (CuAAC) for high-yielding and specific crosslinking of the 
desired residues.  
The AHA substitution locations were selected using crystal structures42, 307 for the 
receptor-ligand interaction as well as alanine scan data of GLP-1 with sequence alignment for 
exendin-4309. Previous work labeling exendin with fluorescent tags has shown variable tolerance 
(negligible impact to >30-fold reduction in binding) at several positions with different 
fluorophores along the peptide backbone105. The requirements for a stabilizing linker are even 
more stringent. First, the linker must be located within the alpha helix portion of the peptide, 
ruling out labeling of the c-terminal and n-terminal regions. Second, the cross-link necessitates a 
larger structure adjacent to the peptide compared to a single fluorophore. Ultimately, methionine 
at the 14th position (M-14) and leucine at the 21st (L-21) were substituted with AHA for exendin-
4 to generate double mutant exendin. Similarly, L-20 and E-27 substitutions were made to GLP-
1 (7-36) for double mutant GLP-1. We present novel stabilized GLP-1R ligands crosslinked with 
dialkyne linkers (Scheme	5.1E) of varying rigidity and demonstrate that all conjugates maintain 
GLP-1R specific targeting. To abbreviate the structure names, the stabilized alpha helices of 
exendin generated with the AlexaFluor 680 linker, propargyl ether linker, and 1,3-
diethynylbenzene are labeled AF680 sExendin, PropE sExendin, and DEB sExendin, 
respectively. AlexaFluor 680 linker, propargyl ether, and 1,3-diethynyl stabilized GLP-1 are 
named AF680 sGLP-1, PropE sGLP-1, and DEB sGLP-1. The novel structures should prove 




Stabilized alpha helical imaging peptides were generated using a novel dialkyne linker as 
shown in Scheme	 5.1A. To generate the dual-purpose linker, N-Boc- 2,2’-
(ethylenedioxy)diethylamine was alkylated with excess propargyl bromide, followed by 
deprotection with trifluoroacetic acid and subsequent purification via flash chromatography. The 
resulting intermediate 1 was further purified on HPLC followed by conjugation to AF680 NHS 
ester to yield 2.   
GLP-1R ligands exendin-4 and GLP-1 were chosen to demonstrate the ability of the dual-
purpose linker to simultaneously stabilize and fluorescently tag targeting peptides under 
investigation for imaging in diabetes105, 287, 306. Based on crystallography data for the receptor-
ligand interaction, the M14 and L21 residues in exendin and L20 and E27 residues of GLP-1 
were substituted with azidohomoalanine (Scheme	5.1B, C). The i, i+7 residues on exendin-4 and 
GLP-1 double mutant peptides were then reacted with 2 to stabilize and label the agents 
(Scheme	5.1D). In addition to alpha helix stabilization with 2, we also investigated the effect of 
linker rigidity on the stabilized peptide with propargyl ether and the more rigid crosslinker 1,3-
diethynylbenzene on the i, i+7 residues of the GLP-1R ligands. A non-stabilized single mutant 
exendin-4 labeled with AF647 was synthesized for quantifying the binding affinity of propargyl 
ether and 1,3-diethynylbenzene stabilized peptides in competition assays. Both AF647-exendin 




Figure 5.1 MALDI-ToF mass spectrometry traces of purified peptides showing successful 
synthesis of stabilized helices 
	
	
 To determine the effect of the alpha helix stabilization on protease resistance, both double 
mutant GLP-1R ligands with and without i, i+7 crosslinks were subject to 500 ng/µl trypsin 
digests at room temperature. Unstabilized double mutant exendin with M14X and L21X 
modifications digested rapidly in the presence of trypsin (half life of 0.7 h, Figure	 5.2). In 
contrast, the stabilizing crosslinker improved protease resistance over six-fold in the case of 
propargyl ether (half-life of 4.5 h) and almost five-fold for 1,3 diethynylbenzene (half-life of 3.2 
h). The fluorescent crosslinker-stabilized exendin demonstrated an almost six-fold increase (half-
life of 3.9 h).  Stabilization of wild-type GLP-1 increased protease stability by 6-14 fold for 
PropE sGLP-1, DBE sGLP-1, and AF680 sGLP-1, respectively.	
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Figure 5.2 Protease stability of stabilized peptides 
Digests were run on HPLC and monitored at 254 nm to separate intact versus degraded 
fragments and areas fit to an exponential decay. 
 
	
 The stabilizing linker increased protease resistance for exendin, but the impact on binding 
affinity from the stabilizing linker was unknown. To test the influence on target binding, the 
affinity was measured in a binding assay using NIT-1 cells (Figure	 5.3). Eleven or 12 point 
curves were done in triplicate for each experiment, and all experiments were repeated on 2 or 3 
separate days. M-14, L-21 azidohomoalanine (AHA) substitutions in exendin-4 did not 
significantly lower the binding affinity as anticipated by their orientation away from the binding 
pocket (Table	5.1). Similarly, GLP-1 also maintained high affinity despite the two substitutions. 
Stabilization of exendin with propargyl ether and 1,3 diethynylbenzene yielded a Kd = 0.9 ± 0.9 
nM and Kd  = 0.8 ± 0.2 nM, respectively. Neither affinity was statistically significantly different 
than the double mutant exendin (p value of 0.6 compared to prop exendin and 0.3 for 1,3 
exendin), demonstrating that steric hindrance from the linker did not significantly increase the 
Kd. The AF680 linker-stabilized peptide had a Kd slightly above the original peptide but still 
maintained high affinity.  For GLP-1, the propargyl ether stabilizer resulted in increased affinity 
with a Kd = 3.5 ± 0.8 nM. In the case of the more rigid 1,3 diethynylbenzene, alpha helix 
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stabilization resulted in similar affinity values. Stabilization with the new dual-purpose 
crosslinker also gave higher affinity for GLP-1R despite the presence of the fluorophore (Kd = 
3.1 ± 0.7 nM). Both AF680 GLP-1 and prop GLP-1 were statistically significantly higher affinity 
than GLP-1 (p value of 0.04 for both), although 1,3 GLP-1 was not (p = 0.08).		
	
Figure 5.3 Representative affinity curves 
In	 vitro	 cell	 binding	 affinity	 assays	 show negligible loss of affinity for exendin and a small 
improvement in binding for GLP-1 stabilized peptides. 
 
 
Table 5.1 Summary of binding affinity values for multiple stabilized peptides 
Peptide Crosslinker Binding affinity (nM) 
Exendin (M14X, L21X) None 0.5 (± 0.2) 
Exendin (M14X, L21X) Propargyl Ether 0.9 (± 0.7) 
Exendin (M14X, L21X) 1,3-Diethynylbenzene  0.8 (± 0.2) 
Exendin (M14X, L21X) AF680 1.4 (± 0.3) 
GLP-1 (L20, E27) None 5.6 (± 0.2) 
GLP-1 (L20, E27) Propargyl Ether 3.5 (± 0.8) 
GLP-1 (L20, E27) 1,3-Diethynylbenzene  4.8 (± 0.3) 
GLP-1 (L20, E27) AF680 3.1 (± 0.7) 
	
 The increase in affinity for GLP-1 was unexpected given the typical negative impact of 
steric hindrance on Kd310. Helix stabilization is known to decrease the entropic penalty of binding 
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by locking the peptide in an alpha helix and limiting the number of conformations294. To 
investigate the effect of the dialkyne cross-linker on the helix structure, circular dichroism 
measurements were taken to determine the % helicity. Non-stabilized double mutant exendin-4 
contained intermediate helicity (57%) in phosphate buffer (Figure	 5.4), consistent with the 
significant helicity of exendin308. The propargyl ether and 1,3 diethynylbenzene linkers had small 
increases in helicity (67 and 59%, respectively), and the fluorescent derivative had 55% helicity. 
Calculations of the fractional helicity are based on estimates of the number of helical residues 
within the peptide sequence308. To experimentally validate these estimates, 50% trifluoroethanol 
(TFE) was used as a solvent to drive the peptides into a helical conformation. The highest values 
for exendin and GLP-1 were between 93-104% indicating the number of helical residues used in 
the calculation was accurate.  
 
Table 5.2 Summary of binding affinity values for multiple stabilized peptides in different 
solvents 
Peptide Crosslinker 𝝌helix (buffer) 𝝌helix (50% TFE) 
Exendin (M14X, 
L21X) None 0.57 0.93 
Exendin (M14X, 




 0.59 0.93 
Exendin (M14X, 
L21X) AF680 0.55 0.82 
GLP-1 (L20, E27) None 0.07 0.6 
GLP-1 (L20, E27) Propargyl Ether 0.38 1.04 
GLP-1 (L20, E27) 1,3-Diethynylbenzene  0.23 0.81 
GLP-1 (L20, E27) AF680 0.3 0.71 
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All the peptides had elevated helicity (> 80%). On the contrary, GLP-1 has very little 
helicity in phosphate buffer (7%), but stabilization with propargyl ether, 1,3 diethynylbenzene, 
and the AF680 stabilizing linker resulted in a significant increase in % helicity (38, 23, and 
30%). The higher helicity for stabilized peptides was maintained in 50% TFE buffer with 60% 
for the GLP-1 peptide and 104%, 82%, and 71% for the propargyl ether, 1,3 diethynylbenzene, 
and AF680 cross-linked peptides.  
	
Figure 5.4 Circular Dichroism spectra of stabilized peptides in different solvents 
The stabilizing linker dramatically improves the helicity of GLP-1 with a smaller increase in 
helicity for the more highly structured exendin peptide. 
 
	
 Owing to its higher stability, AF680 stabilized exendin-4 was used to demonstrate the in 
vivo imaging potential of the fluorescent helix stabilizing crosslinker. To show the specificity of 
the imaging agent for beta cells in the islets of Langerhans, AF680 exendin-4 was injected in 
C57BL/6 mice and allowed to circulate for 3 h. Blood samples were taken and the half life of 
AF680 exendin-4 in plasma was determined by fitting to a biexponential decay. We observed a 
fast decay t1/2 of 2.7 min and a slow decay t1/2 of 67 min (Figure	5.5). To confirm specific beta 
cell targeting, the animal was sacrificed after 3 h and the pancreas removed.  
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Figure 5.5 Plasma clearance and successful in vivo targeting of stabilized peptides 
Stabilized fluorescent exendin clears rapidly from the plasma (top left) and efficiently targets 
islets, providing high tissue contrast (top middle). Beta cells form ~1-2% of the pancreas and are 
located in 100-300 µm Islets of Langerhans that are labeled intensely by the fluorescent peptides 
(arrows). K12C labeled fluorescent exendin is shown for comparison (top right). Histology slide 
of pancreas showing ex vivo anti-insulin staining of islets (left), in vivo delivered AF680 
sExendin (middle) and merge (right). 
 
	
Macroscopic scans of the organ indicate AF680 exendin-4 signal in distinct, punctate 
spots spread along the pancreatic vasculature indicating efficient targeting of the islets of 




 Peptides possess many properties that are ideal for imaging agents311, 312. Their low 
molecular weight allows rapid uptake in target tissue, fast clearance from background regions, 
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and low non-specific uptake. Despite these advantages, significant challenges exist including 
poor stability, low affinity, and difficulty in labeling without lowering affinity due to steric 
hindrance of binding. To help address some of these issues, we designed a dual-purpose linker to 
simultaneously label an alpha helix peptide while stabilizing the secondary structure.  
 For the linker design, propargyl bromide was used to react with the hydrophilic spacer for 
optimal cross-linker length. Previous reports of i, i+7 linkers indicated that a 13-atom linker 
stabilizes an alpha helix conformation294. Linker design was critical to avoid the stabilization of 
other types of helices313 or longer linkers that lack stability314. The facile incorporation of 
azidohomoalanine, either by synthetic techniques (SPPS) or biological systems315 makes this 
cross-linking chemistry advantageous for synthesizing stabilized helices. The 7-carbon span of 
the dialkyne generates a 13-atom cross-link for efficient stabilization of an alpha helix.  
 Stabilization of alpha helices reduces the solvent interaction of the hydrophilic backbone 
and can increase cell permeability292, 316. While membrane permeability is desirable for 
intracellular targets, this would increase the background signal of an imaging agent. A diethylene 
glycol spacer was placed between the amine functional handle and the dialkyne to impart 
additional hydrophilicity to the linker. Although the fluorescent dyes used in this work are 
charged and hydrophilic, the linker will aid in radiolabelling applications where the tag may be 
more lipophilic. 
 As a model system for testing the dual-purpose linker, we chose exendin and GLP-1 
peptides. We and others65, 105, 227, 254, 287, 305, 306 have used exendin and stabilized GLP-145 for 
imaging beta cells and increasing therapeutic efficacy, and the peptides are well characterized. 
Several GLP-1R agonists are in the clinic for treating type 2 diabetes317, and the crystal 
structures of both peptides bound to their target have been published.  
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 The stabilized peptides were synthesized with moderate yield (9-63%) with the expected 
molecular weight shown by MALDI-TOF. Despite the homobifunctional cross-linking 
chemistry, little to no oligomerization was detected. This is likely due to templating effects from 
the peptide backbone297 and is in agreement with the higher yield for the more helical exendin-4 
peptide compared to GLP-1. An additional linker, 1,4 diethynylbenzene, was tested to see if the 
increased strain from a more rigid linear cross-linking agent would stabilize or destabilize the 
helix. However, yields of this reaction were extremely low likely due to inefficient cross-linking 
(data not shown). The stabilized helices showed up to a 6-fold increase in trypsin protease 
stability. For exendin, the three predicted cleavage sites include one site within the cross-link, 
one just outside the cross-link, and a third several residues away. The increased helicity along 
with direct steric hindrance likely contributes to the lack of protease digestion. 
  Despite the larger cross-linking label, the Kd for AF680 stabilized exendin only 
increased by 0.9 nM. Locating the linker opposite the binding interface and including a 
hydrophilic spacer allowed the peptide to maintain high binding affinity in addition to the 
increased protease stability. The other cross-linking agents did not have a significant impact on 
the affinity of exendin. This is likely due to the high helicity of the peptide even without a 
stabilizing side chain crosslink. To corroborate this argument, a three state thermodynamic 
model of binding for helical peptides (supplementary data) was used to show a negligible 
predicted increase in the binding affinity (0.42 to 0.53 nM) for exendin. The larger increase in 
helicity for GLP-1 results in a small but significant predicted increase in binding affinity (Kd ~ 
1.5 nM) in the absence of steric effects and enthalpy changes. 
 The trade-off between a more rigid alpha helix (lowering the entropic penalty but 
reducing the enthalpy of binding) and a more flexible linker has been established for stabilized 
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helices294. The stabilized GLP-1 peptides demonstrated a small but statistically significant 
increase in affinity and a large increase in helicity, consistent with the thermodynamic model. 
GLP-1 is disordered in solution, so stabilizing the alpha helix increases the affinity by a lower 
entropic penalty upon binding. In principle, locking the GLP-1 peptide in a straight alpha helix 
could lower affinity by removing the kink present in the crystal structure. This level of detail is 
not captured in the simple three state model. For GLP-1, it appears that the i,i+7 cross link is 
flexible enough to allow for high affinity interactions, or at the very least, the reduction in the 
entropic penalty dominates the free energy of binding and affinity.   
 Comparing the more rigid 1,3 diethynylbenzene cross-linker versus the propargyl ether, it 
appears the latter has more helix inducing propensity in these two peptides. While both increased 
the protease stability of exendin, the affinity of GLP-1, and the helicity in phosphate buffer for 
both peptides, the propargyl ether did so to a larger extent in each case. The additional flexibility 
likely makes the alpha helix more energetically favorable thereby increasing protease stability, 
affinity, and helicity.   
 The stabilized fluorescent peptide maintained efficient targeting of beta cells in vivo. The 
rapid clearance from the plasma is beneficial for lowering background fluorescence but could 
potentially reduce targeting if insufficient amounts reach the beta cells. Intravital microscopy 
experiments of exendin show rapid uptake in islets within several minutes after injection227. 
Islets are highly vascularized (500 cm2/cm3 blood vessel surface area to volume287) with 
fenestrated endothelium which should allow efficient access to the target cells. For tumors, an 
analysis of molecular weight versus targeting efficiency concluded that lower molecular weight 
high-affinity binders have more efficient targeting275. Small agents were all filtered rapidly by 
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the kidneys, but the lower molecular weight agents extravasated more quickly. It remains to be 
seen whether the same quantitative conclusions apply to the pancreas.  
 We anticipate this dual-purpose linker will have many applications with other peptides in 
imaging and therapeutic development. Recently, Lau et al. used a poly-arginine conjugated 1,3 
diethynylbenzene cross-linker to increase cellular uptake of a p53 alpha helix137. In their MDM2 
targeting peptide, they found a similar trend where a more flexible aliphatic dialkyne produced 
better stabilization than a more rigid 1,3 dialkylbenzene318. This is analogous to our findings 
where propargyl ether resulted in more efficient binding and helicity. Importantly, the propargyl 
ether and fluorescent linkers maintain hydrophilicity for this extracellular target compared to the 
intracellular MDM2-targeting peptides. The ability to both stabilize the alpha helix and impart 
additional functionality through the tertiary amine in our linker minimizes the impact of 
sterically bulky groups. Successful alpha helix stabilization in both the GLP-1R targeting 
peptides and MDM2 peptides provides evidence that this method will work as a general strategy. 
The functional linker should have applications in many stabilized alpha helix applications 
including imaging agents, drug design, surface modification, and affinity separations319, 320. 
 
5.6 Conclusion 
We have reported a novel dual-purpose linker that is capable of labeling GLP-1 receptor 
ligands with an imaging agent modality, stabilizing the alpha helix structure, and increasing 
protease stability while having minimal impact or an improvement on binding affinity.  This 
approach should have utility in engineering novel stabilized alpha helices with improved 
properties for molecular imaging. 
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5.7 Experimental Methods 
 Double mutant exendin-4 (HGEGTFTSDLSKQXEEEAVRXFIEWLKNGGPSSG 
APPPS), double mutant GLP-1 (7-36, HAEGTFTSDVSSYXEGQAAKXFIAWLVKGR), and 
single mutant exendin-4 (HGEGTFTSDLSKQXEEEAVRLFIEWLKNGGPSSGAPPPS), where 
X is the non-natural amino acid AHA, were purchased from Innopep (San Diego, CA). 
Fluorochromes AF647 alkyne and AF680 N-hydroxysuccinimidyl (NHS) ester were purchased 
from Life Technologies (Carlsbad, CA). N-Boc- 2,2’-(ethylenedioxy)diethylamine, rabbit anti-
insulin, and goat anti-rabbit IgG FITC antibodies were purchased from Santa Cruz 
Biotechnology (Dallas, TX). All other reagents, unless specified, were purchased from Sigma-
Aldrich (Milwaukee, WI) and were used as received. Reverse phase high performance liquid 
chromatography (RP-HPLC) was performed on a Shimadzu LC unit using analytical and 
preparative reversed phase Phenomenex Luna C18(2) columns. MALDI-MS spectra were 
collected using a Bruker Autoflex mass spectrometer, and ESI-MS analysis was performed on an 
Agilent Q-TOF 1200 series. NMR spectra were collected using a Varian MR400 spectrometer. 
Fluorescence microscopy images were collected using an Olympus FV 1200 confocal 
microscope. 
 
Preparation of (1)  
 N-Boc- 2,2′-(ethylenedioxy)diethylamine (805 µmol) was added to 
diisopropylethylamine (2.40 mmol) in 3.8 mL MeCN. Propargyl bromide in toluene was added 
dropwise (2.62 mmol). The reaction mixture was stirred overnight at room temperature before 
being concentrated under reduced pressure and then subjected to flash chromatography (80:7:1 
CHCl3: MeOH: NH4OH). The desired fraction was concentrated, deprotected using 50% 
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trifluoroacetic acid in dichloromethane, and purified using preparative RP-HPLC using a linear 
gradient of MeCN in H2O to yield 1 (475 µmol, 59%).1H NMR (400 MHz, CD3OD) δ 3.89 (4H, 
d), 3.77 (2H, t), 3.73 (2H, t), 3.70 (4H, s), 3.18 (2H, t), 3.15 (2H, t), 3.04 (2H, t). 13C NMR(400 
MHz, CD3OD) δ 76.8, 74.6, 69.9, 69.8, 66.5, 51.9, 42.2, 39.2. HRMS: m/z calculated for 
C12H20N2O2: 225.1603, found: 225.1600. 
 
Preparation of (2)  
AF680 NHS ester (1 µmol in DMSO) was added to an aqueous solution containing 1 (10 
µmol) buffered with 7.5% sodium bicarbonate. The reaction was stirred at room temperature for 
30 min followed by purification on preparative RP-HPLC (12 mL/min; A: 0.1% trifluoroacetic 
acid in water, B: 0.1% trifluoroacetic acid in acetonitrile;  20% B 0.1-3 min, 20-40% B 3-11 min 
) to give 2: tR = 10.2 min. MALDI-TOF: m/z calculated: 1063.11, found: 1064.38. All MALDI-
TOF and ESI-Mass Spectrometry data were collected at the University of Michigan Department 
of Chemistry’s Core Facility. 
 
Preparation of Stabilized Peptides 
Propargyl ether (0.3 µmol), 1,3 diethynylbenzene (0.3 µmol), 2 (0.3 µmol), or AF647 
alkyne (0.3 µmol) was first added to 200 µL of 1:1 water:tert-butanol, followed by Cu-TBTA (30 
nmol) and sodium ascorbate (0.3 µmol). Lastly, double mutant peptide (0.3 µmol) was added and 
the solution was gently stirred at room temperature for 12 h followed by purification on 
preparative RP-HPLC (propargyl ether stabilized exendin (PropE sExendin) and 1,3-
diethynylbenzene stabilized exendin (DEB sExendin): 28% B 0.1-7 min, 28-70% B 7-23 min 
(PropE sExendin: 97% purity; DEB sExendin: 98% purity); AF680 linker stabilized exendin 
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(AF680 sExendin), AF680 linker stabilized GLP-1 (AF680 sGLP-1), AF647 labeled exendin: 
25% B 0.1-7 min, 25-70% B 7-20 min (AF680 sExendin: 92% purity; AF680 sGLP-1: 89% 
purity; AF647 exendin: 94% purity); propargyl ether stabilized GLP-1 (PropE sGLP-1): 37% B 
0.1-7 min (PropE sGLP-1: 93% purity); 1,3-diethynylbenzene stabilized GLP-1 (DEB sGLP-1): 
23-38% B 0.1-12 min, 38-50% B 12-20 min (DEB sGLP-1: 92% purity)) at a flow rate of 12 
mL/min. MALDI-TOF: PropE Exendin: m/z calculated 4288, found: 4288; DEB sExendin: m/z 
calculated 4320, found: 4319; AF680 sExendin: m/z calculated 5257, found: 5258; AF680 sGLP-
1: m/z calculated 4370, found: 4372; AF647 sExendin: m/z calculated: MW of dye unpublished, 
found: 4859; PropE sGLP-1: m/z calculated 3401, found: 3400; DEB sGLP-1: m/z calculated 
3433, found: 3435. For quantifying peptide concentrations to determine yield and circular 
dichroism measurements, amino acid analysis was carried out by the University of Michigan 
Proteomics and Peptide Synthesis Core. 
 
Cell Culture  
NIT-1 cells, a GLP-1R positive mouse beta cell line, were generously provided by Dr. 
Ralph Weissleder’s Laboratory and used for receptor binding studies. Cells were grown in F12K 
containing 10% (v/v) heat-inactivated FBS, 50U/mL penicillin, 50 µg/mL streptomycin, and 1.5 
g/L sodium bicarbonate. The passage number for NIT-1 cells used in affinity measurements for 
all peptides was between 4 and 16 
 
In Vitro Receptor Binding Assay  
NIT-1 cells were grown for 48 hours before being harvested with trypsin-EDTA. The 
cells were then washed with PBS, centrifuged, and resuspended in PBS with 1.0% BSA. Cells 
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were aliquoted and suspended in binding buffer containing stabilized GLP-1 or exendin on ice 
(0.05-250 nM). After 3 h, cells were centrifuged and washed (for fluorescent constructs) or the 
buffer was replaced with a second binding buffer containing 20 nM of AF647 exendin. After 1 h, 
cells were washed with PBS with 1.0% BSA and immediately analyzed using an Attune 
Acoustic Focusing Cytometer (Applied Biosystems). Binding affinity curves and statistical 
analysis were carried out using Prism 6.0 software. 
 
Animals 
All animal experiments were conducted in compliance with the University of Michigan 
University Committee on Use and Care of Animals (UCUCA). For measuring plasma clearance, 
AF680 sExendin (1.2 nmol) or a validated K12C fluorescent exendin control peptide227, 287 was 
injected in the lateral tail vein of C57BL/6 mice (6 mice total). At predetermined time points (1, 
3, 5, 15, 30, 60, 180 min), retro orbital blood samples were collected. A LICOR Odyssey CLx 
scanner (Lincoln, NE) was used to measure the fluorescence intensity for each sample and the 
intensities were converted to concentration using a dilution series of AF680 sExendin in mouse 
plasma. After 3 h, the mice were sacrificed and the pancreas resected. Islets were visualized by a 
near-infrared scan on a LICOR Odyssey CLx scanner.  
 
Histology and Microscopy 
Pancreata resected from C57BL/6 mice injected with AF680 sExendin were submerged 
in OCT and frozen in chilled 2-methylbutane. The organ was then sectioned into 6 µm slices, 
fixed with 4% paraformaldehyde for 10 min, and incubated overnight at 4 oC with a rabbit anti-
insulin primary antibody (dilution 1:150 in PBS with 0.1% BSA supplemented with 1% goat 
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plasma), followed by a 30 min room temperature incubation with goat anti-rabbit IgG FITC 
secondary antibody (dilution 1:50 in PBS with 0.1% BSA).  
 
Trypsin Digest 
To assess the proteolytic resistance of stabilized peptides, both stapled and unstapled 
peptides (75 µM) were subject to a trypsin digest (500 ng/µL, pH 7.4, room temperature). 
Enzymatic digest was monitored at 254 nm using RP-HPLC to determine the degradation half-
life. 
 
Circular Dichroism (CD) Measurements  
To quantify peptide secondary structure, CD spectra were collected on a Jasco-815 CD 
spectrometer with a 1 mm Hellma quartz cuvette at 23 oC. Five scans from 185 nm to 260 nm at 
20 nm/min were averaged for peptide samples prepared in 5 mM potassium phosphate buffer, pH 
7.0 at concentrations ranging between 5 µM to 20 µM as determined by amino acid analysis. A 
scan containing only buffer/buffer with cross-linker was subtracted from sample scans. Helicity 






Chapter 6      
A Helix-Stabilizing Linker Improves Subcutaneous Bioavailability Of A Helical Peptide 
Independent Of Linker Lipophilicity 
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this	text.	The	use	of	double	click	chemistry	for	peptide	helix	stabilization	indicated	multiple	




 Stapled peptides address several limitations to peptide-based imaging agents and 
therapeutics such as poor stability and low affinity due to conformational flexibility. There is 
also active research in developing these compounds for intracellular drug targeting. A significant 
effort has been invested in determining the effects of helix stabilization on intracellular delivery, 
but much less is known about the impact on other pharmacokinetic parameters such as plasma 
clearance and bioavailability. We investigated the effect of different fluorescent helix-stabilizing 
linkers with varying lipophilicity on subcutaneous (SC) bioavailability using the glucagon-like 
peptide-1 (GLP-1) receptor ligand exendin as a model system. The stapled peptides showed 
significantly higher bioavailability independent of linker hydrophilicity owing to increased 
protease resistance, and all subcutaneously delivered conjugates were able to successfully target 
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the islets of Langerhans with high specificity. The lipophilic peptide variants had slower 
absorption and plasma clearance than their respective hydrophilic peptides, and the absolute 
bioavailability was also lower due to the longer residence times in the skin. The ease and 
efficiency of double-click helix stabilization chemistries is a useful tool for increasing the 
bioavailability of peptide therapeutics, many of which suffer from rapid in vivo protease 
degradation. Helix stabilization using linkers of varying lipophilicity can further control SC 
absorption rates to customize plasma pharmacokinetics. 
 
6.3 Background 
Peptides acting as hormones and growth factors serve selective and crucial signaling roles 
via binding to specific cell surface receptors43. These characteristics make peptides and 
peptidomimetics attractive candidates as therapeutics, but their rapid renal clearance and poor 
stability from in vivo proteases have limited their broader use in the clinic25, 290. Recently, 
improvements in synthetic and analytical techniques, high throughput screening, and helix 
stabilization chemistries have generated a resurgence in the research and development of 
therapeutic peptides, as demonstrated by the increasing number of peptide therapeutics in clinical 
trials43, 292, 321. 
Peptide therapeutics are often delivered through subcutaneous injection. Although oral 
administration is the preferred route of delivery for therapeutics, it is generally not applicable to 
peptides as the harsh environment of the gastrointestinal tract is abundant with proteases. 
Peptides also suffer from permeability limitations across the intestinal epithelium322, 323. Studies 
that tested stapled peptides (chemically cross-linked helices) for oral administration showed 
increases in oral availability, and while promising, further improvements are needed before 
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clinical translation124. Alternatively, IV delivery requires technically trained personnel (with 
associated risks324-326) and is particularly cumbersome for peptides with fast clearance that 
require frequent dosing. Given the limitations of intravenous and oral routes, subcutaneously 
administered peptide therapeutics have seen commercial success with multiple FDA approved 
molecules and more in clinical trials, notably cancer vaccines, GLP-1 agonists used to treat type 
2 diabetes, and anti-inflammatory agents43, 327, 328.  
SC doses are given as a bolus, and the injected therapeutic is absorbed from the site of 
injection into the blood or lymph capillaries to enter systemic circulation327, 329. These injections 
are readily self-administered and exhibit a slower absorption rate when compared to the 
instantaneous systemic delivery of an IV bolus. This provides effective, long-term treatment and 
may alleviate side effects attributed to high serum concentrations330. The longer residence time in 
the body is especially important for peptide therapeutics given their rapid clearance, and SC 
administration allows the molecule to circumvent the short residence time from renal filtration 
through absorption-limited pharmacokinetics331.  
Molecular characteristics impacting interstitial transport include shape, molecular weight, 
charge, and stability in the presence of extracellular proteases326, 329, 332, 333. The bioavailability of 
a subcutaneously injected therapeutic, defined as the fraction of the dose that makes it to the 
systemic circulation, has been shown to be dose and injection site-dependent for multiple 
antibody treatments334, 335. Further complicating drug design is a lack of robust models to explain 
SC absorption kinetics. For certain antibody treatments, the SC route has been approved, but the 
wide range in bioavailability remains unexplained, although factors such as interstitial pressure, 
applied heat, protein size, formulation, and in the case of IgGs, FcRn binding, are thought to play 
a major role336-339. Assuming negligible cellular uptake/trapping at the site of injection, SC 
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bioavailability is theoretically 100% for a catabolically stable molecule340. However, peptide and 
protein drugs exhibit highly variable SC bioavailability, suggesting degradation during the 
absorption process329, 337, 341. Pretreatment of the site of injection with protease inhibitor-
containing ointments increases the bioavailability of subcutaneously injected insulin342. Others 
have found evidence of degradation products of injected protein and peptides using in vitro 
assays of subcutaneous tissue homogenates or by examining the site of injection343, 344. Given the 
role of proteases in hindering absorption, the design of protease-resistant peptides is crucial for 
the development of highly bioavailable peptide and protein-based therapeutics. Using 
stabilization strategies that can impart varying lipophilic and hydrophilic properties can further 
fine-tune the absorption rate as shown by favorable pharmacokinetics of transdermally applied 
stabilized exendin345, but the impact on bioavailability for the subcutaneous route and effects of 
peptide stability is not well understood. 
One increasingly common way to improve peptide stability is through helix stabilization. 
Although several techniques for generating stapled peptides have been reported, including olefin 
metathesis, lactam ring formation, and disulfide bond formation among others, another 
promising alternative is to use a double copper (I)-catalyzed click reaction between two 
azidohomoalanine (AHA) amino acid substitutions along the peptide sequence137, 187, 295, 298-300. 
Azidohomoalanine is easily incorporated during solid phase peptide synthesis (SPPS) and has 
been previously used to generate fluorescent imaging agents via alkyne fluorophore conjugation 
as well as stapled fluorescent and non-fluorescent peptides such as exendin and Mdm2 
inhibitors137, 187, 346, 347. Based on past results focused on glucagon-like peptide-1 receptor (GLP-
1R) ligand exendin and FDA approval of multiple subcutaneously administered exendin 
analogues for treating type 2 diabetes including exenatide, liraglutide, and dulaglutide, exendin 
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was chosen as the model system for investigating the effect of lipophilicity and stability on SC 
bioavailability267, 348. Helix stabilization and lipophilicity impact the absorption and 
bioavailability in complex ways. Increased protein binding and/or membrane interaction slows 
absorption and can sequester the peptide from proteolytic enzymes but simultaneously increases 
exposure time to epithelial proteases. Many lipophilic agents have been utilized to increase 
plasma protein binding of peptides including fatty acids349, diphenyl cyclohexanol279, and 
lipophilic fluorescent dyes175, 176. Alternatively, albumin-binding peptides can be used for a 
similar purpose 280, 350, 351, although these peptides would also be subject to degradation 
following subcutaneous delivery. Alpha helix stabilization may alter absorption and clearance 
rates in addition to improving protease stability.  
Due to the interplay of these factors, we studied the impact of helix stabilization and 
lipophilicity on SC absorption and bioavailability of stabilized and non-stabilized exendin 
derivatives with hydrophilic or lipophilic fluorescent linkers. Here we report increased 
bioavailability of these stapled peptides compared to their non-stapled counterparts and extended 
plasma exposure using lipophilic linkers. A stronger understanding of the impact of these 
modifications on bioavailability and clearance is crucial for generating predictive models to aid 
in clinical translation. 
 
6.4 Results 
To investigate the effects of peptide stabilization on in vivo subcutaneous (SC) absorption 
using linkers with different lipophilicity, two series of fluorescently labeled exendin probes were 
synthesized (Scheme	6.1). Based on crystallography data for the binding pocket of glucagon-like 
peptide-1 receptor (GLP-1R) for exendin, AHA substitutions were made at the 14th position for 
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single mutant exendin and both 14th and 21st positions for double mutant exendin. These 
substitutions allow for a direct comparison between stapled and non-stapled peptide. A more 
hydrophilic set of peptides was generated by first functionalizing Alexa Fluor 680 NHS ester 
with either 1 or 2 reactive alkynes followed by a single-click cycloaddition for non-stapled 
peptide or a double-click cycloaddition for stapled peptide. Similar syntheses were performed 
using Cy7 NHS ester to generate a lipophilic pair of exendin conjugates. Careful consideration 
was taken when choosing dyes, as dye structure and molecular charge can greatly impact non-
specific cellular and plasma protein interactions165, 352. Cy7 and Alexa Fluor 680 were chosen 
based on plasma protein binding of the free dye as determined by rapid equilibrium dialysis as 
well as previously published data on Cy7 exendin and s-AF680 exendin147, 187.  
	
Scheme 6.1 Design of stabilized and non-stabilized exendin conjugates 
The modified residues are highlighted in red. Fluorophores are first functionalized with one or 
two alkynes using amine-NHS chemistry, followed by either single or double click reactions to 
generate the fluorescent conjugates.	
	
	
Successful synthesis of fluorescently stapled and non-stapled exendin was verified using 
ESI-MS and purity determined on RP-HPLC while monitoring both 214 nm and peak 
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fluorophore absorbance (SI). Alexa Fluor 680 conjugates were ionized in negative mode while 
Cy7 conjugates were ionized in positive mode for ESI-MS. Spectra are shown below. 
	
Figure 6.1 ESI spectra of alkyne functionalized fluorophores for peptide conjugation 
Fluorescent alkyne and dialkyne linkers were purified using RP-HPLC with water with 0.1 % 
TFA (A) and acetonitrile with 0.1% TFA (B).AF680 alkyne: 10-60% B 0.1-16 min; tR=12.1 min. 
AF680 dialkyne: 10-60% B 0.1-16 min; tR=11.7 min. Cy7 alkyne: 70% B 0.1 -15 min; tR=11.3 




Figure 6.2 ESI spectra of fluorescent exendin conjugates  







































































































































































































AF680 exendin: 20-50% B 0.1-24 min; tR=21.4 min. s-AF680 exendin: 20-50% B 0.1-24 min; 
tR=20.1 min. Cy7 exendin: 30-80% B 0.1 -20 min; tR=11.1 min. s-Cy7 exendin: 30-80% B 0.1-
20 min; tR=11.7 min. 
 
 
Post-purification, stabilized peptides were reacted with excess fluorescent AlexaFluor 
647 alkyne to verify no unreacted azides were present. HPLC and MALDI-TOF indicated no 
new species were formed. Isotopic spacing for deconvoluted peptide ESI spectra indicates no 
multimerization of peptide species.   
	
Figure 6.3 HPLC chromatogram of alkyne functionalized fluorophores  
HPLC traces for alkyne functionalized dyes demonstrating high purity at 214 nm and 












































Figure 6.4 HPLC chromatogram of fluorescent peptides 
HPLC traces for fluorescent exendin conjugates demonstrating high purity at 214 nm and 
fluorophore absorbance wavelengths. Purity check method is 10-70% B 0.1-19 min. 
 
The binding affinity of each exendin conjugate to GLP-1R was experimentally 
determined to quantify impact of stabilization and dye lipophilicity. In vitro twelve-point affinity 
curves indicate all conjugates maintain the low nanomolar affinity unmodified exendin exhibits5, 
48, 251, 255. The results also indicate stabilization resulted in a higher affinity (lower Kd) when 
compared to the non-stapled counterpart for each dye (Figure	 6.5). Stabilization with Cy7 
resulted in values of Kd  = 7.2 ± 0.3 nM whereas single-click Cy7 exendin resulted in Kd  = 11.2 
± 0.6 nM. Stabilization with AF680 resulted in values of Kd  = 2.3 ± 0.1 nM whereas single-click 
AF680 exendin resulted in Kd  = 3.3 ± 0.2 nM. The affinity improvement is not surprising given 













































Figure 6.5 Cellular binding affinity assay indicating successful binding of peptide probes 
 
Changes in proteolytic stability due to helix stabilization were investigated through a 
trypsin digest adapted from a previously published protocol187. Digest of fluorescently stapled 
and non-stapled peptides (Figure	 6.6) and unreacted double mutant exendin (SI) in 5 ng/µl 
trypsin indicate the double-click stabilization across the i, i+7 residues significantly improves 
protease resistance. Non-stapled AF680 and Cy7 exendin demonstrated digest half-lives of 4.9 ± 
0.2 h and 9 ± 1 h, respectively. The stapled counterparts showed improvements with digest half-
lives of 13 ± 1 h and 14 ± 1 h, respectively. Unreacted double mutant exendin digested with a 
half-life of 0.8 ± 0.2 h (SI). Digests were monitored using HPLC; the area-under-curve of the 
intact species was quantified over time to fit a degradation rate. 






















Figure 6.7 HPLC chromatogram of trypsin digest for exendin (AF680) 
Traces show trypsin digest of unstabilized (top) and stabilized (bottom) AF680 exendin. As time 
increases, intact peptide peaks diminishes. Area under curve (AUC) used to determine digest 
rate. 
	












































































Figure 6.8 HPLC chromatogram of trypsin digest for exendin (Cy7) 
Traces show trypsin digest of unstabilized (top) and stabilized (bottom) Cy7 exendin. As time 




Gradient used for analysis were all the same: B (0.1% TFA in acetonitrile), 20-60%: 28 
min. Unreacted double mutant exendin was subject to the same digest conditions as well. The 
results indicated the unreacted double mutant exendin digested with a half-life of 0.8 ± 0.2 h, 
consistent with our previous findings. Interestingly, the digest of s-AF680 exendin in this 
manuscript is significantly slower than our previously published values. This is likely due to 
multiple reasons including an increase in overall stapled peptide purity in the current digest as 
well as differences in post-purification work-up of the stapled peptide. Previously, stapled 
peptides were concentrated on a rotary evaporator. The acidic pH resulting from residual TFA 
was then adjusted to pH 7.4 with sodium bicarbonate. All exendin conjugates were rotary 
evaporated with methanol 3x to remove residual TFA and then lyophilized. The current methods 





























































as reported in this manuscript do not require any additional pH adjustment steps. The pH of the 
reaction digest mixture was measured to confirm the appropriate pH. Digests were performed in 
triplicate with the exception of the double mutant unreacted peptide, which was digested once to 
compare with previously published digests in triplicate. 
	
Figure 6.9 HPLC chromatogram of trypsin digest for exendin 
Trypsin digested double mutant exendin is shown. Digest is rapid without helix stabilization. 
 
 
CD spectra of stapled and non-stapled peptides were collected in 1:1 water:acetonitrile. 
Although CD spectra of peptides are typically collected in a mild potassium phosphate buffer, 
the Cy7 conjugates absorbance spectra in aqueous solutions showed a broad shoulder near 700 
nm, inconsistent with the original fluorophore absorbance spectra. The absorbance spectra in 1:1 
water:acetonitrile gave the expected result (SI). Due to concerns about potential aggregation of 
the more lipophilic species, CD characterization was performed in 1:1 water:acetonitrile. Though 
less common, organic solvents have been used for collecting CD spectra of poorly soluble 
peptides137, 347. The 221 nm absorbance on CD indicated a minor increase in helicity due to 
stabilization for AF680 conjugates. AF680 conjugate helicity and the small increase upon 
stabilization agree with previously published values for exendin helicity and are consistent with 
the significant helicity of wild-type exendin. Cy7 conjugates displayed higher helicity, regardless 































of the double-click staple (χhelix=0.84) possibly due to side chain interactions with the lipophilic 
dye. Absorption spectra for the Cy7 conjugates in the mentioned solvents are discussed below. 
In the presence of 0.1% TFA added to the mobile phase, AlexaFluor 680 absorbance max 
shifts from 680 nm to ~550 nm, hence detection at 550 nm on HPLC. This change in absorbance 
is reversible once TFA is removed/neutralized. Cy7 peptides are monitored at 750 nm. 
Stabilized/non-stabilized conjugate purity evaluated at both fluorophore absorbance and 214nm 
absorbance. There was no statistically significant difference in fluorescence intensity between 
stapled and non-stapled conjugates using either Cy7 or AF680 using a dilution series.  
Absorbance spectra of fluorescently stabilized/non-stabilized peptides indicate no changes in 




Figure 6.10 Absorbance spectra for exendin conjugates 
 (Left): absorbance profiles are as expected in 1:1 acetonitrile water; (right): for Cy7 conjugates, 
absorbance in 5 mM potassium phosphate buffer shows a much stronger shoulder, indicative of 
H-aggregates of Cy7 at these high concentrations353. 
 


























sCy7 exendin (CD phospate buffer)
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Figure 6.11 CD spectra for stabilized and non-stabilized exendin probes 
	
	
Table 6.1 Summary of binding affinity, digest half-life, and helicity 
Compound Affinity (nM) Half life (h) 𝝌 helix 
s-AF680 exendin 2.3 (± 0.1) 13 (± 1) 0.65 
AF680 exendin 3.3 (± 0.2) 4.9 (± 0.2) 0.61 
s-Cy7 exendin 7.2 (± 0.3) 14 (± 1) 0.84 
Cy7 exendin 11.2 (± 0.6) 9 (± 1) 0.84 
	
 
Given the specificity of these exendin conjugates for beta cell targeting, the subcutaneous 
bioavailability of the compounds was investigated. One set of C57BL/6 mice was given 1 nmol 














mice was given the same dose subcutaneously. AUC calculated from the subcutaneous delivery 
divided by the plasma concentration AUC provided the absolute bioavailability. The s-AF680 
exendin demonstrated complete bioavailability (103 ± 6%) when compared to non-stapled 
AF680 exendin (65 ± 6%). Similarly, stabilization via a lipophilic Cy7 linker yielded improved 
bioavailability of 82 ± 12% vs. 57 ± 9% for stapled and non-stapled, respectively. The 
differences in bioavailability between stapled and non-stapled peptides are statistically 
significant (p value = 0.0004 and 0.02 for AF680 and Cy7 conjugates, respectively Figure	6.13).   
	
Figure 6.12 Plasma clearance of various exendin probes in mice for IV and SC routes 
Fluorescent exendin with and without helix stabilization were administered either intravenously 
or subcutaneously in mice. The plasma concentration was quantified and plotted versus time to 
determine the effect of helix stabilization on SC bioavailability. Stabilized AF680 and Cy7 













Table 6.2 Summary of bioavailability and clearance rate data 
Compound % Bioavailable IV clearance 
s-AF680 exendin 103 (± 6) kα = 0.173 min
-1 
kβ = 0.011 min-1    %fast = 96 
AF680 exendin 65 (± 6) kα = 0.142 min
-1 
kβ = 0.011 min-1    %fast = 97 
s-Cy7 exendin 82 (± 12) kα = 0.034 min
-1 
kβ = 0.008 min-1    %fast = 76 
Cy7 exendin 57 (± 9) kα = 0.032 min
-1 




Figure 6.13 Unpaired t-test for differences in bioavailability 
	
The fluorescent non-stabilized exendin bioavailabilities agree well with previously 
reported values for exendin-4 in rats354-356. SC injection of non-stapled Cy7 exendin resulted in 
higher plasma concentration than stapled Cy7 due to slower clearance, although overall 
bioavailability increased through helix stabilization. An efficient therapeutic that is able to both 
reach high systemic concentrations and high bioavailability through protease resistance could 

































SDS-PAGE was used to verify that experimentally measured plasma intensities were a result of 
intact peptide absorbed from the skin rather than degradation products (SI). Degradation 
byproducts are fluorescent as well and can lead to errors while quantifying bioavailability, but no 
fluorescent degradation byproducts were detected in the plasma. Fluorescent exendin peptides 
subject to a trypsin digest were also analyzed using SDS-PAGE to verify that fragments differ 




Figure 6.14 Exendin serum stability (SDS-PAGE) 
Left, top: 0 h incubation; right, top: 24 h incubation; left, bottom: 24 h incubation (window 
leveled to bring out fragments). Fluorescent values indicate little degradation of all conjugates in 
either fresh mouse serum or frozen plasma at 37°C over 24 h. The ladder has been window 
leveled differently from the other lanes for ease of visualization. 
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Lane ID (Figure	6.14) 
1. Ladder 
2. s-680 exendin (serum) 
3. 680 exendin (serum) 
4. s-Cy7 exendin (serum) 
5. Cy7 exendin (serum) 
6. s-680 exendin (plasma) 
7. 680 exendin (plasma) 
8. s-Cy7 exendin (plasma) 
9. Cy7 exendin (plasma) 
 
	
Figure 6.15 SDS-PAGE for plasma samples of mice injected with fluorescent exendin 
Plasma samples collected from SC injections. The protein gels (above) indicate plasma 
fluorescence intensity, which is used to calculate bioavailability, is primarily from intact peptide. 
 
Lane ID (Figure	6.15) 
Left: 
1. Ladder 
2. AF680 dialkyne (free fluorophore, not injected) 
3. 680 exendin (not injected) 
4. s-680 exendin (not injected) 
5. 680 exendin (30 min) 
6. s-680 exendin (30 min) 
7. 680 exendin (1 h) 
8. s-680 exendin (1 h) 
Right: 
1. Ladder 
2. Cy7 (free fluorophore, not injected) 
3. Cy7 exendin (not injected) 
4. Cy7 exendin (30 min) 
5. Cy7 exendin (1 h) 
6. Cy7 exendin (2.5 h) 
7. s-Cy7 exendin (not injected) 
8. s-Cy7 exendin (30 min) 
9. s-Cy7 exendin (1 h) 
Image ID 0001567_02
July 22, 2015 Page 1
Image Display Parameters
Channel Color Minimum Maximum K
700 Gray Scale (White on Black) 0.450 3.97 0
800 Gray Scale (White on Black) 0.413 52.1 0
WINDOW&LEVELED&DIFFERENTLY&
























Figure 6.16 SDS-PAGE for fluorescent exendin peptide digested in vitro 
Lane ID (Figure	6.16) 
1. Ladder 
2. s-Cy7 exendin (undigested) 
3. s-Cy7 exendin (digested) 
4. s-680 exendin (undigested) 
5. s-680 exendin (digested) 
6. Cy7 exendin (undigested) 
7. Cy7 exendin (digested) 
8. 680 exendin (undigested) 
9. 680 exendin (digested) 
 
 
Following the last blood sample, each animal was sacrificed, and the pancreas was 
removed for macroscopic imaging to confirm beta cell targeting specificity. As expected, all 
conjugates successfully targeted the islets of Langerhans, visualized as punctate white spots 
scattered across the organ (Figure	6.17) and consistent with previous work showing overlap with 
insulin staining and MIP-GFP76, 187. The combination of in vitro and in vivo sample analysis on 





SDS-PAGE and specific beta cell targeting demonstrates that intact and functional peptide is 
absorbed into the plasma. 
	
Figure 6.17 Macroscopic pancreas images (ex vivo) 
Macroscopic pancreas images demonstrate islet targeting whether peptide is administered 
subcutaneously or intravenously for all exendin conjugates. Beta cells are located in the islets of 
Langerhans and appear as distinct punctate spots 
 
	
To quantify the impact of stabilization and lipophilicity on absorption, degradation and 
bioavailability, a simple three-compartment model was used to calculate first-order absorption 
and degradation rate constants (Figure	 6.18). The exchange rates between the central and 
peripheral compartment and the clearance rate were fit using the intravenous plasma clearance. 
These values were then fixed, and the absorption rate and extracellular degradation rate were fit 
to the subcutaneous absorption data. 
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B: central compartment 
C: peripheral compartment 
kabs: first order absorption, min-1 
kdeg: first order degradation, min-1 
VA: skin compartment volume, L 
kcl: clearance from central compartment, min-1 
k12: transport from central to peripheral, min-1 
k21: transport from peripheral to central, min-1 
CB=central compartment concentration (measured for each peptide), nM 
Cc=peripheral compartment concentration, nM 
XA=moles in skin compartment, nmole 
XA,0=injected SC dose, 1 nmole 
XB,0=0 
XC,0=0 
kα=alpha clearance (biexponential) 
kβ=beta clearance (biexponential) 
fA=fraction fast (fit from biexponential) 
 
Balance on skin compartment: 
dXA
dt
= −kabsXA − kdegXA   with the initial condition, t=0, XA=XA,0=1 nmol 
XA = XA,0 exp(−(kabs + kdeg )* t)   
 





*XA,0 *exp(−(kabs + kdeg )* t)− kcl *CB − k12CB + k21CC   
Balance on peripheral compartment: 
dCC
dt
= k12CB − k21CC   
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k21, k12, and kcl are calculated using the following relationships for biexponential decay: 
kα + kβ = kcl + k12 + k21   






Experimental plasma concentrations (CB) are used to determine alpha and beta clearance 
half lives and are used as input to determine the rate constants between the central and peripheral 
compartments using Prism software. Using the injected dose of 1 nmol (XA,0) and the 
experimentally determined bioavailability, the ODE for the central compartment was used to fit 
for kabs, kdeg, and VA simultaneously. Each peptide was fit separately with absorption and 
degradation half lives summarized in Table	6.3.  
 
 
Table 6.3 Fitted rate constants and volumes for subcutaneous absorption 
Compound kabs (min-1) kdeg (min-1) VA (L) 
s-AF680 exendin 0.0087 (± 0.0018) 0.00065 (± 0.00026) 0.0013 (± 0.00006) 
AF680 exendin 0.0077 (± 0.0014) 0.0041 (± 0.00079) 0.0020 (± 0.00026) 
s-Cy7 exendin 0.0059 (± 0.0015) 0.0013 (± 0.00034) 0.0026 (±  0.00033) 
Cy7 exendin 0.0036 (± 0.0006) 0.0029 (± 0.00044) 0.0014 (± 0.00009) 
 
6.5 Discussion 
Owing to their low off-target effects, ease of synthesis via SPPS, and availability of tools 
for engineering including phage display, bacterial surface display, one-bead-one-compound 
selection and others, peptides hold clinical relevance both as imaging agents and therapeutics. 
There has also been a recent resurgence in investigating peptides for targeting intracellular 
protein-protein interactions. However, significant challenges such as poor affinity, low in vivo 
stability, and rapid systemic clearance exist and lower the potential for clinical efficacy. One 
strategy to address these shortcomings involves secondary structure stabilization45, 124, 292, 357, 
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which has been shown to improve protease stability and affinity by decreasing the entropic 
penalty upon binding. This works by constraining the helix and confers protease resistance by 
increasing helicity358 and sterically hindering digestive enzymes with non-natural amino acids 
and crosslinks. Significant effort has been spent investigating the impact of helix stabilization on 
binding affinity and intracellular delivery, but much less is known about the impact on 
subcutaneous bioavailability. This work used a model exendin system to quantify the interplay of 
helix stabilization and peptide lipophilicity on the absolute SC bioavailability and absorption 
profile of stabilized and non-stabilized alpha helical peptides. 
Currently, multiple peptide therapeutics have FDA approval for SC delivery. However, 
abundant epidermal proteases (e.g. in the extracellular matrix359 and on immune cells360) can 
degrade the peptide, often rendering a large fraction of the injected dose ineffective, especially if 
the dose reaches systemic circulation slowly336. Hydrophilic peptides that are absorbed more 
rapidly can escape the degradation pathway, but rapid plasma clearance of a quickly absorbed 
bolus dose is equally unwanted since the systemic dose may be too low to achieve a sustained 
therapeutic effect. In contrast, lipophilic compounds are known to interact with plasma proteins, 
and plasma protein binding is an established method for slowing the plasma clearance of 
molecules by conjugating lipophilic moieties147, 175, 176, 267, 361. The increase in lipophilicity may 
lower solubility in aqueous formulations compared to the hydrophilic counterparts and can result 
in self-association, aggregates, and/or precipitates. Consequently, poor solubility is a potential 
problem in protein pharmaceuticals332, 362, 363. Although free Cy7 dye is poorly soluble in 
aqueous solutions, the peptide conjugate is much more soluble due to exendin’s high aqueous 
solubility. To further avoid aggregation, fluorescent conjugates were stored in a 1:1 dilution of 
water:acetonitrile and diluted in PBS prior to SC injection; no aggregation is visible prior to 
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injection. Given the complex interactions between self-association, non-specific interactions, 
proteolysis, and absorption rates, the degradation and absorption rates must be considered 
together. Peptide stability and absorption rates were independently changed to quantify the 
impact on absolute bioavailability. A quantitative and mechanistic understanding of these rates is 
critical since variability in animals makes it challenging to scale to the clinic. 
Peptides were synthesized using either single alkyne or dialkyne linkers functionalized 
with Alexa Fluor 680 or Cy7 to independently modify the protease stability and lipophilicity 
(Scheme	6.1). As demonstrated by in vitro cellular affinity assays, all peptides maintained low 
nanomolar affinity. Helix stabilization was able to improve the affinity 1.4-1.6 fold, and this 
small increase for an already helical native peptide agrees well with a three-state thermodynamic 
model of binding187. CD spectra were collected to compare with the differences in binding 
affinity. Interestingly, both Cy7 exendin conjugates displayed high helicity regardless of helix 
stabilization. Non-covalent side chain interactions (such as phenylalanine-phenylalanine 
interactions at i, i+4 residues364, 365 and phenylalanine-lipid interactions366) have been shown to 
contribute to the overall peptide helix stability. The CD measurements presented here indicate 
that a fluorescent pharmacokinetic modifier (Cy7) may have a similar impact as non-fluorescent 
modifiers (lipids) by inducing helicity of peptides with hydrophobic side chains as shown by 
various lipidated GLP-1 peptides366. Intrahelix associations with a nearby F22 residue may 
explain both the increased helicity for the Cy7 variants and reduced affinity. The F22 residue is 
in the center of the hydrophobic binding pocket42, where steric hindrance could lower the affinity 
despite the higher helicity.  
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To observe how the improved affinity and increased protease resistance of the stabilized peptides 
impact SC bioavailability, 1 nmol of each of the four fluorescent exendin conjugates was 
delivered intravenously or subcutaneously to mice (Figure	6.12). The lipophilic Cy7 conjugates 
were absorbed more slowly with the maximum plasma concentration (Cmax) occurring at ~2 h 
compared to the hydrophilic AF680 peptides, which reached Cmax at ~30 min. This is expected 
due to increased non-specific interactions and protein binding when compared to hydrophilic 
molecules348. CD spectra also indicate higher helicity for Cy7 conjugates, and the physical state 
of the peptide at the site of injection is known to affect the pharmacokinetics of absorption332. 
Although helical forms can be readily absorbed from the SC site, increased non-specific 
interactions from the lipophilic dye likely dominate compared to helicity, hence the slower 
absorption rates.  
The higher bioavailability of the stabilized peptides correlates with improved proteolytic 
resistance. Although subcutaneous absorption is a complex process and incompletely 
understood327, the epidermis contains abundant proteases necessary for maintaining homeostasis 
of the skin359. These enzymes have been implicated in degrading peptide therapeutics before 
reaching systemic clearance, reducing their efficacy. Proteases almost universally cleave amide 
bonds in an extended beta strand conformation, rendering the alpha helix conformation more 
stable than linear peptides367. The non-stabilized fluorescent conjugates were not able to achieve 
total bioavailability although the amount was high (65% and 57% for AF680 and Cy7, 
respectively). Cy7 stabilization also showed improved bioavailability over non-stabilized Cy7 
exendin (82% vs. 57%), and complete bioavailability was possible through helix stabilization 
using AF680 (103%). All peptides maintained efficient targeting of islets following 
subcutaneous delivery. These improvements are likely due to the reduced proteolysis from the 
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stabilized secondary structure. Improved absorption has been demonstrated using protease 
inhibitors concurrent with treatment, but these approaches may cause unwanted side effects 
given that defective proteolytic enzymes in the epidermis cause multiple skin disorders359. 
Engineering peptides that are more resistant to these degradation pathways avoids special 
formulation requirements. 
The absorption rate of the peptide in the skin inversely correlated with the plasma AUC 
following intravenous injection. For example, the non-stabilized Cy7 peptide had the highest 
AUC (SI) and also the slowest absorption rate, while the AF680 peptides had the lowest AUC 
and fastest absorption rates. This likely results from the amount of interaction with skin and 
plasma proteins. These data are also consistent with non-specific cellular interactions measured 
in vitro, where non-stabilized Cy7 had the highest level of uptake, correlating to the highest 
plasma protein binding352. Interestingly, when comparing liraglutide and semaglutide, Lau et al. 
found that the slowest clearing peptide (semaglutide) also had the highest subcutaneous 
bioavailability (94% versus 66%)348. They argued that the higher protein binding of semaglutide 
reduced clearance and protected the molecule from protease degradation. For the fluorophore-
clicked peptides, the slower clearing unstabilized Cy7 peptide would then be expected to have 
increased bioavailability (in contrast to the results) in the absence of helix-stabilizing effects. 
Therefore, the more rapidly clearing s-Cy7 peptide likely had to overcome increased protease 
exposure to still attain improved bioavailability, which could explain the lower magnitude of 
improved bioavailability for the lipophilic peptides than with AF680 peptides. This also provides 
guidance for designing stabilizing linkers with increased plasma protein binding345, 348. 
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In situ measurement of the peptide degradation and absorption rates is challenging, which 
contributes to the incomplete understanding of subcutaneous bioavailability. To estimate these 
values, a 3-compartmental model was modified from Lu et al. with parameters fitted using 
MATLAB (Figure	6.18)368. The fitted degradation rates are qualitatively consistent with the in 
vitro degradation rates (SI); slower absorption rates with the lipophilic exendin conjugates are 
also consistent with the compartmental model. The slower absorption of the lipophilic peptides 
likely explains the lower bioavailability of Cy7 conjugates compared to AF680 conjugates due to 
a longer residence time in the skin. The factors affecting delivery are complex and include size, 
pKa, solubility, concentration, injection depth, body movement, blood supply, injection site, 
among many others327, 332. There is a limited understanding how these factors quantitatively 
impact bioavailability, hence the lack of strong predictive models for SC delivery. The current 
model lumps these factors into overall absorption and degradation mechanisms, but a more 
detailed and quantitative understanding of the underlying steps in SC drug delivery will allow for 
better predictions and scaling to the clinic in the future.  
Stabilized alpha helices allow researchers to investigate the impact of physicochemical 
properties on absorption at the site of injection. Adding lipophilic moieties through side chain 
substitution or conjugation is an increasingly used strategy to engineer ‘long-acting’ 
pharmaceutics because patients require fewer doses to maintain an efficacious systemic 
concentration349, 369, 370. However, long residence times in the skin can lower the bioavailability 
of these formulations371. Stabilizing peptides via double-click reaction using a lipophilic dye-
linker molecule simultaneously remedies low bioavailability and promotes plasma protein 




We independently modified the protease stability and lipophilicity of present four 
fluorescently labeled exendin molecules including using stapled stabilized and non-stapled 
stabilized variants with either lipophilic Cy7 or hydrophilic AF680 dyes as pharmacokinetic 
modifiers. Helix stabilization via the double-click staple linker resulted in improved 
bioavailability when all peptides were administered subcutaneously in mice likely from 
improved protease resistance. This result occurred for both hydrophilic and lipophilic 
derivatives, providing an independent method for improving bioavailability. Lipophilicity of the 
stabilizing crosslinker also significantly impacted absorption rates and AUC. The combination of 
imparting lipophilicity to slow systemic clearance and protease resistance to increase 
bioavailability is an attractive strategy for engineering peptide therapeutics.  
 
6.7 Experimental Methods 
Similar to previously published work, either one or two AHA substitutions were made to 
generate single-mutant and double-mutant exendin147, 187. A methionine residue at the 14th 
position was substituted with AHA during solid phase peptide synthesis based on its position 
pointing away from the binding pocket of GLP-1R42. An additional substitution replaced leucine 
at the 21st position with AHA to generate a double mutant exendin; i, i+7 residues correspond to 
positions located two helix turns apart and enabled subsequent helix stabilization.  
 
Materials 
Double mutant exendin-4 (HGEGTFTSDLSKQXEEEAVRXFIEWLKNGGPSSGAPPP 
S) and single mutant exendin-4 (HGEGTFTSDLSKQXEEEAVRLFIEWLKNGGPSSGAPPPS), 
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where is X is the non-natural amino acid azidohomoalanine, were obtained from Innopep (San 
Diego, CA). Alexa Fluor 680 NHS ester and Cy7 NHS ester were purchased from Life 
Technologies (Carlsbad, CA) and Lumiprobe (Hallandale Beach, FL), respectively. N-boc-2m2’-
(ethylenedioxy)-diethylamine was purchased from Santa Cruz Biotechnology (Dallas, TX). 
Other reagents were purchased from Sigma-Aldrich (Milwaukee, WI). ESI-MS spectra were 
collected using an Agilent Q-TOF 1200 series. RP-HPLC was performed on a Shimadzu LC unit 
using Phenomenex Luna C18(2) analytical and semi-prep columns.  
 
Preparation of Fluorescent Alkyne and Dialkyne 
Fluorescent dialkynes are synthesized from a previously published N-(2-(2-(2-
aminoethoxy)ethoxy)ethyl)-N-(prop-2-yn-1-yl)prop-2-yn-1-amine linker (1)187. Propargylamine 
or 1 (5 µmol) was added to 200 µl of 1:1 water:acetonitrile with 20 µl 7.5% sodium bicarbonate. 
Either Cy7 NHS ester or Alexa Fluor 680 NHS ester (0.5 µmol in DMSO) was added and the 
reaction was stirred at room temperature for 30 min followed by purification on preparative RP-
HPLC (AF680 alkyne: calcd: 895.17, found: [M-H]- = 894.16; AF680 dialkyne: calcd: 1064.28, 
found: [M-H]- = 1063.27; Cy7 alkyne: calcd: 586.38, found: [M] = 586.38; Cy7 dialkyne: calcd: 
755.49, found: [M] = 755.49). 
 
Preparation of Stabilized (s-)/non-stabilized Exendin 
 AF680 alkyne, AF680 dialkyne, Cy7 alkyne, or Cy7 dialkyne (300 nmol) was added to 
100 µl of 1:1 water:tert-butanol followed by CuSO4-TBTA (10 nmol in 1:1 water:DMSO) and 
sodium ascorbate (300 nmol in water). Lastly, single mutant or double mutant exendin was 
added (350 nmol) and the reaction was gently stirred at room temperature for 5 h followed by 
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purification using RP-HPLC. The purified peptides were dissolved in methanol and concentrated 
under reduced pressure three times followed by overnight lyophilization (AF680 exendin: calcd: 
5074.22, found: 5074.19; s-AF680 exendin: calcd: 5256.30, found: 5256.26; Cy7 exendin: calcd: 
4765.43, found: 4765.41; s-Cy7 exendin: calcd: 4947.51, found: 4947.50). 
 
Cell Culture 
NIT-1, a GLP-1R positive mouse beta cell line, were grown in F12K containing 10% 
(v/v) FBS, 50 U/mL penicillin, 50 µg/mL streptomycin, and 1.5 g/L sodium bicarbonate. Passage 
number used for cellular assays was between 6-10. 
 
In Vitro Receptor Binding Assay 
NIT-1 cells were grown for 48 h before being harvested with 0.05% trypsin-EDTA, 
washed and resuspended in PBS containing 0.1% bovine serum albumin (BSA). Cells were 
aliquoted and suspended in binding buffer containing fluorescent exendin conjugates ranging in 
concentration (0.01 nM - 340 nM) for 3 h on ice. Cells were then washed two times with 0.1% 
BSA in PBS and immediately analyzed using an Attune Acoustic Focusing Cytometer (Applied 
Biosystems). The binding affinity (Kd) was calculated using Prism 6.0 software. 
 
Trypsin Digest 
To compare the digest half-lives between stapled and non-stapled fluorescent exendin 
conjugates, both peptides were subject to a trypsin digest adapted from previously published 
methods187. In short, 0.05% trypsin-EDTA was diluted to a digest concentration of 5 ng/µL 
(DF100) with PBS (pH 7.4, room temperature). Peptide (45-50 µM) was added and the digest 
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was monitored at 214 nm using HPLC to quantify the AUC of intact peptide (SI). AUC of the 
intact peptide peak was plotted against time and fit to an exponential decay to determine a 
degradation half-life.  
 
Circular Dichroism Spectra 
To quantify and compare changes in peptide secondary structure, CD spectra were 
collected on a Jasco-815 CD spectrometer. Peptides were dissolved in 1:1 water:acetonitrile at 
concentrations determined by amino acid analysis. Scans containing only 1:1 water:acetonitrile 
were collected and subtracted as background. Helicity values for peptides were quantified using 
CD absorbance at 221 nm and the maximum ellipticity372372. 
 
Animals 
Animal experiments were in compliance with the University of Michigan Institutional 
Animal Care and Use Committee (IACUC). All fluorescent exendin conjugates (1 nmol in 100 
µL PBS) were injected in triplicate subcutaneously in the dorsal skin between the shoulders or 
intravenously (1 nmol in 150 µL PBS) via the tail vein of C57BL/6 mice. For SC injections, 
mice were anesthetized with 2.5 % isoflurane. Animals were kept under anesthesia for no longer 
than 5 min for each blood draw and no heating elements were used to reduce local variability in 
heating of the skin. Because injections were localized in the dorsal region, animals were oriented 
on their stomach during the injection and while under anesthesia. Animals were briefly oriented 
to the side during retro-orbital blood sampling but promptly reoriented after the blood draw. 
Previous experiments with inconsistencies in orientation, temperature, and isoflurane 
concentration resulted in inconsistent absorption rates and plasma concentrations (data not 
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shown). For intravenous injections, blood samples were collected at 1, 3, 5, 15, 30, 60, 180, 300, 
and 1440 min and fluorescent peptide concentration quantified using a LICOR Odyssey CLx 
scanner (Lincoln, NE). SC injected peptides were quantified similarly through blood samples at 
pre-determined time points to capture absorption into the blood and plasma clearance. Area 
under curve (AUC) was calculated by applying the trapezoidal rule to a plot of plasma 
concentration as a function of time. For each fluorescent compound, the AUC ratio was taken 
between the SC injection and the intravenous injection to quantify the bioavailability. After 24 h, 
animals were sacrificed and the pancreas removed and macroscopically imaged using the 
Odyssey CLx to verify successful islet of Langerhans targeting. Plasma samples were then run 
on a reducing SDS-PAGE gel and scanned to confirm fluorescent signal from plasma 




Chapter 7      
Concluding Remarks And Future Directions 
 
 
7.1 Summary of Work 
 
In this dissertation, we developed new methods and materials for molecular imaging 
probes to measure beta cell mass (BCM) in diabetes. Chapters 1 and 2 focused on the challenges 
of developing an imaging agent for measuring BCM in diabetes and on the optimal 
physicochemical properties needed for these probes. The molecular weight of exendin probes are 
near optimal for targeting the endocrine pancreas, and this molecule was analyzed in more detail. 
Chapter 3 examined the receptor trafficking properties and modifications in plasma clearance to 
obtain more efficient beta cell targeting. Due to rapid downregulation of the receptor, slow 
plasma clearance does not allow for continual beta cell uptake, so the slower clearance results in 
higher background and lower targeting efficiency. A rapidly cleared agent is therefore ideal for 
measuring BCM. Additionally, the receptor expression of GLP1-R was measured for the first 
time and provided evidence for low exocrine expression of GLP1-R in addition to the high 
endocrine expression. This low level expression on exocrine cells, due to their much higher 
prevalence than beta cells, could explain the failure in the clinic of current imaging agents to 
accurately measure BCM. Chapter 4 investigated this exocrine expression in more detail. Using 
wild type mice alongside a GLP-1R knockout transgenic mouse model, a very low expression of 
GLP1-R was confirmed on exocrine cells. Although absolute expression is very low (850 
receptors per cell on exocrine cells versus 53,000 receptors per cell on beta cells), the much 
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higher prevalence of exocrine cells (99%) relative to beta cells (1%) results in a significant total 
signal from the exocrine pancreas. Chapter 4 tested a method to preferentially block this uptake 
to provide more specific beta cell signal, and near 100% blocking of exocrine signal was 
achievable while sparing 15-20% of the receptor on endocrine cells for quantitative imaging. 
Chapter 5 looked at stabilizing the alpha helix to improve its physicochemical properties. Using 
a unique cross-linker with exendin and GLP1 as model peptides, the properties of alpha helical 
imaging agents could be improved. Due to the high helicity of exendin, this was not needed for 
beta cell imaging agents but could be used for other helical probes. The increase protease 
stability of the cross-linked peptides and use as a therapeutic led us to test the subcutaneous 
bioavailability. These cross-linkers were able to improve SC bioavailability for both rapidly 
absorbed hydrophilic peptides and slowly absorbed hydrophobic conjugates. This method could 
be used to improve the bioavailability of therapeutic peptides in addition to imaging agents.  
For developing clinically translatable agents, we first identified key challenges facing a 
successful imaging agent for quantifying the beta cell mass for type 1 diabetes research (Chapter 
1). Two key challenges include the small size of islets of Langerhans as well as the low volume 
fraction of islets in the pancreas organ. As a result, a probe with high specificity for the beta cells 
over the exocrine pancreas and low non-specific uptake in tissue is required for successful 
clinical translation. 
 Building on previously published work, which indicated peptides have the potential for 
high tissue uptake due to high permeability, we identified a 3-step screening approach for 
imaging agent design (Chapter 2). The three steps include screening for the optimal molecular 
weight, determining the required binding affinity, and reducing the non-specific signal during 
imaging. The screening step is used to determine the optimal molecular weight range, which is a 
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function of the target tissue physiology. To do this, first, a relationship between vessel 
permeability and molecular weight was identified for a variety of tissue types and a wide range 
of imaging agent molecular weights. Using these predicted permeability values, the 
extravasation/extraction fraction into the target tissue was predicted as a function of size for 
different tissue types. 3 kDa and 6.9 kDa were predicted for efficient extravasation into the 
endocrine (beta cell) and exocrine pancreas, respectively. The next step was to identify binding 
affinity. A previously published tissue uptake model was first validated and then used to predict 
the impact of binding affinity on uptake. The internalization rate was a key parameter that 
determined the required affinity for efficient retention in the tissue. This model helped identify 
affinity requirements for different tissue types, including endocrine pancreas. Lastly, two in vitro 
assays were used to determine the impact of different fluorophores on background signal. The 
combination of extravasation predictions, affinity requirements, and plasma protein binding and 
non-specific uptake assays focused our efforts on an exendin agonist as a suitable peptide for 
beta cell quantification. 
 Given our live cell imaging of the exendin/GLP-1R system, rapid internalization was 
observed and we wanted to assess the impact of this internalization on in vivo targeting. On one 
hand, a slow clearing molecule can be repeatedly internalized for high specific signal; on the 
other hand, a rapidly cleared imaging agent results in low background signal. The relative rate 
between these competing factors determines the overall imaging contrast. A series of fast and 
slow clearing fluorescent exendin-based conjugates were synthesized to quantitatively assess the 
impact of these phenomena (Chapter 3). We first verified that moderate expression of the GLP-
1R in vivo precluded the use of avidity for improved binding. Although we achieved slower 
clearance using a lipophilic Cy-7 exendin, the specific pancreas uptake was similar for both fast 
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and slow clearing imaging agents. A detailed in vitro internalization assay revealed a high degree 
of receptor downregulation, indicating that a slow clearing probe will not be repeatedly 
internalized. The work suggested a rapidly cleared exendin is ideal for imaging beta cell mass. 
 Measuring specific signal from the beta cells is important for accurate quantification. 
However, clinical attempts have proven challenging due to non-beta cell GLP-R signal. Mouse 
studies indicated expression of GLP-1R in the exocrine pancreas. Since the time of that 
publication, additional literature evidence has surfaced; GLP-1R is expressed in mice, non-
human primates, and humans. Evidence of GPL-1R in the exocrine pancreas has been 
challenging to identify; antibodies for the receptor are notoriously unreliable and expression is 
low. Additionally, the expression in the exocrine pancreas is extremely low, varies between 
species, and displays heterogeneous distribution across the tissue. However, the confirmation of 
GLP-1R in the exocrine tissue helped explain why radiolabeled exendin has performed poorly in 
the clinic. After independently verifying GLP-1R expression in the exocrine tissue, a multiple 
dosing strategy was explored to preferentially block the exocrine pancreas (Chapter 4). 
Preliminary results look promising as the exocrine GLP-1R is completely blocked. Although the 
majority of beta cell receptors are blocked as well (80-85%), the free receptors are well above 
the number needed to detect using radiolabeled probes (PET or SPECT) for clinical translation. 
 Lastly, due to much of the work and motivation in this dissertation pertaining to peptides 
and peptide-based imaging agents, our final goal was to generate new tools to address the 
shortcomings of peptide-based agents. Though peptides have an optimal molecular weight for 
tissue extravasation, they suffer from poor binding and instability. To address these 
shortcomings, we designed a novel heterobifunctional linker (Chapter 5) to simultaneously 
stabilize the peptide and attach a fluorophore. We demonstrated superior protease resistance 
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through in vitro trypsin digestion as well as improved binding and helicity through in vitro cell 
assays and circular dichroism, respectively. After demonstrating in vivo specificity, the impact of 
helix stabilization on subcutaneous bioavailability was investigated. Comparing the 
intravenously and subcutaneously delivered doses, it was confirmed that stabilization—and 
likely the improved protease resistance conferred—significantly improved subcutaneous 
delivery. Varying the lipophilicity of the fluorescent staple could further control the absorption 
rates. 
 
7.2 Future Work and Directions 
The work in this thesis opens the door to several new avenues of research. This section 
briefly describes two major new avenues for this work, and other members in the group are 
already exploring some of these directions. 
 
Stabilized Alpha Helices for Imaging and Therapy 
Chapter 2 focused on identifying optimal properties of extracellular molecular imaging 
agents with an emphasis on molecular weight, affinity, and background signal. The emphasis on 
extracellular targets such as GLP1-R, though important to this dissertation, does not encompass 
all possible targets, many of which are intracellular. Some of the most important intracellular 
targets for biopharmaceuticals include mitochondrial, nuclear, and cytoplasmic targets including 
intracellular pathogens. Though many of the same considerations such as molecular weight are 
important for extravasation to the target tissue, there is the challenge of efficient cellular uptake. 
“Stapled peptides” using an all hydrocarbon cross-linker have been reported to reach therapeutic 
concentrations in cells and in vivo. However, the results have been controversial, and progress in 
the field has been slow. The stabilization method developed in this thesis can be used to generate 
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novel alpha helices and test cellular uptake rates and cytosolic access to determine if this is a 
feasible class of agents. Design of successful therapeutics for intracellular targets will need to 
place much greater emphasis on membrane permeability and the properties of the payload or 
ligand that will allow for passive cellular uptake. The membrane permeability of molecules 
within this size range (500 to 5,000 Da) are also important for the transient distribution of 
payloads from nanoparticles and antibody drug conjugates, a current area of investigation in the 
lab. 
Regardless of the utility of stabilized helices for intracellular therapeutics, helix 
stabilization can be beneficial for peptide-based imaging agents. This strategy offers the potential 
for a platform technology to develop stabilized alpha helices for imaging agents, therapeutics, 
and separations. Our linker can be used to stabilize any helical peptide that can be readily solid 
phase synthesized. Much research has been conducted in our group on p53-like peptides with 
promising results including improved pepsin stability and increased cell permeability. The ability 
to surface display peptides on bacteria with residues modified for stabilization also holds 
promise for a rapid screening method to identify stabilized peptides, which is currently under 
development by others in the lab. The kinetics of subcutaneous absorption, while initially 
developed for therapeutic delivery, are useful in designing subcutaneously delivered near-
infrared imaging agents for a safe and patient compliant method of disease screening. Finally, the 
ease of synthesis, stability, and small size make stabilized peptides useful for affinity 
chromatography applications. These are only a few projects that showcase the potential of this 




Imaging Beta Cell Mass 
To date, biochemical tests using blood samples are the standard for assessing beta cell 
mass functionality. However, these methods are insensitive to early stages of type 1 diabetes 
when the pancreas has excess capacity to control blood glucose levels. In fact, greater than 90% 
of the pancreas beta cell mass (BCM) may be destroyed before insulin insufficiency and elevated 
blood glucose levels. The inability to detect early stages of the disease has been problematic in 
studying immunomodulatory therapies and the success of islet transplants.. Although methods 
exist to target and quantify the BCM in healthy animal models, these techniques fail in disease 
models and the clinic. An imaging technique with the resolution and sensitivity to quantify the 
BCM would greatly benefit the diabetes community but has so far remained out of reach. 
Particularly for type 1 diabetes, extensive research has been conducted on islet transplantation, 
since this treatment has the potential for curative results. The ability to track transplanted islets 
would improve transplantation technique and post-surgical monitoring. The results of this 
dissertation indicate accurate quantification of BCM in disease models is possible by blocking 
non-beta cell GLP-1R in the exocrine tissue. The studies in this dissertation illustrate the need for 
robust quantification in order to avoid the failure of prematurely engaging in a clinical trial. This 
work will not only be instrumental in designing a clinical trial with current probes but will also 
spark new areas of research. Given the controversy over GLP-1R expression on exocrine cells 
and pancreatitis and the variable patient-to-patient differences (where 50% appear to have 
exocrine GLP-1R expression and the others don’t), our exocrine blocking strategy could identify 
patients who are susceptible to these effects for further study. Comparing the pancreas signal 
with and without an exocrine blocking dose would determine if they had significant GLP-1R 
exocrine expression (a drop in signal) or not (negligible change). Most importantly, our studies 
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will help spearhead the development of a clinical imaging protocol for measuring BCM in 
patients to study the etiology of diabetes and treatment response	
Much of this thesis was focused on developing better imaging agents for measuring beta 
cell mass in diabetes. This included studying the details of the exendin/GLP-1R receptor system 
in mice, with an emphasis on the impacts of slower plasma clearance and avidity on specific 
uptake in the pancreas. One goal of the project was to design stronger binders to GLP-1R while 
another was to slow clearance to increase internalization and target uptake. Unfortunately, low to 
moderate expression of GLP-1R prevented avidity effects, and rapid downregulation stymied 
attempts to increase target uptake. Despite these attempts, the approach led to probably the most 
interesting finding from this project, which was the expression of GLP-1R in the exocrine 
pancreas. Future work should focus on blocking these receptors prior to in vivo imaging. 
Although some have argued that any exocrine expression is grounds for rejection of a potential 
target for imaging beta cell mass, many attempts have been made to discover more specific 
targets to no avail. The rapid internalization, high affinity, and ideal molecular weight of exendin 
solve many of the problems for imaging this challenging target. By using a strategy to block the 
exocrine GLP1-R, the decades of research in developing efficient radiolabeled probes and 
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